The role of telomeric DNA damage, mitochondria biogenesis and mTOR signalling in cellular senescence by Madeira Marques, Francisco Duarte
! 1!
 
 
The role of telomeric DNA damage, 
mitochondria biogenesis and mTOR 
signalling in cellular senescence 
 
FRANCISCO MARQUES 
 
Thesis submitted to Newcastle University for the degree of Doctor of 
Philosophy 
 
Institute for Cell & Molecular Biosciences 
Newcastle University Institute for Ageing 
School of Biomedical Sciences!
Faculty of Medical Sciences 
Newcastle University!
Newcastle-upon-Tyne - the United Kingdom 
November 2014!
! 2!
 
 
Supervisor: Dr. João Passos  
! 3!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“O que hoje não sabemos, amanhã saberemos” 
Garcia de Orta, 1563  
! 4!
INDEX  
CHAPTER 1. INTRODUCTION  
 What is cellular senescence? 17 
 What makes cells senescent? 18 
  The role of telomeres in cellular senescence 18 
  Mitochondrial dysfunction via oxidative stress stimulates and 
reinforces senescence 21 
  Mitochondria dynamics and homeostasis in cellular senescence, 
disease and ageing 24 
 What is the role of cellular senescence in organismal ageing, disease and 
cancer? 26 
 The mTOR pathway – the cells’ survival kit 28 
 mTOR impacts on organismal ageing 31 
 
OBJECTIVES 32 
 
CHAPTER 2. METHODS  
 Cell culture 33 
 Cell fixation 34 
 Cell storage 34 
 Tissue culture treatments 34 
  X-ray irradiation 34 
  Chemical treatments 35 
 Microscopy 35 
  Life-cell imaging 35 
  Telomere PNA probes incorporation 35 
  Transmission electron microscopy (TEM) analysis 36 
 Western blot 36 
 ROS – cellular superoxide levels 39 
Mitochondrial mass – cellular cardiolipin levels (FACS) 39 
Mitochondrial mass – MitoTrackerGreen staining (microscopy) 39 
Mitochondrial membrane potential –Tetramethylrhodamine methyl ester 
(TMRM) staining (microscopy) 39 
Lysogeny broth (LB) 40 
E. coli transformation by heat shock 40 
E. coli glycerol stock 40 
! 5!
Plasmid isolation –PureYieldTM Plasmid Miniprep System 40 
Restriction enzyme digestion 41 
DNA gel electrophoresis 41 
Cell transfection 41 
Plasmids 42 
Immunofluorescence 42 
Immuno-FISH in cells 43 
Immuno-FISH in paraffin embedded tissues 44 
Clonogenic assay 44 
Senescence-associated β-Galactosidase (SA-β-Gal) staining 45 
DNA isolation 45 
RNA isolation 45 
Quantitative RT-PCR 45 
mtDNA copy number assay 46 
MICE 47 
 Ageing cohort 47 
 Short-term rapamycin treatment (from 12 until 16 months of age) 47 
Life-long rapamycin treatment (from 3.5 months of age until15.5 
months of age) 47 
Rapamycin diet 48 
PGC-1β-/- mice 48 
Ethics statement 48 
Statistical analyses 48 
 
CHAPTER 3. TELOMERES ARE FAVOURED TARGETS OF A PERSISTANT DNA 
RESPONSE (DDR) IN STRESS-INDUCED SENESCENCE AND AGEING  
INTRODUCTION 49 
AIMS 50 
RESULTS 50 
DISCUSSION 61 
 Telomeric damage induces the DDR 61 
 Why telomeres are preferentially targeted by oxidative and genotoxic 
damage? 62 
 Telomeres and sub-telomeric regions have impaired DNA damage 
repair 63 
 Cells have more stable damage at telomeres 64 
! 6!
 Oxidative damage as instigator of TAF formation 64 
 Does telomerase counteract telomere dysfunction in senescence? 65 
 TAF as biomarkers of senescence 65 
 Perspectives 67 
 
CHAPTER 4. MITOCHONDRIAL BIOGENESIS IS CRUCIAL FOR THE INDUCTION 
AND DEVELOPMENT OF THE SENESCENT PHENOTYPE VIA THE mTOR 
PATHWAY  
INTRODUCTION 68 
AIMS 70 
RESULTS 71 
I. Inhibition of the mTOR pathway reduces senescence markers 
71 
II. The DDR is linked to mitochondrial biogenesis via the mTOR 
pathway 74 
III. PGC-1β mitochondrial biogenesis is essential for cellular 
senescence 78 
DISCUSSION 112 
 mTORC1 impacts on the DDR and on ROS during stress-induced 
senescence 112 
Mitochondrial biogenesis in senescence 114 
PGC-1β mitochondrial biogenesis 115 
PGC-1β-mitochondrial biogenesis, PGC-1α and antioxidant defence 
enzymes during cellular senescence 116 
Interactions between the mTOR pathway and, mitochondrial 
biogenesis and function 118 
 The Akt-PTEN axis 118 
 The TSC1/TSC2 complex 119 
 AMPK 119 
 VHL-HIF1α 119 
 mTORC1- raptor and mTOR kinase 120 
 p70S6K1 121 
Non-canonical nuclear mTOR complex 121 
mTORC1 regulation of ROS and antioxidant defence enzymes 122 
 
 
! 7!
CHAPTER 5. PYRUVATE-INDUCED SENESCENCE  
INTRODUCTION 125 
AIMS 125 
RESULTS 126 
Pyruvate addition induces cellular senescence 126 
DISCUSSION 132 
 Pyruvate-induced senescence and the role of metabolism in 
senescence 132 
  
CHAPTER 6. EFFECTS OF RAPAMYCIN DIET AND PGC-1β DELETION ON MICE 
CELLULAR SENESCENCE IN VIVO  
INTRODUCTION 135 
AIMS 136 
RESULTS 137 
Rapamycin fed mice have fewer senescent markers in liver 137 
PGC-1β knockout mice have fewer mitochondria and less telomere-
associated foci (TAF) in liver 138 
Den-induced hepatocellular carcinoma is associated with fewer DNA 
damage, lower mitochondrial and PGC-1β protein levels 139 
DISCUSSION 145 
 Hepatocytes from rapamycin treated mice and from PGC-1β KO mice 
have reduced telomeric associated damage 145 
 A role for rapamycin and PGC-1β deletion on mitochondria 146 
 mTOR impacts on liver hepatosteatosis 147 
 Is mitochondria biogenesis a tumour suppressor mechanism? 148 
 
CONCLUSION 149 
REFERENCES 150 
CONTRIBUTIONS 164 
ANEXES 169 
 ANNEX 1. 169 
 ANNEX 2. 172 
ACHIEVEMENTS DURING THE PhD 173 
 
 
! 8!
FIGURES AND TABLES 
 
FIGURE 1| The mTOR pathway 30 
TABLE 2.1| Primary and secondary antibodies for Western Blot 36 
TABLE 2.2| Primary antibodies used for Immuno-fluorescence stainings 42 
TABLE 2.3| Primer sequences for Real-time PCR 46 
TABLE 2.4| Primer sequences used mtDNA copy number assay 47 
FIGURE 3.1| Human and mouse fibroblasts have a chronic DDR in senescence 
51 
FIGURE 3.2| DDF occur at telomeres in stress-induced senescent human 
fibroblasts 53 
FIGURE 3.3| TAF occur in stress-induced senescence in MRC5 fibroblasts 
over-expressing telomerase (hTERT) 55 
FIGURE 3.4| TAF are long-lived while non-TAF are transient 57 
FIGURE 3.5| TAF increase with age in liver and small intestine of C57BL6 mice 
59 
FIGURE 4.1| An activated DDR drives cell growth and increased mTORC1 
activity 83 
FIGURE 4.2| Rapamycin inhibits mTORC1 and decreases the presence of 
senescence markers in stress-induced senescent human fibroblasts 85 
FIGURE 4.3| Rapamycin inhibits mTORC1 activity and decreases the presence 
of senescence markers in stress-induced senescent mouse fibroblasts (MEF) 
87 
FIGURE 4.4| Silencing of TSC2 increases mTORC1 activity, drives ROS 
generation and triggers DNA damage response 89 
FIGURE 4.5| RhebN153T activates constitutively mTORC1 and promotes 
cellular senescence in MEF 91 
FIGURE 4.6| Rapamycin decreases presence of senescence markers in 
replicative senescent (RS) human fibroblasts 92 
FIGURE 4.7| Mitochondrial mass and proteins increase as consequence of a 
DDR 93 
FIGURE 4.8| mTORC1 inhibition by rapamycin decreases mitochondrial within 
damaged cells 95 
FIGURE 4.9| ATM inhibition following a DDR leads to decreased mTORC1 
activity, p21 and VDAC protein levels in HEK293T cells 97 
! 9!
FIGURE 4.10| Autophagy-deficient cells accumulate mitochondria, ROS and 
DNA damage and, rapamycin rescues this phenotype regardless of the lack of 
autophagy 98 
FIGURE 4.11| Mitochondrial biogenesis is triggered following DDR activation 
and repressed upon mTORC1 inhibition in human MRC5 99 
FIGURE 4.12| Mitochondrial biogenesis is triggered upon a DDR in MEF 100 
FIGURE 4.13| PGC-1β KO MEF have disrupted mitochondrial networks, less 
mitochondrial proteins and less mtDNA during stress induced senescence 101 
FIGURE 4.14| PGC-1β depletion slows down the senescent phenotype 103 
FIGURE 4.15| PGC-1β over-expression triggers mitochondrial biogenesis 105 
FIGURE 4.16| PGC-1β-mediated mitochondrial biogenesis promotes cellular 
senescence 106 
FIGURE 4.17| PGC-1β KO MEF senesce slower under normoxic conditions 108 
FIGURE 4.18| PGC-1β and mTORC1 cooperate in the establishment of the 
senescent phenotype 110 
FIGURE 4.19| Mechanistic links between mitochondrial biogenesis (PGC-1α 
and PGC-1β) and the mTOR pathway 123 
FIGURE 4.20| Modulation of mitochondrial biogenesis, mTORC1 and 
autophagy alters mitochondrial numbers within cells and it impacts on the 
development of the senescent phenotype 124 
FIGURE 5.1| Chronic pyruvate supplementation leads to cellular senescence 
128 
FIGURE 5.2| N-acetylcysteine (NAC) rescues pyruvate-induced senescence 130 
FIGURE 5.3| Rapamycin rescues pyruvate-induced senescence (PIS) markers 
131 
FIGURE 5.4| Pyruvate addition induces cellular senescence – Jointly addition 
of pyruvate and NAC, or pyruvate and rapamycin delays senescence onset 134 
FIGURE 6.1| mTORC1-PGC-1β dependent increased mitochondrial content 
contributes to senescence in vivo 140 
FIGURE 6.2| PGC-1β-mediated mitochondrial biogenesis impacts on telomere-
associated damage and cancer in liver 142 
FIGURE 6.3| Mice under rapamycin diet show increased lipid content in 
hepatocytes and more senescence-associated β-Galactosidase activity in sub-
cutaneous adipose tissue 143 
 
 
 
! 10!
ABBREVIATION INDEX  
 
ADP – adenosine diphosphate 
APS – ammonium Persulfate  
Atg5 – autophagy related gene 5 
ATM – ataxia telangiectasia mutated  
ATP – adenosine-5'-triphosphate  
ATR – ataxia telangiectasia and Rad3 related  
AU – arbitrary unit(s) 
BAT – brown adipose tissue 
BCA – bicinchoninic acid 
BrdU – bromodeoxyuridine  
CDK – cyclin-dependent kinase 
CDKI – cyclin-dependent kinase inhibitors 
ChIP – chromatin immuno-precipitation 
COX – cytochrome c oxidase  
CPD – cell population doubling 
CR – caloric restriction 
DAPI – 4',6-diamidino-2-phenylindole  
DDF – DNA damage foci 
DDR – DNA damage response 
DEN – N-Nitrosodiethylamine 
DHE – dihydroethidine 
DHR – dihydrorhodamine 123  
DMEM – Dulbecco's modified Eagle's medium  
! 11!
DMSO – dimethyl sulfoxide  
DN – dominant-negative 
DNA – deoxyribonucleic acid  
DNA-SCARS – DNA segments with chromatin alteration reinforcing senescence 
DNP – dinitro-phenol  
DOX – doxycycline 
DR – dietary restriction 
DSB – double strand break 
ECM – extracellular matrix 
ETC – electron transport chain  
FACS – fluorescence activated cell sorter  
FC – fold-change 
FCCP – carbonilcyanide p-triflouromethoxyphenylhydrazone 
FCS – foetal calf serum  
FISH – fluorescent in situ hybridisation  
FSC – forward scatter  
GFP – green fluorescent protein 
GTP – guanosine triphosphate 
GDP – guanosine diphosphate 
Gy – Gray 
H2O2 – hydrogen peroxide 
HEK – human embryonic kidney cells 
HR – homologous recombination 
HSC – haematopoietic stem cells 
! 12!
hTERT – human telomerase reverse transcriptase (catalytic subunit) 
ICC – Immunocytochemistry 
IR – irradiation / irradiated 
KCl – potassium chloride  
KD – knockdown 
KO – knockout 
MAPK – mitogen-activated protein kinase  
MEF – mouse embryonic fibroblasts 
MitoQ – 10-(6′-ubiquinonyl) decyltriphenylphosphonium bromide 
MMP – mitochondrial membrane potential  
MSHE – mannitol, sucrose,  HEPES-KOH, EDTA buffer 
Mt – mitochondria 
mtDNA mitochondrial deoxyribonucleic acid  
mTOR – mammalian target of rapamycin 
mTORC1 – mammalian target of rapamycin complex 1 
mTORC2 – mammalian target of rapamycin complex 2 
NAC – N-acetyl-L-cysteine  
NAO – 10-n-nonyl-acridine orange 
NCS – neocarcinostatin 
NF-κB - nuclear factor of kappa light chain gene enhancer in B-cells  
NHEJ – non-homologous end joining 
NRF – nuclear respiratory factor  
NT – non-treated 
O2 – oxygen 
! 13!
OIS – oncogene-induced senescence 
OXPHOS – oxidative phosphorylation 
PBGT – phosphate-buffered saline gelatin Triton X 
PBN – N-tert-butyl-α-Phenylnitrone 
PBS – phosphate-buffered saline 
PD – population doubling  
PFA – paraformaldehyde  
PGC-1 – peroxisome proliferation activated receptor γ co-activator 1 
PML – Promyelocytic leukemia nuclear bodies  
PPAR – peroxisome proliferation activated receptor γ 
PROL – proliferation/proliferating 
Pyr – sodium pyruvate 
RAP(A) – rapamycin 
RB – retinoblastoma 
RISC – Rieske iron sulphur protein 
ROS – reactive oxygen species 
RT-PCR – reverse transcriptase Polymerase chain reaction  
s.e.m. – standard error mean  
SAHF – senescence- associated heterochromatin foci 
SASP – senescence-associated secretory phenotype 
SA-β-Gal – senescence-associated β-galactosidase 
SCR – scrambled 
SD – standard deviation  
SDS – sodium dodecyl sulphate  
! 14!
SFM – serum free medium 
shRNA – short-hairpin ribonucleic acid 
SIPS – stress-induced premature senescence 
siRNA small interference Ribonucleic acid  
SMS – senescence-messaging secretome 
SOD – superoxide dismutase 
SSB – single strand break 
SSC – sodium chloride, sodium citrate  
ssDNA – single-stranded deoxyribonucleic acid 
TAF – telomere-associated foci 
TBST – Tris-Buffered Saline and Tween 20 solution 
TCA – tricarboxilic acid cycle 
TE – Tris-EDTA buffer 
TEM – transmission emission microscopy/micrograph 
TEMED – Tetramethylethylenediamine  
TERC/TR – RNA component of telomerase 
TERT – telomerase reverse transcriptase 
TIF – telomeric induced foci  
TMRM – tetramethylrhodamine 
TRF2 – TTAGGG repeat binding factor 2 
Trolox – 6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid 
UCP – uncoupling protein 
UV – ultraviolet  
WB – western blot 
WT – wild type 
! 15!
THESIS ABSTRACT  
 
Cellular senescence is a state of enduring cell-cycle arrest characterised by a 
persistent DNA damage response, elevated Reactive Oxygen Species (ROS), 
mitochondrial dysfunction and a senescence-associated secretome. 
Senescence impacts in vivo not only by acting as a tumour suppressor 
mechanism but also hindering tissue repair and regeneration. Senescent cells 
build-up with age in many tissues from humans, baboons and mice, and 
clearance of senescent cells in mice has been demonstrated to ameliorate 
age-related pathologies.  
The mTOR (mechanistic target of rapamycin) is a primeval and conserved 
pathway among eukaryotes. Inhibition of the mTOR pathway has been shown 
to extend lifespan of model organisms, to be beneficial against cancer 
progression and to ameliorate several age-related diseases. While reports 
suggest that mTOR plays a role in cellular senescence, it is still incompletely 
understood how it contributes to the phenotype.  
Mitochondria sit on the crossroad of many cell fate decisions including 
apoptosis, differentiation and metabolism. Despite requirement for the 
aforementioned processes, the role of this organelle in cellular senescence 
has not been fully elucidated. 
In this thesis, I describe potential mechanisms by which mTOR may impact on 
cellular senescence, given its roles in regulating the DNA damage response 
and mitochondrial homeostasis. Additionally, I inspect the role of 
mitochondrial biogenesis during induction and maintenance of cellular 
senescence. Finally, I study the impact of mTOR inhibition by rapamycin and, 
the effects of compromised mitochondrial biogenesis in liver senescence with 
age in mice. 
!
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CHAPTER 1 – INTRODUCTION  
What is cellular senescence? 
Senescent cells show a long-lasting inability to resume proliferation being 
commonly barred at G1 and G2/M [1]. This enduring cell cycle arrest is caused 
by mutiple inducers. These incude oncogene (in)activation, tumour 
suppressors loss, persistant DNA and telomeric damage, chronic mitogenic 
signalling, chromatin changes, oxidative-, epigenetic-, nucleolar-, mitotic  
checkpoint- and spindle-stresses and BRAFV600E metabolic changes [2-7, 
8{Schmidt, 2010 #51, 9-11] which limits cells’ replicative capacity. Cellular 
senescence was first observed in 1961 by Hayflick and Moorhead [12]. They 
found that human fibroblasts cultured for a long time arrested after a fixed 
number of passages - this process was coined as replicative senescence. 
Senescent cells undergo multiple phenotypic changes, which are collectively 
known as the senescent phenotype. Although many molecular markers have 
been described in senescent cells, currently it is impossible to specify a 
universal marker to identify these cells. The difficulty to pinpoint a sole marker 
has to do with the fact that during the development of the senescent 
phenotype, markers can be expressed at different times, not being expressed 
at all, or are not present simultaneously. One example of this is the sequential 
and temporal expression of the senescent inflammatory secretome [13]. 
Eventually, not all cells senesce equally and there could be perhaps different 
types of senescence. 
Phenotypically, senescent cells are morphologically and metabolically distinct 
from young cells and other non-proliferating cells [14, 15] and, are less prone 
to apoptosis [16]. Furthermore, senescent cells are hypertrophic by exhibiting 
increased cellular volume and a flattened cytoplasm [1]. Senescent cells are 
commonly believed to be insensitive to either growth factors or mitogens [17].  
Senescent cells display changes in nuclear structure and increased nuclear 
area, loss of chromatin and altered gene expression [18, 19]. Furthermore, 
depending on the original senescence stimuli, some senescent cells can 
present nuclear inclusions namely PML (promyelocytic leukemia nuclear) 
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bodies, SAHF (senescence-associated heterochromatin foci) and DNA-
SCARS (DNA segments with chromatin alteration reinforcing senescence) 
[20, 21].  
Senescent fibroblasts have been shown to secrete growth factors, cytokines, 
extracellular matrix, and degradative enzymes, which have been collectively 
called the “senescence-associated secretory phenotype” (SASP) or 
“senescence-messaging secretome” (SMS) [22, 23]. It is believed that the 
main function of secreted factors is to allow inter- and intra-cellular 
communication. In fact, senescent cells have been shown to impact on their 
surrounding environment in different ways: firstly, senescent cells can induce 
senescence in neighbouring young cells [24, 25]; secondly, senescent cells 
have been shown to induce hyper-proliferation of cancer cells, neoplastic 
transformation and tissue damage [26, 27]; finally, this senescence secretome 
is able to reinforce and stabilise senescence via autocrine loops [22]. Not only 
secreted proteins have been shown to play a role in this cell-to-cell 
communication. Elevated ROS production, which is also characteristic of 
senescent cells, has also been implicated in paracrine senescence though 
gap junction-mediated cell-cell contact [24] and in the stability and re-
enforcement of the senescent phenotype [28]. 
Below we detail how high reactive oxygen species (ROS) generation, 
mitochondrial dysfunction and loss of telomere homeostasis contribute 
together to the onset and stability of cellular senescence.  
 
What makes cells senescent?  
! The role of telomeres in cellular senescence  
Since Hayflick’s discovery, the phenomenon of cellular senescence has 
intrigued scientists and has been the object of various studies aiming to 
uncover its underlying mechanisms. A major breakthrough occurred when it 
was theoretically suggested that telomere shortening could function as a 
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counter of the number of cell divisions and, ultimately contribute to replicative 
senescence [29, 30]. Nearly all organisms have in their chromosome ends a 
series of repetitive TTAGGG DNA sequences ending on a 3' protruding 
ssDNA 50-400 bases long overhang, called telomeres [31, 32]. Telomeres are 
protected by a protein-complex denominated shelterin that halts telomere 
recombination preventing top-to-top chromosome fusions [33]. Additionally, 
telomeric sequences cannot be entirely replicated mainly due to the inability of 
the DNA replication machinery, specifically the DNA polymerase, to 
synthesise in a 3’-5’ direction leading to the incomplete replication of the 
lagging strand. This leads to a progressive loss of telomere repeats with each 
cell division. Only in the 1990s, it was experimentally validated that not only 
cell division contributed to gradual telomere shortening and was associated 
with cellular senescence [34] but also, that ectopic expression of telomerase 
(an enzyme specialised in telomere length maintenance) extended the 
replicative lifespan of human fibroblasts in culture [35]. Telomere shortening 
has been hypothesised to destabilise these telomere loops (t-loops) structures 
[36], thereby contributing to telomere uncapping, i.e. loss of the protective 
shelterin components. 
Only recently we have begun to understand the mechanisms underlying the 
recognition of telomeres by cells undergoing senescence. Damaged 
telomeres, whether by inhibition of shelterin components or telomere 
shortening, activated the same DNA damage response (DDR) pathways as 
do double-strand breaks (DSB) [37-39]. This DDR is regarded as a core 
mechanism by which cells prevent replication of damaged DNA and allow 
enough time for its repair [40]. If the DNA damage turns out to be irreparable, 
then the arrest becomes permanent.  
Several reports described that telomeres are sources of senescence signals 
whether the damage was triggered by uncapped telomeres or genotoxic 
stress [3, 4]. Indeed telomeres, via shelterin components, are widely known to 
thwart the majority of the repair pathways in order to prevent chromosomal 
instability [41]. Structurally, telomeres have high presence of guanines, which 
can be highly prone to oxidation [6, 42]. Moreover, tandem oxidative lesions 
have been shown to contribute to the displacement of shelterin components 
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(TRF1 and TRF2) from telomeres [43]. Besides telomeric shortening, recently 
our group has also observed that DNA damage can physically occur at long 
telomeres and, that these lesions seem to be irreparable [3]. We named this 
phenomenon - Telomere-associated foci (TAF). Based on the fact that that 
TAF are induced by ionising irradiation or by hydrogen peroxide, we 
hypothesised that oxidative stress is involved in this type of telomere 
dysfunction [3]. TAF are bigger and more enduring than other genomic 
damage, again suggesting reparability problems [3].  
Mechanistically, shelterin components prevent telomeres from being 
recombined and to be repaired, working therefore as a barrier for genomic 
instability [32],[44, 45],[46, 47]. Shelterin component TRF2 stops non-
homologous end-joining (NHEJ) by inhibiting ligase IV activity avoiding 
therefore chromosomal top-to-top fusions [44-47]. Finally, replicative 
senescent cells with long telomeres and still containing TRF2, have been 
shown to also to co-localise with DDR proteins [48]. 
Besides the presence of persistent DSB at telomeres, also single strand 
breaks (SSB) remain unrepaired for long periods of time after treatment with 
hydrogen peroxide at telomeres [6]. Moreover, damage at telomere regions 
can be a consequence of acute hyper-proliferation, replication forks stalling 
and aleatory completion of telomere DNA replication during the initial stages 
of oncogene-induced senescence (OIS) [49].  
In vivo, DNA damage can be also observed at long telomeres in hepatocytes 
and in enterocytes from mice [3]. These telomere-associated damage (TAF) 
build-up with age in mice liver and intestine and, do not correlate with 
telomere length [3]. Due to its irreparability, we proposed that TAF can be a 
robust marker for senescence in vivo [3]. Indeed, TAF can qualitatively be a 
predictor of mean and maximum lifespan of short- and long-lived mice cohorts 
[50]. Other groups have shown previously that in non-proliferating baboons’ 
skin fibroblasts and neurons, telomeres can be targets of DNA damage [3, 4, 
51]. In humans, TAF are observed in melanocytes of benign- and dysplastic-
neavi, in epithelial cells of precursor lesions to breast- and colon- cancers, but 
are absent in melanoma, colon- and breast carcinoma [49]. Overall this data 
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can pinpoint TAF as biomarkers for senescence, but not necessarily a marker 
for cancerous lesions. Finally, more work needs to be conducted in order to 
understand if only the shortest of telomeres are the sole inducers of a DDR in 
tissues and, which degree of telomere uncapping functions as threshold to 
elicit a DDR during senescence [39]. 
The role of telomeres as inducers of accelerated ageing has been supported 
by studies involving genetically modified mice. Loss of telomere integrity has 
been shown to impact on organismal ageing. Late generation mTERC-/- mice, 
which carry a homozygous deletion of the RNA component of telomerase, 
show a generation-dependent telomere shortening [52]. This mouse model of 
acute telomere shortening, are short-lived and present early onset of ageing 
traits such as stem cell exhaustion, loss of regenerative capacity, cell cycle 
arrest and apoptosis [53]. Moreover, ablation of p21 in mTERC-null mice 
rescued regenerative capacity and extended lifespan [54]. 
In summary, telomeres seem to be hotspots for irreparable DSB and SSB 
and, therefore, they may act as sentinels to oxidative damage within cells and 
tissues, contributing to the senescence in vivo.  
 
• Mitochondrial dysfunction via oxidative stress stimulates and 
reinforces senescence 
As previously stated, telomeres are more sensitive to ROS-derived damage 
than the rest of the genome. Consistent with this idea several studies have 
shown that oxidative stress can accelerate telomere shortening in vitro. A 
variety of interventions, including treatment with free radical scavengers [55], 
overexpression of antioxidant enzymes [56], low ambient oxygen 
concentrations [57, 58], and mild mitochondrial uncoupling [59] have been 
shown to delay telomere shortening, thereby extending the replicative lifespan 
of cultured cells. On the other hand, mild oxidative stress has been shown to 
accelerate telomere shortening and lead to premature senescence [60].  
Several lines of evidence demonstrate that activation of several signalling 
pathways known to impact on cellular senescence can increase ROS levels in 
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cells. Activation of a DDR either by telomere uncapping or genotoxic stress 
[28], overexpression of oncogene BRAFV600E [10], over-expression of 
activated RAS [61], p53 [62], p21 [63] and p16 [64] have all been shown to 
result in elevated ROS generation. The use of antioxidants in the majority of 
those conditions has been shown to prevent or postpone senescence, 
suggesting an essential role for ROS in the process. Altogether, this evidence 
strongly supports the idea that ROS act as signalling molecules during 
senescence, and are not merely the outcome of time-dependent “wear-tear”. 
Indeed, recent evidence has demonstrated that ROS are simultaneously 
mitogenic-hyperproliferative and DNA damaging molecules during OIS [65]. 
These ROS are produced via a cascade involving H-RasV12-Rac1-Nox4 (a 
NADPH oxidase) [65].   
Mechanistically, the links between the DDR efector pathways (p53-p21 and 
p16-Rb) and ROS generation are not yet fully clear. Firstly, the p16-Rb axis 
has been connected with ROS production via PKCδ [64], most likely through 
action of this protein kinase onto NADPH oxidases [66]. New data from the 
Hara group puts forward a model in which both the Rb and AKT signalling 
activation halts mitochondrial superoxide dismutase (SOD2) expression, – 
enzyme responsible for transforming superoxide into hydrogen peroxide – 
leading to ROS accumulation [67]. Additionally, antioxidant defence enzymes 
activity have shown to increase in senescent fibroblasts when compared to 
young proliferating controls [68].  
Besides an outcome of a DDR, high ROS is proposed to be a switch that 
maintains a stabilises the DDR during cellular senescence [28, 67]. Indeed, 
also down-regulation of p53 or p21 reduces ROS either in telomere-
dependent and –independent senescence [28]. p21 (a cyclin-dependent 
kinase inhibitor responsible for the G1 arrest) mediates an increase in ROS 
generation that damages the DNA and activates the DDR, maintaining and 
stabilising therefore, a positive feed-back loop that keep cells in senescence 
[28]. Moreover, ROS can also exert effects on the DDR by promoting 
activation of ataxia-telangiectasia mutated (ATM) by dimerization through an 
oxidised bisulfide-bond [69]. In addition, p21 has been shown to impact on the 
TGF-β and MAPK pathways, which have then been demonstrated to 
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contribute to ROS generation [28, 70, 71]. In settings of lung fibrosis, chemical 
inhibition of NOX4, decreased ROS, p16 and p21 levels [72]. Finally, SASP is 
also connected to ROS production via IL-1–TGF-β–Nox4, thus promoting 
senescence in a paracrine fashion [73]. 
Mitochondria are thought to have evolved from symbiotic α-proteobacteria. 
These organelles reside within cells and, one of their major function is the 
production of energy in ATP form [74]. Despite evidence suggesting a causal 
role for ROS (particularly originated from external sources) in senescence, we 
still do not really understand the role of intrinsic ROS levels in cellular 
senescence. It was proposed that the majority of cellular ROS are originated 
in mitochondria [75]. In cellular senescence, production of high ROS, low 
mitochondrial membrane potential and decreased ATP production– 
mitochondrial dysfunction – are key features [59, 76]. Additionally to the loss 
of energy levels either in oncogene- or replicative- senescence, metabolic 
inefficacy (activation of AMPK) and high mitochondrial ROS that oxides DNA 
have been observed [59, 76-79]. Also, markers of macromolecule oxidation 
such as protein carbonyls and lipofuscin have been shown to be present in 
senescent cells [80, 81].  
 
Direct intereference on mitochondrial functions either silencing of components 
of the electron transport chain (ETC) (such as the Rieske iron sulphur protein 
(RISC)) or, by pharmacollogical inhibition of oxidative phosphorylation (using 
rotenone or oligomycin) promotes proliferation arrest and SA-β Gal activity 
[76]. Once more, this data points out a role of high ROS and ATP shortage in 
senescence. Chronic use of high concentrations of  the uncoupler FCCP also 
prompts cell cycle arrest and, induces cellular senescence in primary 
fibroblasts via increased ROS generation and telomere dysfunction [82].  
Although ROS have been extensively shown to play a role in senescence, its 
functions in organismal ageing are less clear with numerous conflicting results 
mostly obtained from animal models in which mitochondrial function, oxidative 
stress or the DDR have been modulated [83]. In vivo, mechanisms known to 
play a role in cellular senescence have been shown to impact on 
mitochondrial function and ROS generation. For instance, p53-/- mice show 
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defects on complex IV due to reduced expression of Sco2 cytochrome c 
oxidase assembly factor [84]. In late generation mTERC-/- mice, activation of 
p53 represses the promoters of mitochondrial biogenesis genes PGC-1α and 
PGC-1β, thereby reducing mitochondrial function [85]. Moreover, mTERC-/- 
mice have more oxidative damage in intestinal crypts and brain and this is 
dependent on p21 [28]. Another example of the relation between oxidative 
stress and senescence in vivo comes from the SOD2-null mice’s skin, in 
which senescent cells have been shown to accumulate [86]. Finally, mice with 
chronic inflammation (nfkb1 KO mice) have elevated ROS levels, which drive 
senescence and impair regeneration in liver and in intestinal crypts. 
Furthermore, the authors demonstrate that antioxidant BHA rescues cellular 
senescence and liver regeneration in nfkb1 KO mice [50]. Finally, besides 
inflammation, cellular senescence has been associated to a metabolic 
syndrome with enhanced mitochondrial tricarboxylic acid (TCA) cycle usage 
and, in which PDK1 works as a tumour suppression mechanism perhaps via 
ROS increase [10].  
 
Mitochondria dynamics and homeostasis in cellular senescence, 
disease and ageing 
Within organs in the human body, mitochondria exhibit distinct morphology, 
different fuel preferences and biosynthetic abilities. For instance, skeletal-
muscle mitochondria are proficient at oxidizing fatty acids, brain mitochondria 
are competent for ketone oxidation, while adrenal mitochondria are prone to 
biosynthesize steroid hormone [87]. Despite mitochondria having organ 
specific adaptations, overall they share about 75% of their molecular 
components [88].  
Regardless the existing mitochondrial heterogeneity within cells and tissues, 
we can identify core regulatory mechanisms such as: mitochondrial 
biogenesis [89, 90], mitophagy [91], fission and fusion [92], and movement 
[93]. Many of these processes of mitochondrial quality control have been 
implicated in processes such as cancer, degenerative diseases and ageing 
[94, 95]. Moreover, several lines of evidence suggest that disruption of this 
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equilibrium can contribute to cellular senescence.  An example of this is the 
knock-down of the mitochondrial fission protein 1 (Fis1), that has been shown 
to induce senescence via increased ROS generation and activation of a DDR 
[96].  
Knock-down of several core-autophagy genes (Atg7, Atg12 and LAMP2) have 
been shown to contribute to mitochondrial dysfunction (higher mitochondrial 
mass, lower mitochondrial membrane potential, and higher endogenous 
superoxide levels) and increased Sen-β-Gal activity [97]. Atg5 loss in 
macrophages, T-lymphocytes and mouse embryonic fibroblasts (MEF) leads 
to increased mitochondrial mass [98, 99]. Additionally, Atg5-/- MEF have 
higher mitochondrial DNA copies, higher mitochondrial superoxide levels and 
increased secretion of IFN-γ [98]. This data seems to be in disparity with 
Young et al., which showed increased autophagy in OIS, that Atg5 and Atg7 
silencing delayed the expression and secretion of inflammatory cytokines IL-6 
and IL-8 and, decreased SA-β-Gal activity [100].   
Mitochondrial biogenesis is a process by which cells maintain, increase and 
divide their pre-existing mitochondria. The core regulator of this process is the 
PGC-1 family, which comprises PGC-1α, PGC-1β and PPRC1 [101]. In a 
variety of cell types over-expression of PGC-1α and PGC-1β increases 
mitochondria biogenesis and enhances respiration, proposing that both co-
activators are the limiting factors for mitochondrial gene expression program 
[101]. Increasing mitochondrial biogenesis via expression of PGC-1α has 
been shown to speed the rate at which senescence occurred in human diploid 
fibroblasts [102]. Additionally, higher PGC-1α expression increased in 
senescent fibroblasts concomitant with an increase in mitochondrial mass 
[103]. 
In a broader context, PGC-1α does not only impact on cellular senescence, 
but also has multiple effects in pathological settings such as renal fibrosis 
[104], cardiomyopathy [105], and diabetes [106]. This later study, reports that 
endothelial PGC-1α overexpression induced multiple diabetic phenotypes that 
encompassed blunted wound healing, reduced blood flow after hindlimb 
ischemia and aberrant re-endothelialization following carotid injury [106].  
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The exact role of mitochondrial biogenesis during ageing is a controversial 
topic [107]. Whilst Nisoli and colleagues associated the beneficial effects of 
caloric restriction (CR) to enhanced mitochondrial content (which shaped the 
concept that impaired mitochondrial biogenesis represented a loss of function 
during ageing)[108], more comprehensive analyses using quantitative 
proteomic approaches have failed to support such findings [107, 109, 110]. 
Lanza and co-workers have shown by large-scale proteomic analysis and 
whole-genome expression profiling, less mitochondrial protein synthesis 
under CR was coupled with improved antioxidant capacity [110].  
 
What is the role of cellular senescence in organismal ageing, disease 
and cancer? 
Senescence is thought to play a role on cellular physiology within living 
tissues. Senescent cells increase with age in a variety of mammalian tissues 
[111-113] and may represent more than 15% of the cell population in aged 
baboons’ skin [114]. Accumulation of senescent cells is also associated to 
age-related pathologies like osteoarthritis, atherosclerosis and diabetes [115-
117].  
In cancer, senescence is thought to block tumour growth in vivo and, 
antagonistically, it leads to decreased tissue regeneration and the decrease of 
repair mechanisms with age [118-121].  
Consistent with this pleiotropic view, senescent cells can also stimulate and 
confer a suitable environment for cancer progression [27]. Undeniably, 
senescent cells are observed in mouse and human tissues in pre-malignant 
lesions [122], in lung adenomas, in prostatic intraepithelial neoplasia, in 
pancreatic intraductal neoplasia, and in melanocytic naevi [123-126]. 
However, in settings of malignant lesions – lung carcinoma, prostrate 
carcinomas, pancreatic ductal adenocarcinomas and melanomas – 
senescence is heavily abolished (perhaps suggesting that elimination of 
senescent cells weakens the anti-tumourigenic barriers) [124, 126, 127]. More 
examples of the impact of cellular senescence on pathologies was broadly 
revised recently [128] 
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Upon liver damage, hepatic stellate cells divide and secrete extracellular 
matrix (ECM) leading to fibrotic scar formation [129]. Sequentially, senescent 
stellate cells build-up a secretory response leading to pro-inflammatory 
molecules and matrix metalloproteinases secretion, damaging the ECM 
components. Inhibiting the normal activity of these senescent cells lead to the 
aggravation of fibrosis and liver damage, reflecting therefore the importance 
of senescent cells in wound-healing [129]. CCN1 (an extracellular matrix 
protein) induces senescence in fibroblasts – by activating ROS generation via 
NOX1 that culminates on activation of the DDR (p53 and p16) – limits fibrosis 
and resolves skin wound healing [130]. In addition, damaged hepatocytes 
release CCN1 that promotes HSC senescence [131]. Finally, the SASP is 
complex, highly context and microenvironment dependent phenomenon, that 
can be an example of antagonistic pleiotropy, once not all those secreted 
factors are pro-tumorigenic in liver [132].  
Recent evidence indicates that senescent cells may be cleared by the 
immune system both in vitro and in vivo (for instance by natural killer cells) 
[129]. Immune surveillance is a mechanism that not only detects and 
eliminates invading pathogens, but also is able to perceive, locate and 
displace senescent cells within tissues due to SASP secretion [133, 134]. 
Finally, immune surveillance of senescent cells appear to be a fine tuned 
mechanism since naevi can remain for decades without signs of malignant 
transformation [125].   
In senescent cells, p16Ink4a expression increases during ageing and has a role 
on the development of age-related human diseases [135]. Baker and colleges 
reported that clearance p16Ink4a positive senescent cells delays appearance of 
cataracts and kyphosis in mice, strengthens muscle fibbers and make BubR1 
hypomorphic-mice fitter for exercise [136]. Besides this, there is a decrease of 
senescent traits such as SA-β-Gal, IL-6 and metalloproteinase enzymes upon 
p16-positive cells clearance [136].  
Albeit the fact senescence is widely connected to loss of organ function and 
tumour suppression, senescence plays a part during normal cellular 
development and differentiation, for instance during terminal differentiation of 
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megakaryocytes [137]. Briefly, very recently studies identified also senescent 
cells during embryonic development [138, 139]. Finally, the authors propose 
that senescence, alike apoptosis is programmed [138].  
From the aforementioned studies, it is clear that senescence plays an 
important role in vivo during organismal development, ageing and disease. 
Increasing data suggests that de-regulation of nutrient-sensing pathway 
mTOR and cellular metabolism can contribute to these processes and 
modulate cellular senescence and organismal longevity [10, 140]. 
The mTOR pathway – the cells’ survival kit  
mTOR (mammalian/mechanistic target of rapamycin) is an ancient and 
conserved pathway among eukaryotes. It is a key signalling pathway that 
integrates multiple cellular inputs and outputs, channelling those into two 
major mTOR kinase complexes – mTORC1 and mTORC2 [141]. Besides the 
serine-threonine mTOR kinase, each complex share common subunit proteins 
namely Deptor, mLST8 and TTI1-TEL2; while mTORC1 has Raptor and 
PRAS40 as specific associates, mTORC2 contains Rictor, Protor and mSIN1 
[141]. These two complexes are modulated by numerous stimuli as amino 
acids, growth factors and glucose among others. In turn, these basic blocks 
are put into varied cellular anabolic processes that include protein synthesis, 
energy generation or lipids biosynthesis, contributing to cell growth, survival 
and division [141]. Upstream of the mTOR complexes we find the IGF-1–
PI(3)K–Akt axis. Downstream of Akt, there is the TSC-TBC complex 
(composed from TSC1 (hamartin), TSC2 (tuberin) and TBC1D7) that 
negatively impacts on mTORC1 activity. In more detail, this effect is mediated 
by a GTPase-activating protein (GAP) domain within tuberin,that accelerates 
conversion of Rheb-GTP to Rheb-GDP. From the two known mTOR 
complexes, mTORC1 is by far the best studied to date in respect to 
downstream cellular functions. For instance, mTORC1 coordinates 
messenger RNA translation and protein synthesis through the 
phosphorylation status of ribosomal protein S6 kinase 1 (S6K1) and the 4E-
BP protein [142]. mTORC1 activity is measured by the phosphorylation status 
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of S6K1 at T389, or by phosphorylation of S6 at S235/S236 [143]. mTORC1 
activity can be blunted by amino-acid starvation or using rapamycin. 
Rapamycin or sirolimus, is a drug first found and isolated from the bacteria 
Streptomyces hygroscopicus from Easter Island, also known as Rapa Nui 
[144]. This chemical compound has anti-proliferative properties, is commonly 
used to prevent organ transplantation rejection and, itself and its analogues 
have been used in several clinical trials [145]. Although rapamycin is known to 
selectively interfere with some mTORC1 processes for more than two 
decades, it remains to be elucidated how rapamycin mechanistically modulate 
mTORC1 functions [146]. On reverse, deletion of either TSC1 or TSC2, or 
use of a mutant Rheb allows a high constitutively active mTORC1 [147]. 
FIGURE 1 depicts in summary the mTOR pathway. 
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FIGURE 1| The mTOR pathway.  
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mTOR impacts on organismal ageing 
Genetic studies have highlighted the role of mTOR as a master regulator of 
lifespan and ageing in yeast, worms, flies and mice [140, 148-153]. 
Additionally, dietary restriction (DR) acts through the mTOR pathway [149]. 
Other mark of mTOR involvement in ageing is the extension of mice lifespan 
when rapamycin is administered, being therefore the first known evidence that 
mTOR inhibition effects and increases lifespan in mammals [140]. Rapamycin 
supplemented diet ameliorate health span and lifespan of several cancer mice 
models [154-159]. mTOR inhibition by rapamycin besides attenuating disease 
progression [160], it also was beneficed health span of a mouse model of 
mitochondrial disease (Leigh syndrome) [161]. 
Stem cells exhaustion is one of the features that accompany organismal 
ageing. mTOR impacts on cell stemeness tuning the Wnt signalling (critical 
rheostat for stem cell renewal and proliferation) [162-164] and, by promotion 
pluripontency genes expression (Oct4, Sox2, Nanog and Telomerase)[165].  
Besides ageing, the mTOR pathway could be linked to cellular senescence 
via the DNA damage and mitochondrial dysfunction (aim and discussed 
throughout this dissertation). 
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OBJECTIVES 
 
• Investigate the impact of mTOR on mitochondrial dysfunction during 
cellular senescence; 
• Evaluate the relative contribution of mitochondrial homeostatic 
mechanisms such as autophagy and mitochondrial biogenesis to the 
development of the senescent phenotype; 
• Examine the impact of mTOR dependent mechanisms on the 
maintenance of a DNA damage response during cellular senescence;  
• Analyse the impact of mTORC1 inhibition using rapamycin and 
mitochondrial biogenesis in senescence in vivo. 
  
! 33!
CHAPTER 2 – METHODS  
Cell culture  
Human embryonic lung MRC5 fibroblasts, human foreskin BJ fibroblasts 
(CRL-2522™), MRC5 fibroblasts transfected with the catalytic subunit of 
telomerase (MRC5-hTERT)[166], MRC5 fibroblasts bearing a fluorescent 
53BP1 fusion protein - AcGFP-53BP1c [167] were grown in Dulbecco’s 
modified Eagle’s medium – high glucose (DMEM, Sigma D5796, Dorset, UK) 
supplemented with 10% heat inactivated foetal calf serum (FCS)(Sigma©-
Aldrich, Ayrishire, UK), Penicillin/Streptomycin and 2mM glutamine under 
atmospheric oxygen conditions (air plus 5% CO2). All fibroblasts used in all 
experiments were between PD20 and PD30 unless they were immortalized. 
Replicative senescent MRC5 cells were generated by continued passaging (2 
to 3 months) until the population doubling was lower than 0.1. Once cultures 
were in deep-senescence state, Ki-67 staining was conducted to verify lack of 
proliferation. Cells’ media was replaced two times per week. 
Human embryonic kidney cells HEK293, human breast cancer MCF7 (CRL-
2351™), human primary glioblastoma U87 (HTB-14™), human colon 
carcinoma cells HCT116 (ATCC CCL-247™), HeLa (CCL-2™) cells and 
human fibrosarcoma T19 cells -containing a stably integrated dominant 
negative TRF2∆B∆M expression cassette under the control of a Tet-off promoter 
doxycycline inducible was a gift from Titia de Lange, Rockefeller University, 
NY [44] - were cultured in similar conditions as those used for fibroblasts. 
Mouse embryonic fibroblasts (MEFs) were obtained from C57BL/6 wild-type 
mice. MEFs from autophagy-related protein 5 (Atg5)-deficient - Atg5-/- (kind 
gift from Dr. Viktor Korolchuk and Dr. Noboru Mizushima [168]), PGC-1β-/- 
(kind gift from Dr. Antonio Vidal-Puig) and respective matched wild-type, were 
cultured in Advanced DMEM/F-12 (Invitrogen #12634) plus 10% FSC, 
Penicillin/Streptomycin and 2mM glutamine at 3% oxygen in a 3-gas cell 
culture incubator (Zapf Instruments, Sarstedt, Germany).  
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In order to inducible knockdown of TSC1 or TSC2, HEK293 cells were first 
transduced with lentivirus encoding the doxycycline/tetracycline-sensitive tTR-
KRAB repressor and a DsRed reporter. Afterwards, cells were transduced 
with lentivirus encoding the specific shRNA and a GFP reporter (pLVTH 
vector), both under the control of tTR-KRAB. Expression of shRNA was 
induced by treating cells with 2µg/mL doxycycline for 3 days. Target 
sequences of shRNA: TSC1 shRNA 1 (5’- GACACACAGAATAGCTATG-3’), 
TSC2 (5’-CGACGAGTCAAACAAGCCAAT-3’), and non-targeting scramble 
shRNA (5’- TGGTTTACATGTCGACTAA-3’). Cells were a kind gift from Dr. 
Kathrin Thedieck.  
Cell fixation 
Media was aspirated from a 12 well plate with a Pasteur pipette connected to 
a vacuum pump. Next a brief wash with 1xPBS was done. After removing the 
PBS, cells were fixed using 1mL of 2% PFA for each well. After ten minutes 
incubation at room temperature, PFA was aspirated. Coverslip were covered 
with 400µl PBS and store at -80°C until use further use. 
Cells storage  
Cells were centrifuged at 1200 rpm for 3 minutes. After removal of the media, 
cells were re-suspended in FBS with 10% DMSO HYBRI-MAX© (D2650 - 
Sigma©-Aldrich). Afterwards, cells were aliquoted in cryotubes and placed in 
a Cryo-Freezer previously thawed. Vials were put at -80oC and then stored 
into a liquid nitrogen tank - Biorack 6000 (Statebourne Cryogenics, 
Washington, UK). 
Tissue culture treatments 
X-ray irradiation 
Stress-induced senescence in MRC5 fibroblasts was induced by X-ray 
irradiation with 20Gy (unless stated otherwise). Mouse embryonic fibroblasts 
and HEK293T cells were X-ray irradiated with 10Gy. All cancer cells and T19 
cells were irradiated with 20Gy X-ray radiation. The cell X-radiator (X-Rad 
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225, Precision X-Ray INC, N-BRANFORD, CT USA) was used for every cell 
line/experiment. Following irradiation all culture medium was refreshed. 
Chemical treatments 
Cells were stimulated with neocarzinostatin (80ng/ml) (Sigma-Aldrich N9162) 
and H2O2 (400µM) in serum free media for 1 hour. Following treatment, 
culture medium was refreshed. Immediately after irradiation, medium was 
replaced by fresh DMEM containing the drug of choice. Cells treated with 
etoposite (50 µM) were continuously treated every 3 days for 10 days after 
irradiation. ATM (Ataxia telangiectasia mutated) kinase was inhibited using 2-
morpholin-4-yl-6-thianthren-1-yl-pyran-4-one (Ku55933) (Pfizer S1092) at 
10µM one day post-X-ray radiation. mTORC1 activity was inhibited using 
rapamycin (Sigma-Aldrich #R8781). All experiments were conducted using 
rapamycin at 100nM unless stated otherwise. N-acetyl-cysteine (NAC) (Sigma 
A9165) was used as antioxidant at 2.5nM for 24 hours. A 250µM Trolox (6-
Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid) (Sigma 238813) 
solution was made in water and filter sterilized. Samples were treated with 
Trolox one day prior to analysis. A 1M sodium pyruvate solution was made. 
After filtration (0.45µm filter), working solutions were prepared by dissolving 
the pyruvate solution in full DMEM media at 10 or 50mM.  
Microscopy 
Live-cell imaging 
For live cell time-lapse microscopy, cells were plated in Iwaki glass bottomed 
dishes (Iwaki) and imaged on an inverted Zeiss LSM510 equipped with a 
Solent incubator (Solent Scientific) at 37oC with humidified 5% CO2, using a 
40x 1.3 NA oil objective.  Autofocus was performed at each time point prior to 
capturing z-stacks to ensure the whole cell was captured (1.65µm pinhole 
every 1.5µm over 4.5µm total z range).  Cells and AcGFP-53BP1c foci were 
tracked manually using ImageJ (http://rsb.info.nih.gov/ij/). 
Telomere PNA probes incorporation  
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Incorporation of telomere specific PNA probe by glass beads was performed 
as described [169]. Cy-3 labelled telomere specific (C3TA2)3 peptide nucleic 
acid (PNA) probe (Panagene) was dissolved in 80mM KCl, 10mM K2PO4, 
4mM NaCl, pH 7.2, to a final concentration of 1µM. Mouse embryonic 
fibroblasts (MEFs) were grown in glass bottomed dishes and PNA probe was 
pipetted onto the culture. 0.12g of 75µm alkali washed glass beads (Sigma) 
were carefully and evenly sprinkled onto the surface of the dish. 
Transmission electron microscopy (TEM) analysis 
Transmission electron microscopy was performed at the Electron Microscopy 
Research Services – Newcastle University. Mitochondrial volume fraction, 
mitochondrial area and mitochondria number were tracked manually using 
Image J (http://rsb.info.nih.gov/ij/). Results presented consist of data from 3 
rapamycin-fed and 3 control male C57BL/6 mice 16 month old, 20 electron 
micrographs, 2000 mitochondria per animal were analysed. 
Western blot 
Western blotting was performed using conventional techniques. Mitochondrial 
protein abundance was determined by western blotting using antibodies 
against mitochondrial proteins TOMM20, VDAC, NDUFB8, SDHA, UQCR2, 
MT-CO1 and MT-CO2 (Table 2.1). 
Protein Species Host Dilution 
Reference/ 
Manufacturer 
p21 Human 
Rabbit 
monoclonal 
1:1000 #2947 - Cell signalling 
p21 
Human 
Mouse 
Rabbit 
polyclonal 
1:1000 ab7960 - Abcam 
PGC-1α 
Human 
Mouse 
Mouse 
monoclonal 
1:1000 
ST1202 - EMD 
Millipore 
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PGC-1β 
Human 
Mouse 
Rabbit 
polyclonal 
1:1000 ab61249 - Abcam 
NDUFB8 
Human 
Mouse 
Mouse 
monoclonal 
1:1000 ab110242 - Abcam 
UQCRC2 
Human 
Mouse 
Mouse 
monoclonal 
1:1000 ab14745 - Abcam 
MT-CO1 
Human 
Mouse 
Rabbit 
monoclonal 
1:250 ab14705 - Abcam 
MT-CO2 Human 
Mouse 
monoclonal 
1:1000 ab110258 - Abcam 
SDHA 
Human 
Mouse 
Mouse 
monoclonal 
1:1000 ab14715 - Abcam 
TOMM20 
Human 
Mice 
Mouse 
monoclonal 
1:1000 ab56783- Abcam 
VDAC1/Porin 
Human 
Mouse 
Mouse 
monoclonal 
1:1000 ab14734 - Abcam 
SOD2 
Human 
Mouse 
Rabbit  1:500 806-984 - Millipore 
S6 
Human 
Mouse 
Rabbit 
monoclonal 
1:1000 #2217- Cell signalling 
S6(Ser235/236) 
Human 
Mouse 
Rabbit 
monoclonal 
1:1000 #4858- Cell signalling 
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p70S6K 
Human 
Mouse 
Rabbit 
polyclonal 
1:1000 #9202 - Cell signalling 
p70S6K(Thr389) 
Human 
Mouse 
Rabbit 
polyclonal 
1:1000 #9205 - Cell signalling 
TSC2 
Human 
Mouse 
Rabbit 
monoclonal 
1:1000 #4308 - Cell signalling 
β-tubulin 
Human 
Mouse 
Rabbit 
polyclonal 
1:2000 #2146 - Cell signalling 
α-tubulin 
Human 
Mouse 
Mouse 
monoclonal 
1:2000 T9026 Sigma Aldrich 
GAPDH 
Human 
Mouse 
Rabbit 
monoclonal 
1:5000 #5174 - Cell signalling 
FLAG - 
Mouse 
monoclonal 
1:1000 F3165 - Sigma Aldrich 
Atg5 
Human 
Mouse 
Mouse 
monoclonal 
1:1000 
 
A2859 - Sigma Aldrich 
Secondary antibodies Dilution Reference/Manufacturer 
Goat anti-rabbit IgG -HRP conjugated 1:5000 A0545 - Sigma-Aldrich 
Rabbit anti-mouse IgG -HRP 
conjugated 
1:5000 A2554 - Sigma-Aldrich 
TABLE 2.1| Primary and secondary antibodies used for Western Blot 
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ROS - cellular superoxide levels (FACS)  
Cellular superoxide levels were measured using 10µM of dihydroethidium – 
DHE - (Molecular Probes, D-1168). Cells were stained in serum-free media 
(SFM) for 30 minutes at 37oC in the dark, red (FL3 channel) median 
fluorescence intensity was measured by flow cytometry (30,000 cells were 
analysed per condition). 
Mitochondrial mass - cellular cardiolipin levels (FACS) 
In order to measure mitochondrial mass, cells were stained with the 
fluorescent dye 10-n-nonylacridine orange – NAO (Molecular Probes – 
A1372). Cells were re-suspended in 1 ml of DMEM containing 10µM of NAO. 
After incubation for 10 minutes at 37°C in the dark, NAO fluorescence 
intensity was measured by flow cytometry. Green (FL1 channel) fluorescence 
was recorded. 
Mitochondrial mass – MitoTracker Green staining (microscopy) 
Cells were plated at a suitable density on coverslips avoiding confluence 
during the experiments. MitoTracker Green FM (Invitrogen M7514) was 
diluted 1 in 1000. Add 200µl MitoTracker Green and 30µl (100µg/ml) Hoechst 
33342 (Invitrogen) to 2.8ml SFM. After incubation at 37°C for half an hour, 
dyes were removed and cells washed. Mount in PBS and image immediately 
and for no longer than 25 to 30 minutes. 
Mitochondria membrane potential - Tetramethylrhodamine methyl ester 
(TMRM) staining (microscopy) 
Cells were plated at a suitable density on coverslips avoiding confluence 
during the experiments. MitoTracker Green FM (Invitrogen M7514) and 
TMRM (Invitrogen) 1:1000. 1µl TMRM working solution, 200 µl MitoTracker 
Green FM and 30µl (100µg/ml) Hoechst 33342 (Invitrogen) were added to 2.8 
ml serum free media. Cells were incubated at 37°C for 30 minutes. After dyes 
removal, cells were washed, mounted in PBS and imaged immediately and for 
no longer than 25-30 minutes. 
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Lysogeny broth (LB)  
Ten grams of tryptone, 5g of yeast extract and 10g of NaCl were weighed and 
suspended in 800 ml of distilled/deionized water. After homogenisation, 
further water was added to make a total volume of 1L. Media was sterilised by 
autoclaving it at 121°C for 20 minutes. For plates, 15g of agar was added to 
the media. When media cooled down, (before solidification) the antibiotic 
resistance advised for selection was added.  
E. coli transformation by heat shock 
Prepare the water bath to 42°C. Add 1µg plasmid (in TE or water) into 150µl 
chemical competent cells. Incubate the mixture on ice for 30 minutes. Heat-
shock the mixture on 42°C bath for 45 seconds. Bring the tube back in ice for 
2 minutes. Add 250µl of S.O.C medium. Incubate the tube at 37°C for 1 hour. 
Spin down cells 10.000g. Remove 300µl of the supernatant and re-suspend 
the pellet. Plate cells in LB agar plates containing 100µg/ml ampicillin. 
Incubate the plates overnight at 37°C (12-16 hours). Pick a satellite colony 
and incubate in 5ml LB medium with the adequate antibiotic (1:1000 dilution). 
Incubate at 37°C and 200 rpm at least 6 to 8 hours (until media start to 
become opaque). The next day take 1ml of the grown culture and inoculate 
200ml of LB medium with antibiotic resistance overnight.  
E. coli glycerol stock 
Take 1 ml of the 10 ml of overnight culture (37°C and 200 rpm) and add 500µl 
of 50% glycerol. Store at -80°C. 
Plasmid isolation – Pure Yield™ Plasmid Miniprep System (Promega – 
A2492) 
Centrifuge the overnight culture for fifteen minutes at 4000 rpm. Afterwards 
re-suspend pelleted bacterial cells in 400µl Cell Resuspension Solution. Add 
400µl Cell Lysis Solution and gently invert the tube four to six times to mix. 
Add 400µl Neutralization Solution and invert the tube immediately but gently 
four to six times. The solution should become cloudy. Centrifuge for ten 
minutes at 10000x g. Thoroughly mix the resin and add 1ml to each 
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Minicolumn/syringe assembly. Carefully transfer the supernatant to the resin 
in each assembly. Open stopcocks of the vacuum manifold. Apply vacuum to 
pull the liquid through the column. Release vacuum when all the liquid has 
passed the column. Add 2ml Column Wash Solution (containing ethanol, 
avoid leaving the bottle opened for long time) and apply vacuum again. 
Continue vacuum for about thirty seconds to dry the resin. Transfer mini-
column to an Eppendorf and dry the column by centrifugation. Transfer the 
mini-column to a new micro-centrifuge tube, add 50µl 70°C deionised water 
and wait for one minute (for plasmids bigger than 10Kb use 80°C deionised 
water). Centrifuge at 10000x g for one minute. Remove and discard mini-
column. Lastly, measure DNA concentration on the Nanodrop. 
Restriction enzyme digestion   
One microgram of PGC-1β was digested using 0.3µl of BamHI and/or EcoRV 
enzymes. Digestion mixture was incubated at 37°C for three hours. DNA-
digestion product was verified by agarose gel electrophoresis. 
DNA gel electrophoresis   
Prepare your 1% agarose-gel by taking 100ml of 1x TAE-buffer in a 200ml 
Erlenmeyer flask. Weigh one gram agarose and add to the TAE-buffer. Add 
Ethidium Bromide-solution to the agarose gel in a final concentration of 
0.5µg/ml when it is hand warm. Poor the gel and put a comb in the 
electrophoresis unit. After hardening of the agarose-gel, pull out the comb. 
Load the samples using 6x concentrated DNA-loading buffer. Use 5µl of the 
1Kb Plus DNA Ladder (Invitrogen) as a MW marker. Run the gel on 80-100V 
for 30 to 45 minutes. 
Cell transfection (using Lipofectamine 2000TM Invitrogen and GunJ – Glyn 
Nelson) 
For each well prepare 1µg of your plasmid (DNA) and add the transfection 
reagent at a ratio of 2:1 from the volume of DNA in 100µl Opti-MEM 
(Invitrogen - 31985-062). Mix gently by flicking the Eppendorf tube. Incubate 
at room temperature thirty minutes. Add this mixture dropwise to the cells.  
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Plasmids 
For overexpression of activated Rheb both HeLa cells and MEFs were 
transduced with empty vector or pcDNA3-flag-Rheb-N153T (Addgene 
#19997). Overexpression of PGC-1β was conducted using pcDNAf:PGC-1β 
(Addgene #1031). 
Immunofluorescence 
Take a new 12 well plate and transfer the 19 mm cover slips with the help of 
forceps (cells always facing up). Wash twice in PBS for 5 minutes. Then 
permeabilize cell membranes using 1ml PBG-Triton X for 45 minutes. This 
step should be done at room temperature and with slightly shake. Remove 
solution and add 400µl of primary antibody in PBG-Triton X per cover-slip. 
Alternatively, add 60µl droplet into PARAFILM® and placed the coverslip with 
the cells facing the diluted primary antibody. Incubate at room temperature 2 
hours. In lieu of this, incubation with the primary antibody can be done 
overnight at 4°C. Wash twice in PBGT for 5 minutes. Incubate samples with 
the secondary antibody (Alexa Fluor® 594 or Alexa Fluor® 488) (Invitrogen) 
at room temperature 45 minutes in dark (wrap the 12 well plate with 
aluminium foil). Put samples to shake slightly. Aspirate secondary antibody 
and wash three times with PBS (10 minutes each wash). Incubate each 
sample in 400 µl DAPI for 10 minutes. Remove DAPI and wash three more 
times with PBS (10 minutes each wash). Prepare clean slides and label them. 
Add 10 µl anti-fade (DABCO or Vector) mounting medium on the middle of the 
slides. Flip-flop coverslip, put cells facing the mounting medium. Let it dry and 
protect slides from light. Examine slides under the fluorescence microscope. 
A complete list of primary antibodies used in all experiments is depicted in 
Table 2.2. 
Protein Species Host Dilution Reference/Manufacturer 
Ki67 
Human 
Mouse 
rabbit 
polyclonal 
1:250 ab15580 - Abcam 
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γH2A.X(Ser139) Human Mouse 1:2000 
AB10022 - Upstate 
Millipore 
53BP1 
Human 
Mouse 
rabbit 
polyclonal 
1:200 
NB100-305 - Novus 
Biologicals 
53BP1 Human 
Rabbit 
polyclonal 
1:500 #4937 - Cell signalling 
p21 
Human 
Mouse 
rabbit 
polyclonal 
1:200 ab7960 - Abcam 
SDHA 
Human 
Mouse 
Rabbit 
monoclonal 
1:1000 #11998- Cell signalling 
FLAG - Mouse monoclonal 
1:1000 F3165 - Sigma Aldrich 
Atg5 
Human 
Mouse 
Mouse 
monoclonal 
1:1000 
 
A2859 - Sigma Aldrich 
 
 TABLE 2.2| Primary antibodies used for Immuno-fluorescence stainings 
 
Immuno-FISH in cells 
Immuno-FISH were performed as described [59]. Briefly, cells grown on 
sterile coverslips were fixed with 2% paraformaldehyde and γ-H2A.X (Upstate 
Biotechnology) or 53BP1 (Cell Signalling) immuno-staining for 1h at room 
temperature was performed as described above. After application of the 
secondary antibody, cells were washed with PBS and FISH was performed. 
20µl of Cy-3 labelled telomere specific (C3TA2)3 peptide nucleic acid (PNA) 
probe (4ng/µl) (Panagene) was applied to the cells followed by co-
denaturation at 80°C and hybridisation for 2 hours at room temperature in the 
dark. Cells were then washed 3 times for 10 minutes with wash buffer made 
from 70ml Formamide (70%) 30ml SSC 2% (3ml stock SSC 20% + 27ml H20) 
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and 3 times for 5 minutes with TBS-Tween 0.05%. Cells were incubated with 
DAPI, mounted and imaged using a Leica DM5500B fluorescence 
microscope. In depth Z stacking was used (Images were captured as stacks 
separated by 0.247µm with 100×objective) followed by Huygens (SVI) 
deconvolution. 
 
Immuno-FISH in paraffin embedded tissues 
For Immuno-FISH in formalin-fixed paraffin embedded liver mice sections, 
following antibody incubations, sections were incubated with avidin–DCS 
(diluted to 1:500; Vector Lab) for 30 min. Subsequently, tissue sections were 
washed 3 times in PBS and fixed in 4%PFA for 20 min and dehydrated with 
70%, 90%, 100% ethanol for 3 min each. Sections were air dried and then 
denatured for 10 min at 80°C in hybridization buffer [70% formamide (Sigma), 
25mM MgCl2, 1M Tris pH 7.2, 5% blocking reagent (Roche, Welwyn, UK)] 
containing 25µg/ml Cy-3 labeled telomere specific (CCCTAA) peptide nuclei 
acid probe (Panagene), followed by hybridization for 2 hours at room 
temperature in the dark. The slides were washed for 10 minutes with 70% 
formamide in SSC 2%, following by a 10 minutes wash in SSC 2% and a final 
wash in PBS for 10 minutes. Nuclei were stained by DAPI for 10 minutes, 
mounted and imaged in a Leica DM5500B fluorescence microscope. In depth 
Z stacking was used (a minimum of 40 optical slices with 63×objective) 
followed by Huygens (SVI) deconvolution.  
Clonogenic assay 
Colony assay of wild-type and PGC-1β-/- MEF grown at 3% or 21% O2 
(normoxia) were followed for three weeks after seeding 10.000 cells. Cells 
were re-seeded and counted every three to four days. After PFA fixation and 
a brief wash with PBS1x cells were stained in Crystal violet solution. After a 
thorough wash in water, cells were solubilized in methanol and optical 
absorbance was monitored at 540nm using FLUOstar Omega reader (BMG-
Labtech). 
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Senescence-associated β-Galactosidase (SA-β-Gal) staining  
For senescence-associated β-galactosidase staining, cells were fixed with 2% 
formaldehyde in PBS for 5 minutes and stained as described in [170, 171]. 
Briefly, following fixation, cells were washed once with PBS and incubated at 
37°C for 16 hours in freshly prepared senescence-associated β-galactosidase 
staining solution containing 2mM magnesium chloride, 150mM sodium 
chloride, 40mM citric acid, 12mM sodium phosphate dibasic, 5mM potassium 
ferrocyanide, 5mM potassium ferricyanide and 1mg/l – 1-5-bromo-4-chloro-3-
inolyl-β-d-galactoside (X-Gal) enzyme at pH 6.0. Following staining, nuclei 
were counterstained with DAPI and randomly chosen fields were imaged (20x 
objective). For in vivo liver and fat Sen-β-Gal assay, tissues were fixed in 4% 
PFA one day at room temperature. Next, tissues were rinsed in PBS 1X trice 
for ten minutes. After preparing the same Sen-β-Gal solution described 
above, tissues were incubated overnight at 37ºC. Next day, tissues were 
rinsed extensively in 1xPBS solution. For primary MEF and mouse tissues 
Sen-β-Gal pH was adjusted to 5.5 [172]. 
DNA isolation 
DNA was extracted using DNeasy 96 Blood & Tissue Kit (Qiagen # 69581) kit 
and guidelines. 
RNA isolation 
Total RNA was extracted using the RNeasy minikit (Qiagen). Complementary 
DNA was generated using Superscript II (Gibco). 
Quantitative RT-PCR 
PCR reactions were performed on an Opticon 2 (Bio-Rad) using SYBR Green 
PCR Master Mix (Applied Biosystems) and TaqMan Universal PCR Master 
Mix (Applied Biosystems). Expression was normalized to GADPH expression. 
Primers used are depicted in Table 2.3. 
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Gene Species  Sequence 
PGC-1β Human Forward 5’ AGTCAACGGCCTTGTGTTAAG 3’ 
  Reverse 5’ ACAACTTCGGCTCTGAGACTG 3’ 
PGC-1α Human Forward 5’ TGAGAGGGCCAAGCAAAG 3’ 
  Reverse 5’ ATAAATCACACGGCGCTCTT 3’ 
GAPDH Human Forward 5’AAATCCCATCACCATCTTCC 3’ 
  Reverse 5’ GACTCCACGACGTACTCAGC 3’ 
PGC-1β  Mouse Forward 5’ CGCTCCAGGAGACTGAATCCAG 3’ 
  Reverse 5’ CTTGACTACTGTCTGTGAGGC 3’ 
PGC-1α Mouse Forward 5’ AATCAGACCTGACACACG 3’ 
  Reverse 5’ GCATTCCTCAATTTCACCAA 3’ 
CXCL1 Mouse Forward 5’ GACTCCAGCCACACTCCAAC 3’ 
  Reverse 5’ TGACAGCGCAGCTCATTG 3’ 
IL-6 Mouse Forward 5’ CTACCAAACTGGATATAATCAGGA 3’ 
  Reverse 5’ CCAGGTAGCTATGGTACTCCAGAA 3’ 
p16 Mouse Forward 5’ TTGCCCATCATCATCACCT 3’ 
  Reverse 5’GGGTTTTCTTGGTGAAGTTCG 3’ 
β-actin Mouse Forward 5’ TAAGGCCAACCGTGAAAAG 3’ 
  Reverse 5’ ACCAGAGGCATACAGGGACA 3’ 
TABLE 2.3| Primer sequences for Real-time PCR  
 
mtDNA copy number assay 
Ratio between mitochondrial ND1 and a nuclear reference gene (ND5 or B2M 
- β2- microglobulin) was measured in human and mouse fibroblasts, and 
HEK293T cells by RT-PCR (primers in Table 2.4). 
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Gene Species  Sequence 
B2M Human Forward 5’ CCAGCAGAGAATGGAAAGTCAA 3’ 
  Reverse 5’ TCTCTCTCCATTCTTCAGTAAGTCAACT 3’ 
ND1 Human Forward 5’ CCCTAAAACCCGCCACATCT 3’ 
  Reverse 5’ GAGCGATGGTGAGAGCTAAGGT 3’ 
ND1 Mouse Forward 5’ ACACTTATTACAACCCAAGAACACAT 3’ 
  Reverse 5’ TCATATTATGGCTATGGGTCAGG 3’ 
ND5 Mouse Forward 5’ CCACGCATTCTTCAAAGCTA 3’ 
  Reverse 5’ TCGGATGTCTTGTTCGTCTG 3’ 
TABLE 2.4| Primer sequences used for mtDNA copy number assay 
 
MICE 
! Ageing cohort (used in Chapter 3) 
Three male C57BL/6 mice per age group - 3, 12, 22, 36 and 42 months old 
were sacrificed. Tissues were immediately perfusion fixed. Formalin-fixed 
paraffin embedded 3 µm sections were prepared from liver and gut.  
! Short-time rapamycin treatment (from 12 until 16 months of age) 
C57/BL6 male mice at 12 months of age were divided into 2 groups 
(N=10/group), matched for body mass, food intake and age. Mice were both 
fed with control diet or rapamycin for four months starting at twelve months of 
age and sacrificed at 16 months of age.  
! Life-long rapamycin treatment (from 3.5 months of age until 15.5 
months of age) 
C57/BL6 male mice at 3.5 months of age were divided into multiple groups 
(n=6-11/group), matched for body mass, food intake and age. Mice were both 
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fed with control diet or rapamycin for three, six or twelve months. Mice were 
sacrificed at 6.5, 9.5 and 15.5 months of age.  
! Rapamycin diet 
Control and Rapamycin diet was purchase from TestDiet - Control diet: 
5LG6/122 PPM EUDRAGIT 3/8 #1814831 (5AS0) and Encapsulated 
Rapamycin diet: 5LG6/122 PPM ENCAP RAP 3/8 #1814830 (5ARZ). Mice 
were fed ad libitum and weight and food intake was monitored weekly. 
! PGC-1β-/- mice  
Wild-type and PGC-1β-/- C57/BL6 mice were sacrificed at 7 and 18 months of 
age. Tissues were either paraformaldehyde-fixed paraffin embedded or frozen 
in liquid nitrogen and stored at -80oC for biochemical analysis. Professor 
Antonio Vidal-Puig and Dr. Sergio Cuenca-Rodriguez are the holders of the 
PGC-1β-/- mice colony in the University of Cambridge - Metabolic Research 
Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, 
Addenbrooke’s Hospital, Cambridge, UK. 
Ethics statement 
Animal procedures were performed in accordance with the UK Home Office 
regulations and the UK Animal Scientific Procedures Act [A(sp)A 1986]. The 
project was approved by the Faculty of Medical Sciences Ethical Review 
Committee, Newcastle University. Project license number 60/3864. 
Statistical analyses  
We conducted One-Way ANOVA, Student Two-Tailed t-test, linear and non-
linear regression analysis and Gehan-Breslow test using Sigma Plot 11.0. 
Wilcoxon-Mann-Whitney tests were conducted using IBM SPSS Statistics 19.  
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CHAPTER 3 – TELOMERES ARE FAVOURED TARGETS OF A 
PERSISTENT DNA DAMAGE RESPONSE (DDR) IN STRESS-
INDUCED SENESCENCE AND AGEING 
 
INTRODUCTION 
Telomeres are found at the end regions of chromosomes and they are known 
to shorten in each replication cycle [29, 30, 34]. Once telomeres become 
critically eroded, they trigger a DNA damage response that elicits cellular 
senescence [37-39].  
In mice, senescence is unanimously regarded as being telomere independent 
[174], once telomeres in these animals are extremely long and, in order to 
reach a critical size to engage on senescence, it would take multiple 
replication rounds [175].  
It is generally believed that cells treated with high concentrations of hydrogen 
peroxide stress, do not exhibit telomere length shortening however, under 
mild oxidative conditions, telomeres can be damaged, accumulating single 
strand breaks (SSB) that, combined with cellular division, accelerates 
telomere shortening [6, 42].  
Besides SSB at telomeres caused by oxidative stress, the loss of telomere 
protective capacity, in other words, lost of shelterin components, can lead to 
telomere induced damage foci (TIF)[38]. TIF have been reported in multiple 
human primary cells that engage DDR pathways [37, 176] and in cancer cell 
lines [177]. Additionally, damaged telomeres are thought to be unable to 
retain their normal conformational architecture (e.g. their t-loop) and, also, are 
incapable of keep enough TRF2 to halt non-homologous end-joining (NHEJ) 
fusions [177].  
Finally, previous observation in senescent cells, induced either by X-ray 
irradiation or by H2O2 treatment, has evidenced that certain DNA damage foci 
are persistent [178]. Despite this observation, the nature and location of these 
lesions is not known. 
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AIMS 
• Are persistent DNA damage foci (DDF) located at telomeres during 
stress-induced senescence?  
• Are telomere-associated foci (TAF) present in vivo in mice liver and 
small intestine and, do they change with age? 
 
RESULTS  
Senescent cells can be characterised by having an unresolved DNA damage 
response [37] (FIGURES 3.1a and 3.1d). Upon induction of senescence using 
X-ray ionising radiation, human MRC5 fibroblasts display high number of 
γH2A.X damage foci that gradually become repaired with time (FIGURES 
3.1a). Interestingly, after several days, double stranded lesions labelled by 
γH2A.X or 53BP1 are still present within the nucleus (FIGURES 3.1a, 3.1d, 
3.2c and 3.2e). Similarly, this feature was seen in mouse embryonic 
fibroblasts (MEF) following X-ray radiation treatment, suggesting that this 
process is common across species upon induction of senescence by 
genotoxic stress (FIGURES 3.1b-3.1e). Moreover, increasing doses of X-ray 
radiation lead to a linear increase of DNA damage foci number in both human 
and mouse fibroblasts (FIGURES 3.1d, 3.1e, and 3.2a),  
Overall this unrepaired damage foci may be important for the induction of the 
senescent phenotype. Finally, also replicative senescent MRC5 fibroblasts 
show persistent DNA damage foci [178].  
 
Based on the existing literature that telomere binding proteins impede proper 
DNA repair at telomeres, we hypothesized that unrepaired DNA damage foci 
could specifically be located at telomeres.   
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FIGURE 3.1| Human and mouse fibroblasts have a chronic DDR in senescence 
a) γH2A.X-labelled double strand breaks (DSB) are seen in senescent MRC5 treated with 
20Gy. Data are mean ± s.e.m. of n=15. Scale bar=10 µm; b) Representative image of 
53BP1 damage foci in MEF in stress-induced senescence; c) Quantification of number of 
53BP1 foci in MEF up to six days following ionising radiation  (n=4,4,6,1 experiments); d) 
53BP1 damage foci increase with increasing doses of DNA damage in MEF at day 3 post-
irradiation (representative image); e) Quantification of number of 53BP1 foci 3 days 
following 10Gy. Data are mean ± s.e.m. of n=50-120 cells per condition. Prol – 
proliferating/proliferation. 
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To address this hypothesis, telomere labelling by FISH together with γH2A.X 
staining was performed after induction of senescence by ionising radiation. 
We saw that young cells barely had any γH2A.X foci or telomere-associated 
foci (TAF) (FIGURES 3.2a, 3.2b and 3.2e). After increasing doses of X-ray 
radiation, more damage foci were located at telomeric regions and, 
furthermore, the percentage of cells harbouring telomere-associated foci 
(TAF) increased with time (FIGURES 3.2b-3.2d). Finally, once cells are 
senescent (9 days after irradiation) a mixture of TAF and non-TAF are present 
in these cells (FIGURE 3.2e).  
To verify that DSB lesions signalled by phosphorylated H2A.X were 
preferentially enriched at telomeres ten days after 20Gy, we collaborated with 
Dr. Jelena Mann and conducted ChIP for γH2A.X along the short-arm of 
chromosome 12. This was then followed by a real-time PCR method for 
telomeric repeats previously described and validated for replicative senescent 
cells [179]. While distal regions from telomeres had very few γH2A.X 
associated to chromatin in senescence, sub-telomeric and telomeric repeats 
were highly enriched with phosphorylated histone H2A.X (FIGURES 3.2f and 
3.2g). Besides ionising radiation, also acute oxidative stress (induced by 
hydrogen peroxide) or treatment with DNA damaging drug neocarzinostatin 
induced TAF in MRC5 fibroblasts and consequently senescence (data not 
shown). 
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FIGURE 3.2| DDF occur at telomeres in stress-induced senescent human fibroblasts 
a) γH2A.X foci numbers increase linearly with increasing doses of ionising radiation  (1, 5, 
10, 20Gy). Data are mean ± s.e.m. of n=15; b) Total number of telomeric colocalizing 
γH2A.X foci (TAF) 1 day post ionising radiation  (1, 5, 10, 20Gy). Data are mean ± s.e.m. of 
n=15; c) Representative images of TAF in MRC5 fibroblasts 2, 6 and 16 days post 20Gy. 
Scale bar = 10 µm; d) Percentage of TAF up to 26 days after 20 Gy ionising radiation. Data 
are mean ± s.e.m. of n=15; e) Mean number of TAF (black) and non-TAF (red) up to 26 
days after 20Gy ionising radiation. Data are mean ± s.e.m. of n=15; f) γH2A.X is enriched at 
sub-telomeric regions of chromosome 12p after 10 days 20Gy ionising radiation. Each PCR 
reaction was conducted trice and the data are mean of two independent ChIP experiments; 
g) γH2A.X protein is enriched at telomere repeats after 10 days 20Gy ionising radiation; red 
line denotes the non-irradiated control; h) Graphs represent quantification of γH2A.X (green) 
and telomere signals (red) in selected regions of interest (dotted lines c)).  
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Telomerase is a key enzyme that synthesises and elongates telomeric 
sequences. Moreover, telomerase prevents cells to enter replicative 
senescence and extends their replicative potential [35]. Telomere shortening 
has previously been shown to be responsible for triggering a DDR when cells 
reach the end of their replicative lifespan. In order to test whether TAF were 
generated independently of telomerase presence and possibly telomere 
shortening, we over-expressed hTERT in MRC5 fibroblasts [166] and 
characterised these cells in terms of TAF presence and other senescence 
markers following treatment with X-ray irradiation (FIGURE 3.3). MRC5-
hTERT exhibited TAF after induction of senescence by ionising radiation 
likewise parental MRC5, TAF number was constant with time following 
irradiation and the majority of foci generated by ionising radiation were non-
telomeric and gradually became repaired (FIGURES 3.3a-3.3c). MRC5-
hTERT after X-ray ionising radiation still arrested irreversibly did not exhibit 
the Ki67 proliferation marker and were positive for Sen-β-Gal activity 
(FIGURE 3.3d).  
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FIGURE 3.3| TAF occur in stress-induced senescence in MRC5 fibroblasts over-
expressing telomerase (hTERT) 
a) Representative images of TAF in MRC5 fibroblasts over-expressing hTERT seven days 
after 20Gy. γH2A.X foci (green), telomeres (red), white arrows indicating colocalizing foci 
are magnified in the right panel. Graphs represent quantification of γH2A.X  (green) and 
telomere signals (red) in selected regions of interest (dotted lines). Scale bar=10 µm; b) 
Comparison between percentage of TAF in MRC5 with or without telomerase 
overexpression. Power curve (solid line) and 95% CI (dotted lines) (R=0.977, p=0.0001). 
Data are mean ± s.e.m. of n=15; c) Mean number of TAF and non-TAF in MRC5-hTERT 
fibroblasts up to seven days after 20Gy ionising radiation. Data are mean ± s.e.m. of n=15; 
d) Representative images of staining for Sen-β-Gal activity (DAPI – light blue, Sen-β-Gal 
activity – cytoplasmic darker blue) and proliferation (DAPI – blue, Ki67 – red). Scale bar=20 
µm. 
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To better understand the nature of telomere-associated foci, mouse 
embryonic fibroblasts were transfected using AcGFP-53BP1c [167] and, upon 
the initiation of a DDR, foci dynamics were monitored using live-cell 
microscopy (FIGURE 3.4). In order to scrutinise DDF at telomeres we 
conducted microbead-mediated incorporation of a fluorescently labelled 
telomere PNA probe. Due to their stability, PNA probes form PNA/DNA 
heteromultiplexes that are suitable for visualisation of telomeres over several 
hours [169].  
Comparable to what we observed by ImmunoFISH in human fibroblasts 
fibroblasts, TAF were induced and their numbers remained fairly constant 
over time in MEF following ionising radiation (FIGURE 3.4a). Additionally, 
53BP1 foci repair kinetics in MEF was similar to γH2A.X foci repair kinetics in 
human MRC5 and, MEF equally presented an unresolved DDR (TAF and 
non-TAF) in senescence (FIGURES 3.4b and 3.4c). In order to assess TAF 
persistence and reparability, live-cell imaging was performed three days post 
ionising radiation and foci-lifespan and their colocalization with telomeres was 
traced manually (FIGURE 3.4d). We observed that TAF were stable 
structures that remained present during the whole or the vast majority of the 
experiment (FIGURES 3.4d-f). In this experiment we calculated that on 
average TAF had a half-life of 90±11.9 minutes and about 50% of TAF 
survived more than six hours. Furthermore, the data highlights that non-TAF 
are the short-lived damage focus which have a half-life of 48±3.5 minutes and 
a maximal lifespan of about three hours (FIGURES 3.4d-f).  
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FIGURE 3.4| TAF are long-lived while non-TAF are transient  
a) 53BP1 TAF percentage increases with time in MEF following 10Gy ionising radiation; b) 
Mean number of TAF and non-TAF in MEF up to ten days after ionising radiation (20Gy); c) 
Telo-FISH representative images of MEFs 1, 3 and 10 days following 10Gy irradiation. 
53BP1 (green), telomeres (red) and yellow outline co-localisation (TAF). White boxes 
denotes TAF and image on the right portraits at a higher magnification of a single Z plane; 
d) Confocal life cell imaging of MEFs expressing AcGFP:53BP1 together with a PNA Cy5-
labeled telomere probe three days post-irradiation at indicated times (minutes). Images are 
maximum intensity projections. The white arrows indicate TAF which were persistent during 
the entire time series (white boxes and magnified image on the right), blue arrows represent 
short-lived non-TAF; e) Kaplan-Meyer survival curves for AcGFP:53BP1 TAF and non-TAF. 
Two hundred foci were followed belonging to 8 cells, p<0.001 – Gehan-Brelow test; f) 
Representative AcGFP:53BP1 foci tracking during 6h in MEF three days post-irradiation. 
Each line represents one single focus identified at the indicated time interval. TAF (red) and 
non-TAF (black).  
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Following the in vitro observations, we asked if telomere associated foci would 
also be present in vivo in mouse organs and, if they would accumulate 
randomly with age. The reasons why we used mice has to do with: 1) the view 
that telomeres do not play an active role in mouse senescence [174] and, 2) 
due to the fact that mouse telomeres are extremely long [175]. 
To address this, we performed immuno-FISH in liver (FIGURE 3.5g) and 
small intestine (FIGURE 3.5h) from a mice cohort ranging from 3 to 42 
months of age. In both organs we observed that TAF mean numbers per cell 
increased exponentially with age (FIGURES 3.5a. and 3.5c). Additionally, the 
percentage of foci co-localising with telomeres per cell (% TAF) also 
increased linearly on hepatocytes and on the small gut of mice with age 
(FIGURES 3.5b and 3.5d). Whilst the number of TAF increased significantly, 
damage located elsewhere in the genome (non-TAF) increased with age but 
not significantly (FIGURES 3.5e and 3.5f). Telomere shortening has been 
proposed as one source of telomere damage. Despite the fact that mice have 
huge telomeres [175], we analysed telomere length and tested whether TAF 
were preferentially at shorter telomeres. To test this, we used mean telomere 
intensity as readout for mean telomere length in both TAF and non-TAF. In 
the 36 months old intestinal crypts no significant alteration on telomere length 
was observed between TAF and non-TAF, whereas in hepatocytes, we saw a 
mild preferential location of TAF at telomeres with increased mean length 
(FIGURE 3.5i).  
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FIGURE 3.5| TAF increase with age in liver and small intestine of C57BL/6 mice 
a) Mean number of TAF per cell increases exponentially with age in hepatocytes from male 
C57BL/6 mice. Data are mean ± s.e.m. of n=3 per age group; b) Percentage of TAF 
increase linearly with age in hepatocytes from mice; c) Mean number of TAF per cells 
increases exponentially with age in the small intestine enterocytes from mice. Data are 
mean ±s.e.m. of n=3 per age group; d) Percentage of TAF increases linearly with age in 
enterocytes from mice; e) Mean number of non-TAF per cell does not increase with age in 
hepatocytes from mice; f) Mean number of non-TAF per cell does not increase with age in 
small intestinal enterocytes from mice; g) Representative immuno-FISH images of 
hepatocytes from 12-month- and 42-month-old mice. Green: γH2A.X; red: telomeres; blue: 
DAPI, Scale bar: 3µm; h) Representative immuno-FISH images in mice crypts at different 
ages (12, 36 and 42 months). Boxes indicate areas of colocalization between γH2A.X and 
telomeres (green: γH2A.X; red: telomeres; blue: DAPI; Scale bar: 20µm)(images are from 
one single Z plane); i) Histograms showing telomere intensity for telomeres colocalizing (or 
not) with DNA damage foci in both the liver and gut from 36-month-old mice; red dotted line 
represents median intensity. Mann–Whitney test shows no significant difference in telomere 
intensities distribution between TAF and non-TAF for the small gut (p=0.08) and a slight 
increase in liver telomere intensity in non-TAF (p=0.002). Intensity of 1,000 telomeres was 
analysed per condition. 
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DISCUSSION 
Telomeric damage induces the DDR  
Our data demonstrates that telomeres are hotspots for irreparable DSB. Here 
and other several reports described that telomeres are sources of senescence 
signals whether the damage was triggered by uncapped telomeres or 
genotoxic stress [14, 22]. It was previously demonstrated that telomere 
shortening trigger a normal DDR via p53, p21 and p16 [176][7] upon telomere 
uncapping. Telomere protection is regulated by the shelterin protein complex 
[180]. Removal of shelterin components induces acute phenotypes in which 
telomeres are perceived in a similar manner to genomic breaks.  
Various reports have also highlighted that not only telomere shortening can 
induce the DNA damage response.  Firstly, telomere-dependent DDR can 
occur not only due to telomere shortening, but also occur in long telomeres 
[177, 181] and in early-passage human primary cells. Additionally, replicative 
senescent cells harbour DDR+ telomeres in which TRF2 and RAP1 (two 
shelterin proteins) are still present, therefore, evidencing presence of a DDR 
and a non-fusogenic state at telomeres [48]. Although TRF2 can be present at 
telomeric double strand breaks in senescent cells, TRF1 is about ten-fold 
more prevalent in its telomeric co-localisation than TRF2 [176]. Telomere 
uncapping triggers TRF2 displacement from telomeres [182], although its 
absence is not crucial for activation of a DDR [176]. This might suggest that 
TRF2 is a potentially limiting factor that thresholds telomere damage.  
Chromosomal instability (namely anaphase bridges and metaphase fusions) 
arises whenever insufficient shelterin components such as TRF2 are not 
retained at telomere regions [182]. Uncapped telomeres spontaneously occur 
after telomere erosion and are characterised by the loss of the majority of 
shelterin proteins, and this is correlated with telomere shortening. Genetic 
expression of a TRF2 dominant negative form (TRF2∆B∆M) can also drive cells 
into senescence [182-184] via oxidative stress [28]. Unlike genomic breaks, 
uncapped telomeres do not activate the G2/M checkpoint, but rather their 
damage is transmitted to the daughter cells which activate a p53-dependent 
G1 cell cycle arrest [39]. In senescent cells Chk2 is phosphorylated at 
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telomeres probably representing that telomeres engaged on a DDR due to 
uncapping [176]. Despite this observation, more insight if this process occurs 
at the shortest telomeres or at uncapped telomeres remains an attractive 
possibility.  
 
Here we observed that human and mouse senescent cells accumulate up to 5 
or 6 TAF per nucleus, which is in agreement with recent data in which the 
accumulation of 5 G1-phase DDR-positive telomeres are sufficient to trigger 
cellular senescence mediated by p53 [48]. Previous reports have observed a 
20% co-localisation between γH2AX foci and telomeres [112], however our 
data suggests a higher percentage of TAF in senescent cells (40% in MEF 
and 40-60% in MRC5). Altogether these data contradict former reports in 
which no co-localisation was visualised between 53BP1 and TRF2 at 
telomeres following genotoxic stress [21]. 
 
Why telomeres are preferentially targeted by oxidative and genotoxic 
damage?  
Probabilistically, in order to obtain 4 or 5 TAF per cell post ionising radiation 
between 24000 and 30000 DSB would have to have been generated. Since 
this numbers hardly correspond to the reality (it is estimated that an average 
of 40 DSB are generated per Gy [185], this indicates that telomeres are 
particular susceptible to genotoxic insults and oxidative damage [42]. One 
reason could be the high abundance of guanine triplets present on the 
telomeric sequences that are highly prone to oxidative modifications [186, 
187]. A second potential explanation could be the location of telomeres within 
the nucleus. Telomeres have been shown to be associated with the nuclear 
envelope during certain phases of the cell cycle (early G1) therefore, 
presenting themselves at the periphery of the nucleus [188]. Senescent cells 
are permanently arrested at G1 [1] therefore, many of their telomeres are 
likely to be at the nuclear periphery. Also senescent cells produce elevated 
levels of reactive oxidative species which cause DNA damage [28]. Another 
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possibility could be the proposed role of oxidative stress in reducing both 
TRF2 and TRF1 binding-activity to telomeres [43].  
Very recent observations reinforce the idea that telomeres are hypersensitive 
regions to DNA damage not only during senescence. In more detail, during 
mitosis cells are very sensitive to ionising radiation because they inactivate 
DSB repair [189]. Moreover, during M-phase, DSB repair is inhibited, being 
therefore a conserved cellular mechanism in place to avoid telomere 
recombination and telomere fusions [190]. Additionally, forced activation of 
DNA repair during mitosis elicits telomere sister chromatid fusions leading to 
dicentric chromosomes and aneuploidy. This phenomenon is observed in the 
presence of exogenous genotoxic stress and is dependent on Aurora-B 
kinase [190]. This kinase has also been demonstrated to lead to telomere 
uncapping during prolonged mitosis arrest [191]. Finally the same study 
proposes that mitotic telomeres are unprotected due to Aurora B repression of 
shelterin [190].  
Altogether, telomeres work as sentinels during cellular senescence due to a 
combination of vulnerability to oxidative damage, nuclear location and 
inhibition of DSB during mitosis. 
Telomeres and sub-telomeric regions have impaired DNA damage repair  
γH2AX damage foci have the tendency to spread over adjacent areas where 
the DSB occurred [179]. In replicative senescent human BJ fibroblasts γH2AX 
have been shown to spread over 570 Kb into the sub-telomeric regions [179]. 
Similarly, our data also pinpoints that phosphorylation of H2AX increases 
when moving towards the edges of chromosomes including sub-telomeric and 
telomeric regions starting at approximately 250 Kb [179]. Telomeric single 
strand breaks and UV-induced damage are difficult to be repaired [192]. In 
yeast also sub-telomeric DSB repair is inhibited up to 0.6 Kb from telomeres 
[193]. Subtelomeres in human cancer cells have been shown to be deficient 
for DSB repair by unknown reasons [194]. Potentially these effects at 
subtelomeres are a combination of damage spread from telomeres, the 
telomere-position effect (TPE – reversible gene silencing due to telomere 
proximity) and epigenetic repression of repair mechanisms that could lead to 
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chromosomal instability (e.g. end-to-end fusions) and oncogenic 
transformation [195]. 
Cells have more stable damage at telomeres 
We observed that telomere-associated foci (TAF) are bigger than other 
genomic damage (data not shown and [3]), which matches previous 
observations in which large dimension foci are persistent in senescent cells 
[21]. Also our life-cell imaging corroborates that TAF are more stable than 
other transient damage located elsewhere in the genome. One possibility why 
TAF are bigger has been proposed to be due to aggregation of telomeres 
[48]. 
Oxidative damage as instigator of TAF formation 
A mixture of TAF and non-TAF is present in senescent cells (here) and [196]. 
Upon X-ray radiation, the percentage of TAF augments linearly with time 
suggesting that besides the original damage caused by radiation at telomeres, 
there is another motile force to induce TAF formation in cells. Prior work had 
shown by live-cell imaging that focus lifespan increased in both replicative 
senescence and irradiation-induced senescence of human fibroblasts [178, 
197]. Under these conditions, half of all DDR foci were short-lived and 
dependent on oxidative stress [28]. Using life-cell imaging we show that TAF 
in MEF are long lived while the short-lived ones are transient (and likely to be 
ROS-dependent). Preliminary data from our group using the antioxidant N-
acetyl cysteine (NAC) immediately after irradiation does not prevent the 
accumulation of TAF in MRC5 until day 3, pointing out that ROS scavenging 
for a short period of time does not prevent TAF generation. Despite the fact 
that TAF are not reduced in vitro under short antioxidant treatment, short-lived 
non-telomeric damage was strongly inhibited (data not shown). Overall, this 
negative result does not invalidate a role of ROS on TAF formation especially 
in vivo (discussed below). Besides oxidative stress, in OIS genome hyper-
proliferation causes replication forks stalling and hinges full telomere DNA 
replication causing TAF [49]. In contrast, irreparable damage at telomeres can 
be irrespective of telomere length and cell proliferation (here and in [3, 4]). 
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 Does telomerase counteract telomere dysfunction in senescence? 
In our hands, primary cells over-expressing telomerase once exposed to X-
ray radiation arrested and were positivity for Sen-β Gal activity.  Similarly, 
d’Adda di Fagagna has equally demonstrated that MRC5 overexpressing 
hTERT became senescent following X-ray irradiation and harboured 
senescent markers including Sen-β-Gal positivity [173]. Whilst we report that 
human MRC5 fibroblasts over-expressing telomerase have TAF, previous 
observations in another human primary fibroblast strain immortalised with 
hTERT no TIF were found [176]. A potential difference was that while we 
cultures our MRC5-hTERT at atmospheric oxygen conditions, Herbig et al. 
cultured their LF1 fibroblasts at hypoxic conditions (2% O2)[176]. Could be 
this differences between TAF and TIF in hTERT over-expressing cells be due 
to oxidative stress? More explicitly, hTERT expression and transcription is up-
regulated in vivo under hypoxic conditions via HIF-1a (reviewed in [198]). The 
presence of TAF in MRC5-hTERT cells reinforces the hypothesis that not only 
short telomeres can trigger a DDR. This matches the observations that 
hTERT expression does not stops stress-induced premature senescence 
(SIPS) and hence, senescence can be engaged independently of telomere 
attrition [199, 200]. More mechanistic insight will be required to understand 
why hTERT overexpressing cells have TAF but not TIF. Again telomere 
structural state, presence of shelterin components (such as TPP1) and a free 
telomere loop (t-loop) might influence hTERT activity and its recruitment to the 
telomere ends (reviewed in [201]). 
TAF are biomarkers of senescence  
DNA damage is seen at telomeres of non-proliferating baboons’ neurons, 
hepatocytes from mice and in baboons’ skin fibroblasts [3, 4, 51]. Telomere 
damage bulked-up with age in mice liver and intestine and does not correlate 
with telomere length. Shelterin components are still present together with TAF 
that are not the shortest of telomeres (R. Anderson) there questions the 
dogma that only the shortest telomeres set a DDR. Non-telomeric damage 
(non-TAF) tends to increase with age, but not to significant levels, suggesting 
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therefore that this kind of DSB might have faster repair and turnover rates 
than those at telomeres.  
We observe that TAF number and percentage that accumulate with age are 
more drastically seen in the gut (high proliferative tissue) rather than in liver 
(which is largely a post-mitotic tissue). Indeed, TAF are also increased in the 
transient-amplifying cells of the gut that have a high mitotic index (data not 
shown), suggesting a role for DNA replication in TAF generation, possibly due 
to the mitotic inhibition of telomere repair proposed in vitro [190].  
Cellular senescence can function as a tumour suppression mechanism. 
Although TAF can be used as a biomarker of senescent cells and as a 
predictor of mean and maximum lifespan of long-lived mice cohorts [50], this 
marker’s robustness in cancer is weak [49]. In vivo, TAF are observed in 
melanocytes of benign- and dysplastic-neavi, epithelial cells of precursor 
lesions to breast- and colon- cancers but, are absent in melanoma, colon- and 
breast carcinoma [49]. Oncogenic signals trigger hyper-proliferation, 
replication forks stalling and aleatory completion of telomere DNA replication 
[49]. Telomere damage independent of length has therefore roles in tumor 
suppression [49]. Furthermore, telomere length independent roles of 
telomerase in tumour progression can also be observed since over-
expression of TERT cannot bypass TAF induction by irradiation, 
chemotherapy induced DNA damage (using neocarzinostatin) or hydrogen 
peroxide [3].  
Similarly to Herbig’s data [49], we observe that mouse liver treated with the 
carcinogenic agent diethylnitrosamine (DEN) do not have TAF in the cancer 
areas but, only on the adjacent non-tumorigenic tissue (observation by Diana 
Jurk). This perhaps supports the idea that genomic instability at telomeres 
might be a requisite for cellular transformation and, additionally, senescent 
cells that repair their telomeric damage or, that may lose their telomere 
integrity might be able to bypass senescence.  
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Perspectives 
Can telomeres trigger a DDR with shelterin components still present? Roger 
Reddell’s and Jan Karlseder’s groups have put forward a model in which 
telomeres can be adopt three differential protective states that regulates 
distinct cellular functions [202]. In more detail, telomeres adopt a closed-state 
that prevents the DDR activation via insulation of the chromosome end within 
the telomere loop (T-loop) [32]. An intermediate stage can be observed once 
cells reach their replicative lifespan or, in cells with insufficient insulation of 
telomeres by sheltering components leading to exposure of chromosome 
termini and elicitation of a DDR. Overall, more experiments have to be 
conducted to verify which shelterin components and their abundance play a 
role in protecting telomeres effectively from damage. 
 
In summary, telomeres seem to be more vulnerable to DNA damage and, 
therefore, they may act as sentinels to oxidative- and genotoxic- stress 
mediated DNA damage within senescent cells. 
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CHAPTER 4 – MITOCHONDRIAL BIOGENES IS CRUCIAL FOR THE 
INDUCTION AND DEVELOPMENT OF THE SENESCENT PHENOTYPE 
VIA THE mTOR PATHWAY 
 
INTRODUCTION 
According to the endosymbiotic theory, mitochondria are derived from an 
ancestral α-proteobacteria that was incorporated into the eukaryotic cell [203]. 
With time, mitochondria have gradually transferred its genes to the nuclear 
genome. Nowadays, the mitochondrial genome is characterized for having 
only 37 genes which 13 of those encode some components of the respiratory 
chain, 2 ribosomal RNAs and several tRNAs. Besides ATP generation, 
mitochondria play important roles many cellular processes like metabolisms, 
development, apoptosis and ageing [204]. Mitochondria have been also 
implicated in cellular senescence through its capacity to produce reactive 
oxygen species (ROS), which impinge on random molecular damage. More 
precisely, mitochondrial ROS promotes genomic damage [174], accelerates 
telomere erosion [6] and sustain signalling pathways necessary for the 
maintenance of the senescent arrest active [28]. Controlling mitochondria 
numbers is a complex balance between biogenesis [89], fusion and fission 
[92] and mitophagy [91], which might have serious repercussion on disease 
(such as neurodegenerative diseases) [87]. Although increased mitochondrial 
biogenesis is benefic in settings of exercise resistance and endurance, for 
instance, mitochondria over-proliferation was described to promote 
cardiomyopathy in mice [205]. Mitochondria biogenesis is an intricate process 
regulated by the PPAR gamma co-activator-1 (PGC-1) family of nuclear 
transcriptional co-activators, which have a critical role on the control of lipid, 
glucose and energy metabolism. Three main PGC-1 isoforms are known: 
PGC-1α, PGC-1β and PPRC (PGC-1-related co-activator)[206]. Wu and 
colleagues demonstrated that PGC-1α co-activates nuclear respiratory factor 
1 (NRF1) and -2 (NRF2)[207]. NRFs regulate expression of mitochondrial 
transcription factor A (mtTFA/TFAM), a nuclear-encoded transcription factor, 
essential for replication, maintenance and transcription of mitochondrial DNA 
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[208-212]. Besides PGC-1α, PGC-1β is critical for a normal mitochondrial 
gene program and thought to regulate basal mitochondrial biogenesis levels 
[213, 214] in cells and in a variety of tissues [207, 215, 216]. Despite the wide 
literature available on PGC-1α and mitochondrial biogenesis the role of PGC-
1β-mediated mitochondria biogenesis is far less known. Overall, mitochondria 
content within cells have been hypothesised to be an important factor 
underlying cellular senescence [217].  
 
Besides formation of new mitochondria, mitochondria content within cells is 
also regulated by autophagy. Autophagy is a homeostatic cellular process that 
eliminates old or malfunctioning proteins and organelle in the cellular 
cytoplasm. Furthermore, this recycling process allows the release of nutrients 
for cellular functions. During metabolic challenge, autophagy assumes key 
roles on cellular survival. The autophagic process can be categorized 
depending on the nature of the cargo degraded. Macroautophagy (commonly 
referred as autophagy) describes the mechanism by which cytoplasmic 
components (proteins and organelles) are engulfed in double-/multi-vesicular 
bodies – autophagosomes – and their posterior delivery to lysosomes for 
large scale degradation [218]. The molecular biology behind the autophagic 
process started with the discovery of the Atg (autophagy) genes in yeast in 
the early 1990's [219]. Atg5 protein is a major component of the canonical 
autophagy pathway being involved on the formation of the autophagosome 
membrane and it localizes preferentially on the cytoplasmic side of the outer 
limiting membrane. The Atg5-Atg12-Atg16 polymer has coating functions that 
aids the autophagosomal membrane curvature [220]. Cells without Atg5 have 
a compromised autophagy and have been shown to accumulate dysfunctional 
mitochondria [98]. 
 
Besides the role autophagy on mitochondrial dysfunction and senescence, 
mitochondrial morphology and numbers regulation by fission and fusion 
events were also shown to contribute to cellular senescence [96, 221]. In 
more detail, decreased mitochondrial fission by hFIS1 lead to excessive 
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mitochondrial elongation. This sustained mitochondrial elongation was then 
associated with increased ROS, decreased mitochondrial membrane potential 
and DNA damage. Additionally, cells in which hFIS1 was silenced are 
morphologically similar to senescent cells in terms of its morphology, in other 
words, they are large, flat, and had increased cellular granularity. Besides 
this, cellular proliferation was significantly reduced and cells were positive for 
Sen-β-Gal activity. Finally this study showed that silencing of hFIS1 or OPA1 
(a protein required for mitochondrial fusion) could rescue the above-
mentioned senescent markers. Altogether, this data highlight the importance 
of mitochondrial fusion and fission balance in cellular senescence [96]. 
 
 
 
 
 
AIMS 
Despite the fact that mitochondria is known to be contribute to cellular 
senescence, the molecular pathways linking mitochondrial homeostasis 
during cellular senescence are less understood. Based on this, we sought to 
investigate: 
• If mitochondria biogenesis does plays a role during cellular senescence 
• If impaired mitochondrial clearance (via autophagy) impacts on the 
senescent phenotype 
• Does the mTOR pathway play a role in the induction and/or in the 
maintenance of stress-induced cellular senescence via mitochondria 
dysfunction? 
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RESULTS  
 
I. Inhibition of the mTOR pathway reduces senescence markers 
Senescent cells are phenotypically hypertrophic compared to young cycling 
cells [14]. Likewise, we see that primary human and mouse fibroblasts 
increased their size as a consequence of extensive replication or, of the 
activation of the DDR that would culminate in senescence (FIGURES 4.1a-
4.1c). Cellular growth can be coordinated by the mTOR pathway [222]. We 
observed mTORC1 activation during early stages of senescence induction in 
human fibroblasts (FIGURE 4.2a). To address a potential role of the mTOR 
pathway in modulating cellular senescence we devised a series of 
experiments in which this pathway was targeted either chemically or 
genetically. Based on previous data from our group in stress-induced 
senescence on MRC5 cells, we chemically inhibited mTORC1 activity using 
100nM of rapamycin since this concentration fully ablated mTORC1 activity 
(FIGURE 4.2a). Following this intervention, both human and mouse 
embryonic fibroblasts in stress-induced or replicative senescence were 
analysed for senescence markers including DNA damage foci, ROS, Sen-β-
Gal positivity, mitochondrial mass and cell size (FIGURES 4.2, 4.3 and 4.6).  
 
Consistent with the observation that mTORC1 activity was increased following 
20Gy and that rapamycin decreased fully mTORC1 activity (FIGURE 4.2a), 
human MRC5 treated with rapamycin were smaller than control irradiated 
cells, were more elongated and looked similar to young fibroblasts (FIGURE 
4.2b).  
 
The DNA damage response is one trigger and effector pathway of cellular 
senescence. We noticed that γH2A.X damage foci were significantly reduced 
on cells treated with rapamycin from day 3 post-irradiation but, not prior to that 
time point (FIGURES 4.2c and 4.2d). Additionally, using an alkaline COMET 
assay (which identifies DNA double-strand breaks - DSB and single-strand 
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breaks - SSB) we confirmed that rapamycin treatment hinders DNA damage 
accumulation at those time points (data not shown). Lastly, we saw reduction 
of p21 protein and mRNA levels upon mTORC1 inhibition (ANNEX 1). 
Regarding proliferation, rapamycin reduced proliferation of young cells 
(perhaps leading to quiescence) and, did not rescue proliferation of stress-
induced senescent cells (FIGURE 4.2e). Surprisingly, inhibition of mTORC1 
for three days following irradiation with rapamycin and, subsequent removal of 
rapamycin lead to a 15% rescue in cellular proliferation at day ten (ANNEX 1). 
Increased mitochondrial content and reactive oxygen species are another two 
features of senescent cells. In X-ray irradiated cells both markers were 
reduced once mTORC1 was inhibited by rapamycin (FIGURES 4.3d, 4.8 and 
4.10).  
 
Additionally, data from our group has demonstrated that in irradiation-induced 
senescent MRC5 fibroblasts pro-inflammatory IL-6 protein levels were 5-fold 
decreased after nine days upon rapamycin treatment (ANNEX 1). Besides IL-
6 and while performing a cytokine mRNA array, we saw that mTORC1 
inhibition stopped the majority of the SASP components expression including 
IL-8, GRO-α, TNF-α, IFN-γ but, had hardly any effect on IL-1α or IL-1β 
(ANNEX 1). Finally, also Sen-β-Gal positivity was reduced using rapamycin 
during stress-induced senescence (ANNEX 1).  
 
Similarly to the aforementioned phenotype in MRC5, primary mouse 
embryonic fibroblasts (MEF) increased mTORC1 activity following ionising 
radiation and, when MEF were treated with 100nM of rapamycin mTORC1 
activity was fully ablated (FIGURE 4.3a and data not shown). Senescence-
associated markers were reduced including: cell size (FIGURE 4.3b), 
mitochondrial mass (FIGURE 4.5a) and ROS levels (FIGURE 4.3d). 
Additionally, 53BP1 damage foci, p21 protein levels and Sen-β-Gal positivity 
were diminished following rapamycin treatment (FIGURES 4.3c, 4.3e and 4.3f 
respectively). 
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Overall, this data places the mTOR pathway as a central mediator of the early 
events that drive the senescent phenotype. 
 
In order to strengthen the argument that mTORC1 is involved in senescence, 
we used human embryonic kidney (HEK293T) cells containing a doxycycline-
inducible short-hairpin RNA construct against either TSC1 or TSC2 (FIGURE 
4.4a). Knockdown (KD) efficiency and expression levels were both 
determined by the percentage of cells expressing the shRNA (GFP – 
positivity)(FIGURE 4.4b) or by western blot (FIGURE 4.4c). Doxycyclin-
induced cells showed enhanced constitutively active mTORC1 activity and 
increased cell size (FIGURES 4.4d and 4.4e). Phenotypically these 
hypertrophic cells had more γH2A.X damage foci and higher levels of p21 
protein upon TSC2 silencing (FIGURES 4.4h and 4.4g). Upon TSC2 KD, cells 
had enhanced ROS and higher levels of the mitochondrial biogenesis 
regulator PGC-1β (FIGURES 4.4f and 4.4i). These preliminary results 
suggest that mTORC1 hyper-activation by TSC2 silencing leads to the 
appearance of some senescence markers. 
 
Besides TSC2 silencing, we also constitutively activated mTORC1 using a 
mutated form of the GTPase Rheb - RhebN153T - in primary mouse 
fibroblasts (MEF)(FIGURE 4.5). In terms of cell size we saw an increase 
(FIGURE 4.5a), which did matched with the increased mTORC1 activity 
(FIGURE 4.5b). In proliferating conditions, MEF expressing RhebN153T show 
declined Ki67 levels (FIGURE 4.5c), increased synthesis of mitochondrial 
proteins (VDAC and TOMM20)(FIGURE 4.5d). Furthermore, more DNA 
damage foci were detected under concurrent activation of the DDR and 
RhebN153T-mediated mTORC1 activation (FIGURE 4.5e). Finally, 
RhebN153T expression lead to increase fraction of cells positive for Sen-β-
Gal (FIGURE 4.5f). 
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In order to address a potential role of mTORC1 on the maintenance of cellular 
senescence we treated replicative senescent (RS) cells with rapamycin. 
Firstly we observed that senescent cells halved their cell following three days 
treatment and remained small during the whole experiment (FIGURE 4.6a). 
Following three days treatment we detected a reduction of mitochondrial mass 
but not superoxide levels (FIGURE 4.6c). Only at day ten of chronic 
rapamycin use we noticed less ROS levels (FIGURE 4.6b). Although no 
differences were seen in terms of 53BP1 foci upon rapamycin treatment, the 
number of Sen-β Gal positive cells significantly declined by day ten (ANNEX 
1). Furthermore, we saw a decline of mitochondrial DNA copies (mtDNA) 
upon mTORC1 inhibition (FIGURE 4.6d). We also preliminary observed that 
in RS cells, rapamycin was unable to fully abrogate mTORC1 activity 
(personal communication from B. Carroll and V. Korolchuk). Finally, nutrient 
starvation (which normally halts mTORC1 activity) was also not effective in 
fully abolish mTORC1 activity (in collaboration with B. Carroll and V. 
Korolchuk - [223]. These findings indicate perhaps that the mTOR nutrient 
signalling pathway becomes deregulated during cellular senescence. 
 
Altogether, mTORC1 activity is changed during cellular senescence and this 
pathway is required for the sustainability of certain senescent traits such as 
ROS, high mitochondrial mass, DNA damage, increased cell size, Sen-β-Gal 
positivity and the senescence secretome (SASP/SMS). 
 
II. The DDR is linked to mitochondrial biogenesis via the mTOR 
pathway 
Mitochondrial mass increase has been observed in replicative and oncogene 
induced senescence [59, 76]. In order to investigate the link between the DNA 
damage response (DDR) and the mitochondrial increase we initially triggered 
a DDR using ionising radiation, oxidative stress (with H2O2), telomere 
uncapping, chemotherapeutic or DNA damaging drugs in a wide panel of 
mouse and human primary and cancer cells. A mitochondrial mass increase, 
between two- and four-fold was observed (FIGURE 4.7a). 
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Further work conducted in the lab has demonstrated that kinetically, 
mitochondrial proteins (e.g. NDUFB8, SDHA, UQCRC2 and TOMM20) 
expression and mitochondrial mass peaked between day one and three after 
ionising radiation. Both in human and primary mouse fibroblasts, we saw that 
the mitochondrial increase was linearly correlated with the dose of X-ray 
irradiation and consequently with the number of DDF (FIGURES 4.7b, 4.7c 
and 4.13g). Another positive correlation was seen between mitochondrial 
mass and positivity for Sen-β-Gal activity. Both in MRC5 and in MEF we 
observed two negative correlations between mitochondrial mass increase and 
proliferation, and between mitochondria mass increase and decreased p21 
levels (data not shown). In order to confirm that mitochondrial numbers and 
volume fraction increased following X-ray irradiation, similarly to what was 
previously described in replicative senescence [59], we used transmission 
electron microscopy (TEM). Using this technique we observed increased 
mitochondrial number and volume fraction three days following irradiation 
(FIGURE 4.7d). Additionally, we saw that mitochondria DNA copy number 
was also increased following activation of a DDR in 3 different cell lines: MEF, 
MRC5 and HEK293T cells (FIGURE 4.7e). 
 
Reactive oxygen species (ROS) and mitochondrial mass increased in parallel 
following activation of the DDR. Moreover, when ROS levels were normalised 
per mitochondrial mass unit there was no change (however one should keep 
in mind that there is an increased number of mitochondria in senescence). 
Together with this, addition of PBN or NAC quenched the ROS levels per cell 
but unaffected mitochondrial mass during stress-induced senescence 
(FIGURE 4.7f). 
 
Previously, we observed that inhibition of mTORC1 with rapamycin led to 
decreased mitochondria mass in MRC5 and MEF. In order to verify that the 
effects of rapamycin were not constrained to ionising-radiation-induced 
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senescence in MRC5 and MEF, we took all the cell lines depicted in FIGURE 
4.4a and we treated them with rapamycin immediately after the multiple 
senescence triggers. We realised that mTORC1 inhibition induced a universal 
response by reducing mitochondrial mass (FIGURE 4.8a). This was further 
confirmed used MitoTracker Green or immunostaining against mitochondrial 
protein SDHA (FIGURES 4.8b and 4.8e). Additional work conducted in the lab 
has demonstrated by western blot that mitochondrial proteins of different 
complexes of the electron-respiratory chain (NDUFB8 – CI, SDHA – CII, 
UQCRC2 – CIII, MT-CO1 – CIV) and TOMM20 were decreased following 
rapamycin treatment. Using TEM we also saw that irradiated MRC5 treated 
with rapamycin had fewer mitochondria (FIGURE 4.8c). Moreover, both 
MRC5 cells and primary MEF under rapamycin conditions had fewer 
mitochondrial DNA copies (FIGURES 4.8d and 4.8f respectively). Finally, 
addition of rapamycin does not change the ratio between ROS and 
mitochondrial mass (FIGURE 4.8g). 
 
Next, we aimed to dissect links between the DDR towards mitochondrial mass 
via mTORC1. Whilst examining the literature available [224, 225], we 
hypothesised that the mechanism could be a phosphorylation cascade from 
ATM towards AKT and, from AKT towards mTORC1. Firstly, after induction of 
a DDR we inhibited ATM kinase and mTORC1 chemically alone or jointly. We 
then proceeded to analyse mitochondria mass by FACS, γH2A.X foci, p21 
and SA-β-Gal positivity and we observed that both single and double 
inhibitions provided the same outcome, suggesting that these two signalling 
nodes are connected with no further cumulative effects (Rhys Anderson – 
ANNEX 2). Furthermore in MRC5, inhibition of ATM lead to decreased 
phosphorylated AKT (S473), less phosphorylated p70S6K1 (a direct readout 
for mTORC1 activity), less p21 and less NDUFB8 protein levels (data not 
shown). Irradiated HEK293T cells treated with ATM inhibitor Ku55933 lead 
likewise to a reduction of phosphorylated p70S6K1, p21 and mitochondrial 
VDAC protein levels (FIGURES 4.9a-4.9c). Of note, triple inhibition of PI3K, 
mTORC1 and mTORC2 by LY294002 led similarly to a reduction of 
mitochondrial mass in senescence (data not shown). 
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After establishing this link, we focused on the downstream mechanism of 
mTORC1 that would be interfering with mitochondrial content. We started 
looking into autophagy, a known process that recycles damaged organelles 
and proteins. The rationale behind this was that mTORC1 inhibits autophagy 
[226], hence inhibiting mTORC1 with rapamcyin would promote autophagy, 
therefore being a mechanism for the reduction of mitochondrial content 
observed whenever mTORC1 was inhibited. 
 
To address this, we used ATG5 knockout (KO) MEF that have defective 
autophagy (for instance lacking LC-3 an essential protein for the 
autophagosome formation)(FIGURE 4.10a). Prior to induction of a DDR, Atg5-
null and wild-type (WT) MEF showed no differences in terms of size, number 
of DDF, ROS or mitochondrial mass levels. After activation of a DDR by 
ionising radiation we observed that ATG5 knockout MEFs had more 53BP1 
damage foci, had higher ROS and higher mitochondria mass levels compared 
to matched wt control MEF (FIGURES 4.10b and 4.10c). Additionally, Atg5 
KO MEF had significantly larger surface areas than wild-type controls 
following IR (at three and six days after X-ray irradiation)(FIGURE 4.10b). To 
address if mitochondrial mass decrease observed by rapamycin treatment 
was dependent on autophagy, we treated both cell lines with rapamycin three-
days following X-ray radiation (FIGURE 4.10c). We observed that both ROS, 
53BP1 foci and mitochondrial mass were significantly reduced in both cell 
lines upon mTORC1 inhibition (FIGURE 4.10c), suggesting that the effects of 
rapamycin observed at 3 days after X-ray irradiation are not solely dependent 
on activation of autophagy.  
Cellular autophagic activity can be assessed by the autophagic flux analysis. 
This process comprises the autophagosome synthesis, the delivery of the 
autophagic substrates to the lysosome and the degradation of the autophagic 
substrates (LC3-II and p62) inside the lysosome [227]. If there is a blockage 
on autophagy LC3-II and p62 accumulate. Work done in the lab by Graeme 
Hewitt showed that the autophagic flux seems not to be altered on the first 
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days following activation of the DDR by X-ray radiation. This data indicates 
that the increased mitochondrial content on the early stages after activation of 
a DDR, are likely not a consequence of impaired mitochondrial degradation, 
but rather, activation of mitochondrial biogenesis. 
 
III. PGC-1β mitochondrial biogenesis is essential for cellular senescence 
Based on the previous results we hypothesised that maybe the formation of 
new mitochondria (biogenesis) was being affected by mTORC1. Firstly we 
started to look into two master-regulators of mitochondrial biogenesis – PGC-
1α and PGC-1β – mRNA and protein levels following a DDR.  
 
After we induced senescence by X-ray irradiation in MRC5 human fibroblasts, 
and following the induction of a DDR, we observed increased protein and 
mRNA levels of PGC-1α and increased PGC-1β mRNA levels. That increment 
was halted once rapamycin was added (FIGURES 4.11a-4.11c).  Secondly, 
we analysed wild-type MEF and following induction of a DDR we saw 
increased PGC-1α and PGC-1β (FIGURES 4.12a and 4.12b). Finally, we 
observed increased mRNA levels for both co-transcriptional factors PGC-1α 
and PGC-1β once cells became senescent (FIGURE 4.12c). 
 
Additionally, hyper-activation of mTORC1 by TSC2 silencing (FIGURE 4.4e) 
lead to increased p21 levels (after three days after doxycycline addition) and 
increased levels of PGC-1β (at ten days after doxycycline addition) and 
(FIGURES 4.4g and 4.4i).  
 
Since we saw that mitochondria biogenesis was being affected downstream of 
the mTOR pathway and, once this pathway was able to modulate the 
senescent phenotype, we made several working hypothesis:  
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1. Does mitochondria biogenesis impact on the senescent phenotype via 
ROS?  
2. Are there cumulative effects between mitochondria biogenesis and the 
mTOR pathway? 
 
To test the first question we used multiple systems that would manipulate 
mitochondrial biogenesis and mitochondrial content within cells. Those 
included decreasing mitochondrial biogenesis using PGC-1β KO MEF, 
increasing mitochondrial biogenesis by over-expression of PGC-1β and, 
increasing mitochondrial content and TCA cycle usage by pyruvate addition 
(this Chapter and Chapter 5).  
 
Primary PGC-1β KO and wild-type matched MEF were induced to become 
senescent using either ionising radiation or by culturing under normoxic 
conditions (following the rational that MEF under atmospheric oxygen 
conditions became senescent) [174].  
 
Firstly, we confirmed that MEF lacking PGC-1β had less mitochondria and, 
that mitochondrial biogenesis was impaired on these cells following 10Gy. 
This was achieved by using either Mitotracker Green staining, by flow 
cytometric analysis – NAO staining, by mtDNA copy assay, and by WB 
against VDAC (FIGURES 4.13a-4.13d). Furthermore, PGC-1β KO MEF were 
unable to increase SDHA expression back to wild-type control levels upon 
increased doses of ionising radiation (FIGURE 4.13e). Furthermore, we found 
no compensatory effects of PGC-1α in PGC-1β-null MEF following ionising 
radiation (FIGURE 4.13f). Finally, a very strong correlation between DNA 
damage (53BP1 numbers) and mitochondrial mass was observed in wild type 
and PGC-1β KO MEF (FIGURE 4.13g).  
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Besides mitochondrial content being altered, also senescence markers were 
changed among which were 53BP1 DDF, p21 and p16 levels, proliferation, 
Sen-β-Gal and reactive oxygen species (FIGURE 4.14). Regarding the DNA 
damage response, we observed that in PGC-1β KO MEF 53BP1 damage foci 
were reduced so were p21 (a downstream target of p53) levels (FIGURES 
4.14a and 4.14b). Finally, p16 mRNA levels were also dampened nine days 
post-irradiation (once cells became senescent)(FIGURE 4.14c).  
 
In the case of proliferation we observed that while wild-type MEF arrested, 
there was about 20% of PGC-1β KO MEF still cycling at day three (FIGURE 
4.14e) and circa 5% were still proliferating at day nine after 10Gy (data not 
shown). Together with this, we saw that the percentage of PGC-1β KO MEF 
positive for Sen-β-Gal activity (at day nine and day fifteen after ionising 
radiation) was reduced compared to matched wild-type controls (FIGURE 
4.14h and data not shown). Of note, we also noticed that pro-inflammatory 
chemokine CXCL1 (or GRO-α) was reduced in PGC-1β KO MEF nine days 
following irradiation, indicating perhaps that the senescence-associated 
secretory phenotype (SASP) might also be down-regulated in these cells 
(data not shown). Finally, we saw a reduction of ROS in PGC-1β KO MEF 
both in proliferating or following ionising radiation when compared to wild-type 
cells (FIGURE 4.14f).  
 
Based on these results we thought that perhaps the antioxidant defence 
mechanisms could explain the lower ROS levels observed. To address this, 
we probed for superoxide dismutase 2 (enzyme responsible for the 
conversion of superoxide into hydrogen peroxide). The rationale for looking 
into SOD2 has to do with the fact that SOD2 is a know target of PGC-1α 
[228]. Another reason is because it was recently proposed that SOD2 can be 
up-regulated in certain keratinocytes cell lines upon rapamycin treatment 
[229]. While wild-type MEF increased mitochondrial SOD2, in PGC-1β KO 
cells SOD2 expression did not increased following irradiation (FIGURE 4.14g) 
suggesting perhaps, that the decreased ROS levels seen on PGC-1β KO 
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MEF cannot be explained by up-regulation of ROS-detoxifying enzymes such 
as SOD2.  
 
Having established that PGC-1β-driven mitochondrial biogenesis impacted on 
cellular senescence we conducted experiments in which this biogenesis 
orchestrator was enhanced and we proceeded to characterise those 
transfected cells in terms of senescence markers. Firstly, we acquired a 
mouse PGC-1β plasmid (FIGURE 4.15a) and we checked by restriction 
enzyme analysis if the construct was correct (FIGURES 4.15b and 4.15c). 
Then we proceeded to transfect MEF and we verified that PGC-1β protein 
was being expressed (nuclear staining)(FIGURES 4.15d and 4.15e). Finally, 
mitochondrial SDHA protein levels were augmented upon PGC-1β 
transfection (FIGURE 4.15f), validating therefore the system. Besides SDHA, 
also mitochondrial mass and ROS levels were also enhanced (FIGURES 
4.16a and 4.16c). In terms of DNA double stranded breaks, we saw higher 
numbers of 53BP1 foci (FIGURE 4.16c). Together with this, pro-inflammatory 
IL-6 mRNA levels increased upon PGC-1β over-expression (FIGURE 4.16e – 
preliminary data). Lastly, we observed that enhancement of mitochondrial 
biogenesis lead to a premature cell cycle arrest (FIGURE 4.16d) and 
increased number of cells positive for Sen-β-Gal activity (at day six post-
irradiation)(FIGURE 4.16e). 
 
In order to verify if ROS was one of the signals emanating from mitochondria 
that would trigger DDF, we over-expressed PGC-1β and treated those cells 
with the antioxidant Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-
carboxylic acid)(FIGURES 4.16g and 4.16h). To test the antioxidant effects of 
this drug, we measured ROS by DHE fluorescence after X-ray irradiation and 
observed a reduction in ROS levels upon Trolox administration (FIGURES 
4.16g). Finally, Trolox reversed the 53BP1 damage accumulation derived 
from PGC-1β over-expression (FIGURE 4.16h). 
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Following this data, we subjected PGC-1β KO MEF to 21% oxygen (settings 
that lead to induction of senescence as opposed to 3% oxygen, in which MEF 
can grow indefinitely – [174]. Under high oxygen conditions, PGC-1β KO cells 
grew better than wild-type MEF (FIGURE 4.17a) and senesced slower – 
evaluated by increased p21 levels (FIGURE 4.17b), more 53BP1 DDF 
(FIGURE 4.17c), increased mitochondrial mass (FIGURE 4.17d), higher ROS 
levels following 4 day and 22 days at 21% O2 (FIGURE 4.17e), increased 
autofluorescence levels (FIGURE 4.17f) and increased number of cells 
positive for Sen-β-Gal activity (FIGURE 4.17g). Finally, PGC-1β KO cells 
were smaller than WT controls (data not shown).  
 
Having seen that PGC-1β KO MEF were smaller, and once cell size is 
regulated by the mTOR pathway, we investigated if there were additive effects 
of inhibition of mTORC1 and mitochondrial biogenesis (FIGURE 4.18). Firstly 
we saw that PGC-1β KO MEF had reduced mTORC1 activity after activation 
of the DDR by 10Gy (FIGURE 4.18a). Secondly, we did not see cumulative 
effects for 53BP1 foci nor for positivity for Sen-β-Gal activity when rapamycin 
was added to PGC-1β KO cells following ionising radiation (FIGURES 4.18b-
4.18d). Regarding mitochondrial content, we saw a small reduction of 
mitochondrial mass between PGC-1β KO rapamycin treated MEF and control 
cells (FIGURE 4.18 preliminary data). More experiments need to be made in 
order to confirm this result, and to verify if the effects of rapamycin reducing 
mitochondrial on PGC-1β KO MEF are due to reduction of PGC-1α or 
promotion of mitophagy. In opposition, we realised that RhebN153T over-
expression in PGC-1β KO MEF was not able to promote 53BP1 foci increase 
that was observed on wild-type MEF (FIGURE 4.18f).   
 
Overall this data indicated that PGC-1β-mediated biogenesis is a key process 
in the induction and stabilisation of the senescent phenotype via ROS. 
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FIGURE 4.1| An activated DDR drives cell growth and increased mTORC1 activity  
a) MRC5 fibroblasts increase size during stress-induced senescence. Vertical dashed lines 
represent the median cell size - proliferating=0.30, 2 days 20Gy=0.60, 5 days 20Gy=0.95; Mann-
Whitney test p-value<0.001; b) Cell size of young (grey) and replicative senescent MRC5 (red). 
One-way ANOVA p-value<0.001; c) Primary MEF increase their size following activation of the 
DDR. Vertical dashed lines denotes the median cell size – proliferating = 604 cells, 3 days 10Gy 
= 982 cells, 6 days 10Gy=1263 cells; Mann-Whitney test p-value<0.001 (proliferation versus 3d 
10Gy) and p-value<0.05 (3d 10Gy versus 6d 10Gy). 
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FIGURE 4.2| Rapamycin inhibits mTORC1 and decreases the presence of senescence 
markers in stress-induced senescent human fibroblasts 
a) Representative WB showing absence of mTORC1 activity upon 100nM rapamycin and 
increased mTORC1 activity following activation of the DDR; b) Rapamycin inhibition of 
mTORC1 decreases cell hypertrophy characteristic of senescence. Dotted line represent 
average cell size - proliferating=0.30, 2 days 20Gy=0.60, 2 days 20Gy and rapamycin 
treatment=0.32, 5 days 20Gy=0.95, 5 days 20Gy and rapamycin treatment=0.38. Mann-
Whitney test p-value<0.001; c) Kinetics of γH2A.X foci repair in MRC5 after irradiation in the 
presence of rapamycin; d) Rapamycin treated MRC5 have fewer γH2A.X during stress 
induced senescence at day 3 and 10 post-irradiation; e) Rapamycin diminishes proliferation 
of young MRC5 and does not rescue proliferation of senescent cells (time-point analysed 
was three days following ionising radiation). One-Way ANOVA p-value<0.05. 
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FIGURE 4.3| Rapamycin inhibits mTORC1 activity and decreases the presence of 
senescence markers in stress-induced senescent mouse fibroblasts (MEF) 
a) mTORC1 activity is increased on the first 3 days following activation of a DDR in primary 
mouse fibroblasts (representative WB measuring p70S6K (T389)); b) MEF increased size in 
response to a DDR and, rapamycin treatment halts cellular size increase. One-Way ANOVA p-
value<0.05; c) 53BP1 damage foci are reduced upon mTORC1 inhibition by rapamycin (n=3, 
at least 125 cells analysed per condition)(two-tailed T-test, p-value<0.05); d) ROS levels 
increase as response to a DDR and are decreased upon rapamycin administration during an 
activated DDR (n=3, two-tailed T-test, **p-value<0.001 and *p-value<0.05); e) Nuclear p21 
intensity was measured from 200 cells following a DDR activation. Rapamycin treated cells 
have decreased p21 levels at 9 days post-irradiation (two-tailed T-test, **p-value<0.001 and *p-
value<0.05); f) mTORC1 inhibition by rapamycin decreases number of cells positive for Sen-β-
Gal staining at 9 days following 10Gy. One-Way ANOVA p-value<0.001. 
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FIGURE 4.4|  Silencing of TSC2 increases mTORC1 activity, drives ROS generation and 
triggers the DNA damage response 
a) HEK293T cells harbouring short-hairpins against TSC2 (sh-TSC2) or a scrambled DNA 
sequence (sh-c) were induced using doxycycline (DOX) for three days. Upon shRNA 
expression the cells express GFP; b) Percentage of shRNA induction – GFP positive cells by 
FACS; c) HEK293T doxycycline treated cells exhibits TSC2 KD (efficiency of 77.8% ±4.22), 
data are mean ± s.e.m. of n=6. Mitochondrial proteins (complex I NDUFB8, complex III 
UQCRC2 and TOMM20) are increased in DOX treated sh-TSC2 HEK293T cells. d) Cell size 
is increased in DOX-induced TSC2shRNA cells. Data are mean ± s.e.m. of n= 85 cells per 
condition. Two-tailed T-test * p-value=0.0023; e) mTORC1 activity is increased 1.9 fold after 
TSC2 knock-down (KD); f) DHE fluorescence intensity of HEK293T sh-TSC2 cells three days 
after 10Gy, data are mean ± s.e.m. of n=3; ; g) p21 protein levels were elevated upon 
mTORC1 activation via TSC2 silencing; h) γH2A.X foci increase upon TSC2 silencing. Data 
are mean ± s.e.m. of n= 20 cells per condition. Two-tailed T-test *p-value=0.0449; i) PGC-1β 
protein levels are increased upon TSC2 KD after 10 days doxycyclin induction. 
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FIGURE 4.5| RhebN153T activates constitutively mTORC1 and promotes cellular 
senescence in MEF 
a) MEF cell size is increased upon  RhebN153T over-expression. Cells were analysed 3 days 
following transfection. n= 113/134 cells respectively. One-way ANOVA p<0.001; b) western blot 
showing  that mTORC1 is constitutively active upon RhebN153T over-expression. p70S6K1 
phosphorylation was used as mTORC1 activity readout. c) MEF over-expressing RhebN153T 
proliferate less than pcDNA (EV) transfected cells. Cells were double stained for Ki67 and FLAG 
and the analysis was conducted after one day. One-way ANOVA p<0.05. d) MEF over-expressing 
RhebN153T have more mitochondrial proteins VDAC and TOMM20. Cells were analysed 3 days 
following transfection, 2 days following 10Gy. e) 53BP1 DDF are increased in irradiated cells over-
expressing RhebN153T. One-way ANOVA p<0.001; f) The fraction of Sen-β-Gal positive MEF is 
increased  seven days following transfection with RhebN153T. One-way ANOVA p<0.001;   
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FIGURE'4.6!
FIGURE 4.6| Rapamycin decreases presence of senescence markers in replicative 
senescent (RS) human fibroblasts 
a) Replicative senescent cells are bigger than young proliferating cells and rapamycin 
treatment reduces cellular hyperthropy; b) ROS levels are increased in replicative senescent 
(RS) compared to young MRC5 fibroblasts. mTORC1 inhibition by rapamycin for 10 days 
decreases ROS levels (two-tailed T-test, p-value=8.53E-06); c) Mitochondrial mass measured 
by NAO staining in the FACS is reduced in RS cells upon rapamycin treatment (two-tailed T-
test, p-value<0.001); d) Mitochondrial DNA (mtDNA) copy number is increased in replicative 
senescent cells and mTORC1 inhibition by rapamycin reduces its copy number (two-tailed T-
test, p-value<0.001). 
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FIGURE 4.7| Mitochondrial mass and proteins increase as a consequence of a DDR 
a) Mitochondria mass was increased between 1 and 4 days following activation of a DDR by 
various genotoxic stresses (X-ray irradiation, etoposide, neocarcinostatin – NCS, hydrogen 
peroxide H2O2 or telomere dysfunction (TRF2ΔBΔM) in multiple primary and cancer cell lines. 
n=3 independent experiments per cell line or treatment; b) Positive correlation between DNA 
double strand break γH2A.X foci and mitochondrial mass in MRC5 following increasing 
doses of X-ray radiation; c) Positive correlation between 53BP1 DDF and mitochondrial 
SDHA protein levels in MEF following different X-ray doses. Representative images of SDHA 
mitochondrial networks in MEF. n=3; d) Illustrative electron micrograph of young proliferating 
(Prol) and 20Gy irradiated MRC5 fibroblasts (at three days). Mitochondria were pseudo-
coloured in pink. Graphs are quantification of mitochondria volume fraction (%V/v) and 
mitochondrial numbers N mitochondria) of at least twenty cells per condition; e) 
mitochondrial DNA copies were increased 2 to 3 days following X-ray irradiation. Data are 
mean±S.E.M of n=3, *p<0.05; f) (top) mitochondrial increased in parallel with ROS levels (or 
basal oxygen consumption rate) and when ROS was normalised per unit of mitochondrial 
mass it became unchanged upon induction of senescence. MRC5 were treated three days 
with rapamycin and mitochondrial mass and ROS was measured by NAO and DHE staining. 
Antioxidant treatment (PBN and NAC) reduced ROS in X-ray senescent cells but, it does not 
affect mitochondrial mass. ROS were measured by DHE staining and mitochondrial mass by 
NAO staining. 
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FIGURE 4.8| mTORC1 inhibition by rapamycin descreases mitochondrial content within 
damaged cells  
a) mTORC1 inhibition by rapamycin halts the increase on mitocondrial mass. The panel of 
cells used here was the same one used in FIGURE 5.1.a; b) Representative MitoTracker 
Green images of primary human and mouse fibroblasts treated with rapamycin after activation 
of a DDR y ionising radiation; c) mTORC1 inhibition by rapamycin descreased number and 
volume fraction of mitochondria. Data of at least twenty T.E.M. per condition; d) rapamycin 
decreased mitochondria DNA copies number upon X-ray irradiation. n=1 q-PCR samples ran 
in triplicate, **p<0.001; e) SDHA intensity (in red) increased upon DDR activation and 
rapamycin decreased SDHA content within cells. Samples were analysed nine days following 
10Gy. Rapamycin treatment was effectuated immediately after the DDR stimulus. Data are 
mean±s.e.m. of n=3-4 cells per condition. One-Way ANOVA, *p<0.05; f) mtDNA copies are 
reduced in primary MEF upon co-treatment with rapamycin and ionising radiation. Data are 
mean±S.E.M of n=3, *p<0.05. g) when ROS was normalised per unit of mitochondrial mass it 
became unchanged upon induction of senescence. The stoichiometric ratio between ROS and 
mitochondrial mass remains unchanged even when MRC5 were treated three days with 
rapamycin. Mitochondrial mass and ROS was measured by NAO and DHE staining.  
96!
a	
FIGURE'4.9!
FIGURE 4.9| ATM inhibition following a DDR leads to decreased mTORC1 activity, p21 and 
VDAC protein levels in HEK293T cells (preliminary data) 
a) mTORC1 activity (ratio phosphorylated p70S6K1/total p70S6K1/GAPDH) was reduced after 
one day 10Gy irradiation when ATM kinase was inhibited chemically using Ku55933; b) p21 
protein levels were reduced following an active DDR when ATM was inhibited; c) mitochondrial 
protein VDAC levels were reduced following an active DDR when ATM was inhibited. In all 
conditions cells were pre-treated with 10 µM prior to X-ray irradiation. Media was refreshed with 
Ku55933 following irradiation and samples were collected one day following the treatment. n=2 
independent WB, bars represent standard error. 
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FIGURE 4.10| Autophagy-deficient cells accumulate mitochondria, ROS and DNA damage 
and, rapamycin rescues this phenotype regardless of the lack of autophagy 
a) Positive control – representative WB depicting that Atg5 knockout (KO) MEF do not  express 
Atg5. Representative images of LC-3 expression (red) in wild-type and Atg5 KO MEF; b) Atg5-null 
MEF are bigger than matched wild-type cells. Mann-Whitney test, (iii vs. iv – p<0.001, v vs. vi – 
p<0.001); c) effects of 10Gy irradiation and rapamycin on 53BP1 damage foci number, 
mitochondrial mass and ROS levels in Atg5 KO MEF. Cells were analysed three days following 
irradiation and treated immediately following IR with rapamycin. Data are mean±s.e.m. of n=3-4, 
one-Way ANOVA, *p<0.05. +/+ – wild-type, -/- – knockout.  
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FIGURE 4.11| Mitochondrial biogenesis is triggered following DDR activation and 
repressed upon mTORC1 inhibition in human MRC5 
a) PGC-1α mRNA increased after the DDR was activated and its expression levels were 
repressed once mTORC1 was inhibited using rapamycin. Data are mean± s.e.m. of n=3, one-
Way ANOVA, *p<0.05. Representative WB showing an increase for PGC-1α following the 
DDR; b) PGC-1α protein levels are repressed following mTORC1 inhibition by rapamycin. n=3; 
c) PGC-1β mRNA levels increased following activation of a DDR (20Gy) and were repressed 
when using rapamycin. n=3, one-Way ANOVA, *p<0.05.  
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FIGURE 4.12 | Mitochondrial biogenesis is triggered upon a DDR in MEF 
a) Representative WB depicting increased PGC-1α and PGC-1β following 10Gy radiation in 
wild-type MEF; b) PGC-1β protein levels are increased following activation of the DDR. n=2; c) 
PGC-1α and PGC-1β mRNA levels in senescent MEF (9 days after 10Gy). n=3, one-Way 
ANOVA *p<0.05 and **p<0.001, FC - fold-change. 
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FIGURE 4.13| PGC-1β KO MEF have disrupted mitochondrial networks, less 
mitochondrial proteins and less mtDNA during stress induced senescence 
a) MitoTracker Green staining on wild-type (wt) and PGC-1β KO MEF 3 days following 10Gy 
irradiation; b) PGC-1β KO MEF have less mitochondrial mass under proliferating and 
irradiation conditions. Data are mean±s.e.m. of n=3, one-Way ANOVA, *p<0.05; c) Kinetics of 
mitochondrial DNA copy number in wt and PGC-1β KO MEF following 10Gy irradiation. Data 
are mean±s.e.m. of n=3; d) Mitochondrial outer membrane protein VDAC expression following 
activation of a DDR in wt and PGC-1β KO MEF. Data are mean±s.e.m. of n=3, +/+ − wild-type 
and -/- − PGC-1β KO MEF ; e) Histogram depicting the frequency of SDHA intensity in wt and 
PGC-1β KO MEF three days following different X-ray irrdation doses. n=3 and dashed line 
indicates median fluorescence. Representative mitochondrial SDHA networks; f) 
Representative PGC-1α WB in wt MEF and PGC-1β KO MEF kinetically after activation of the 
DDR with 10Gy; g) Positive correlation between amount of mitochondrial SDHA and 53BP1 
damage foci in wt MEF (left graph) and in PGC-1β KO MEF (right graph) at three days 
following 10Gy. 
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Figure 4.14| PGC-1β depletion slows down the senescent phenotype  
a) Representative WB for cyclin-depend kinase inhibitor p21 in wild-type (wt) and PGC-1β KO 
MEF; b) p21 nuclear staining intensity histograms three days following 10Gy. Dashed line 
indicates median fluorescence; c) p16 mRNA levels at day ten in wild-type (wt) and PGC-1β KO 
MEF. Data are mean±S.E.M. of n=3. *p<0.05. 0Gy indicate proliferating cells; d) 
Immunofluorescence staining and graphic quantification of 53BP1 DDF three days following 
10Gy irradiation. Data are mean±S.E.M. of n=3, one-way ANOVA, *p<0.05; e) Proliferation 
stanining for wild-type and PGC-1β KO MEF at day nine. Ki67 proliferation marker (nuclear red 
staining). Data are mean±S.E.M. of n=3, one-way ANOVA, *p<0.05;  f) ROS levels in wild-type 
and PGC-1β KO MEF following three days irradiation. Data are mean±S.E.M. of n=3, one-way 
ANOVA, *p<0.05; g) Superoxide dismutase protein levels followed kinetically in wild-type and 
PGC-1β KO MEF. n=1; h) Effects of 10Gy in senescence-associated β-galactosidase positivity 
in wild-type and PGC-1β KO MEF at day nine. Perinuclear blue precipitate indicates positivity for 
Sen-β-Gal activity. Data are mean±S.E.M. of n=3, one-way ANOVA, *p<0.05. 
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FIGURE 4.15| PGC-1β over-expression triggers mitochondrial biogenesis 
a) Sheme of PGC-1β plasmid (Addgene #1031); b) Theoretical digestion of PGC-1β plasmid; c) 
PGC-1β plasmid single digestion with BamHI or double digestion using BamHI and EcoRV; d) 
Representative image of FLAG immunostaining following transfection of pcDNA (empty vector - 
EV) and pcDNAf:PGC-1β; e) mRNA expression of PGC-1β with or without 10Gy irradiation (ten 
days). Data are mean±s.e.m. of n=3; f) representative double staining for FLAG and mitochondrial 
protein SDHA two days after transfection. Dashed black line indicates median SDHA fluorescence. 
n=100 cells per condition. 
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Figure 4.16|  PGC-1β-mediated mitochondrial biogenesis promotes cellular senescence 
a) Effects of PGC-1β over-expression on mitochondrial mass increase (NAO staining by flow 
cytometry). Data are mean±S.E.M. of n=3, one-way ANOVA, *p<0.05; b) PGC-1β over-
expression induced increased 53PB1 damage foci in wild-type MEF. Data are mean±S.E.M. of 
n=3, one-way ANOVA, *p<0.05; c) PGC-1β over-expression induced increased ROS levels in 
wild-type MEF. Data are mean±S.E.M. of n=3, one-way ANOVA, *p<0.05; d) PGC-1β over-
expression induced premature cell cycle arrest in proliferating cells. Ki67 staining (red), Data are 
mean±S.E.M. of n=3, 200 cells per condition, one-way ANOVA, *p<0.05; In a) to d) cells were 
analysed three days following transfection and two days after 10Gy irradiation; e) interleukin 6 
(IL-6) mRNA levels increase upon PGC-1β over-expression on proliferating cells –RT-PCR n=1 
samples run in triplicate; f) Effects of 10Gy in senescence-associated β-galactosidase positivity 
in wild-type and PGC-1β over-expressing MEF. Perinuclear blue precipitate indicates positivity 
for Sen-β-Gal activity. PGC-1β over-expressing cells were analysed seven days post tranfection, 
six days following irradiation. Data are mean±S.E.M. of n=3, one-way ANOVA, *p<0.05; g) 
Antioxidant trolox reduced ROS levels three days after 10Gy irradiation. n=1, samples ran in 
triplicate, *p<0.05; h) Double staining FLAG (transfected cells - red) and 53BP1 DDF (green) 
two days following transfection with PGC-1β plasmid and treated 1 day prior to analysis with 250 
µM trolox. Data are mean±S.E.M. of n=3, one-way ANOVA, *p<0.05;  
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Figure 4.17|  PGC-1β KO MEF senesce slower under normoxic conditions 
a) Quantification of cell proliferation Ki67 stanining for wild-type and PGC-1β KO MEF 
under 21% oxygen at day six. Clonogenic assays at 3 and 21% oxygen after three weeks. 
Initial cell concentration was 2x105 and 5x103 cells respectively. Population doubling 
calculation of wild-type and PGC-1β KO MEF under normoxic conditions. Data are mean
±S.E.M. of n=3, one-way ANOVA, *p<0.05; b) (top) representative p21 WB for wild-type 
and PGC-1β KO MEF following four days under 3% or 21% atmospheric oxygen levels. 
(bottom) p21 nuclear staining intensity histograms six days following 21% oxygen 
conditions. Dashed line indicates median fluorescence; c) Quantification of 53BP1 DDF 
immuno-staining ten days at 21% atmospheric oxygen conditions. Data are mean±S.E.M. 
of n=3, one-way ANOVA, *p<0.05; d) Mitochondrial mass of for wild-type and PGC-1β KO 
MEF under 21% oxygen at day four. SDHA fluorescence was increased in wild-type MEF 
under 21% oxygen at day four. One-way ANOVA, *p<0.05; e) ROS levels in wild-type and 
PGC-1β KO MEF following four and twenty-two days in normoxic conditions. Data are 
mean±S.E.M. of n=3, one-way ANOVA, *p<0.05, **p<0.001; f) Autofluorescence levels in 
wild-type and PGC-1β KO MEF after twenty-three days in normoxic conditions. Data are 
mean±S.E.M. of n=3, one-way ANOVA, *p<0.05, **p<0.001; g) Effects of 21% oxygen in 
senescence-associated β-galactosidase positivity in wild-type and PGC-1β KO MEF at 
day ten. Perinuclear blue precipitate indicates positivity for Sen-β-Gal activity. Data are 
mean±S.E.M. of n=3, one-way ANOVA, *p<0.05.  
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Figure 4.18| PGC-1β and mTORC1 cooperate in the establishment of the senescent 
phenotype 
a) phophorylated ribossomal S6 protein at serine 235 and 236 (readout for mTORC1 activity) is 
reduced in PGC-1β KO MEF three days following 10Gy; b) immunofluorescence staining and 
c) graphic quantification of 53BP1 DDF three days following 10Gy irradiation. Cells were 
treated with rapamycin immediately after ionising radiation stimuli. Data are mean±S.E.M. of 
n=3, one-way ANOVA, *p<0.05; d) Effects of 10Gy in senescence-associated β-galactosidase 
positivity at day nine in wild-type and PGC-1β KO MEF treated with rapamycin. Data are mean
±S.E.M. of n=3, one-way ANOVA, *p<0.05; e) Effects of 10Gy on MitoTracker Green intensity 
in wild-type and PGC-1β KO MEF treated with rapamycin. Irradiated cells were analysed two 
days following 10Gy. n=33-76 cells per condition (preliminary data); f) Graphic quantification of 
53BP1 DDF three days following 10Gy irradiation and two days following RhebN153T 
transfection. Data are mean±S.E.M. of n=3, one-way ANOVA, *p<0.05. 
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DISCUSSION 
 
mTORC1 impacts on the DDR and on ROS during stress-induced 
senescence  
The DDR is a vital component for the induction and maintenance of cellular 
senescence [230]. The two main nodes of the DDR shown to be crucial for 
senescence are the p53-p21 and the p16-Rb axis [230]. Our data shows that 
shortly after induction of a DDR by ionising radiation (6 hours), mTORC1 
activity is up regulated. This data contrasts with the published literature, 
where generally is claimed that p53 activity antagonises mTORC1 and vice-
versa, that mTORC1 regulates p53 stability via MDM2 phosphorylation at 
S163 by p70S6K1 [231, 232]. In the irradiation model, p53 serine 15 
phosphorylation spikes on the first five hours and then decays, being 
expressed at a basal level in human fibroblasts [28]. This might allow 
consequently increased activation of mTORC1. 
 
mTORC1 activity is tightly controlled by the upstream TSC and Rheb 
components. Here we show that silencing of TSC2 or a constitutively active 
Rheb GTPase promotes DDF accumulation.  Additionally to our observation 
that p21 protein levels increase in HEK293T cells following silencing of TSC2, 
p21 protein increase has been also reported in TSC2-null MEF [233]. 
Moreover, TSC2-null MEF showed other signs of senescence such as lack of 
proliferation, increased fraction of cells in G1 and increased size [233]. 
Similarly, transient over-expression of RhebN153T in MEF leads to decreased 
proliferation. 
 
Apart from the impact of TSC2 on the DDR, earlier studies in which TSC1 was 
deleted in hepatocytes lead to an accumulation of γH2A.X [234]. Additionally, 
mTORC1 activation via TSC1 loss in haematopoietic stem cells (HSC) lead 
not only to an up-regulation of p21, but also p16 and p19 transcription [164].  
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Besides these links, the DDR can also input onto mTORC1 functions via 
REDD1 - a known p53-transcriptional target induced following DNA damage 
during development [235] and during senescence [236]. This report on 
osteoblast senescence by γ-radiation puts forward evidence that REDD1 has 
protective roles in senescence since it antagonizes mTOR phosphorylation 
and its downstream targets, decreases Sen-β-Gal positivity in cells, as well as 
it dampens SASP secretion (e.g. IL-6 and IL-8) [236, 237]. Finally, REDD1 
overexpression shortly following irradiation lead to a decline of p21 protein 
levels at day one, suggesting maybe a role for REDD1 in the senescence G1 
arrest. 
 
Another two possible links established between the DDR and the mTOR 
pathway are: the Akt direct phosphorylation by ATM [224] and the ATM 
activation of TSC2 via LKB1/AMPK upon high oxidative stress [238]. Any of 
the previously mentioned axes involving Akt, REDD1, or ATM have been 
shown to impact on- and to be triggered by oxidative stress [235, 239, 240]. 
Here we show that either TSC2 silencing promotes superoxide levels 
increase. Additionally, we observed that ROS levels were more drastically 
elevated upon TSC1 depletion than in TSC2 knockdown in HEK293T cells 
(data not shown). All this data is in agreement with previous observations that 
both hepatocytes and in haematopoietic stem cells (HSC) lacking TSC1 had 
higher ROS levels [164, 234]. Finally, NAC treatment reduced the ROS 
burden in HSC without TSC1 [164]. Overall, this puts forward the notion that 
the mTOR signalling is not only a sink for oxidative stress cues, but also a 
generator of ROS.  
 
Besides the role of TSC2, here we showed that the small GTPase Rheb is 
able to induce a DDR, reduce proliferation and induce Sen-β-Gal activity in 
primary mouse embryonic fibroblasts. These observations are in divergence 
with the fact that constitutively active Rheb(N153T) mutant cells are more 
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clonigenic than their control cells [241]. Finally, Rheb over-expression was 
suggested to promote Sen-β-Gal positivity in MEF [242]. 
 
Mitochondrial biogenesis in senescence 
Mitochondrial biogenesis is a process by which cells maintain, increase and 
divide their pre-existing mitochondria. The core regulator of this process is the 
PGC-1 family, which comprises PGC-1α, PGC-1β and PPRC1 [101].  
 
In a variety of cell types over-expression of PGC-1α and PGC-1β increases 
mitochondria biogenesis and enhances respiration, proposing that both co-
activators are the limiting factors for mitochondrial gene expression program 
[101]. Increasing mitochondrial biogenesis via expression of PGC-1α speeded 
the rate at which senescence occurred in human diploid fibroblasts [102]. 
Additionally, higher PGC-1α expression increased in senescent fibroblasts 
concomitant with an increase in mitochondrial mass [103]. Contradictory 
views are defended by Ron De Pinho’s group on the role of telomere 
dysfunction, p53 and, PGC-1α- and PGC-1β-mitochondrial biogenesis 
(reviewed in [243]). In mouse models of accelerated ageing due to telomere 
dysfunction (TERC-null mice), p53 activation downstream of telomere 
dysfunction binds to the promoters of PGC-1α- and PGC-1β inhibiting the 
expression of these biogenesis regulators [85]. As consequence, 
mitochondria become dysfunctional, produce less ATP and show increased 
ROS generation [85]. 
 
In a broader context, PGC-1α does not only impact in cellular senescence but 
also has multiple effects in pathological settings such as renal fibrosis [104], 
cardiomyopathy [105],  and diabetes [106]. This later study, reports that 
endothelial PGC-1α overexpression induced multiple diabetic phenotypes that 
encompassed blunted wound healing, reduced blood flow after hindlimb 
ischemia and aberrant re-endothelialization following carotid injury [106].  
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Besides the PGC-1 family, mitochondrial biogenesis is a complex process that 
involve other transcription factors and proteins including the NRF1/2a (nuclear 
respiratory factors), PPAR (peroxisome proliferator-activated receptor) family 
(α, β, γ, δ), ERRα (Estrogen-related receptor) and calcium/calmodulin protein 
kinases II and IV (CaMKII and CaMKIV)[244-246]. Altogether, these proteins 
activate target genes that encode fatty-acid oxidation (FAO), oxidative 
phosphorylation and antioxidant defence enzymes [247].  
Furthermore, during mitochondrial biogenesis there is a necessity for 
proliferation of mitochondrial membranes, meaning that phospholipids such as 
cardiolipin are essential. In heart, cardiolipin is the main structural 
phospholipid within mitochondrial inner membrane (representing 8 to 15% of 
the total phospholipidic mass). Moreover, cardiolipin is the sole phospholipid 
that is both produced and localized exclusively within mitochondria [246, 248].  
 
Our data points out during stress-induced senescence mitochondrial mass 
increased, pinpointing therefore that mitochondrial biogenesis is occurring. 
Moreover we observed in MRC5 and MEF increased mRNA and protein 
expression of the biogenesis regulators PGC-1α and PGC-1β upon 
senescence induction.  
 
PGC-1β mitochondrial biogenesis 
PGC-1β KO cells have less mitochondria. Besides mitochondrial de novo 
formation, PGC-1β endorses mitochondrial fusion and elongates 
mitochondrial tubules via association with mitofusin 2 (Mfn2) promoter and co-
transcriptional activation of ERRα [214]. 
 
Another more plausible hypothesis for the less mitochondria present in 
PGC1β null cells, is that PGC-1β positively regulates mitochondrial fusion by 
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mitofusin 2 (Mfn2)[214], so in the absence of PGC-1β, mitochondrial fusion 
might be compromised thus mitochondria fail to fuse and elongate and, 
ultimately, fail to promote cellular senescence. Furthermore, this lack of 
enlarged mitochondria that can evade autophagic degradation [249], might 
shift the balance towards smaller mitochondria, that can potentially being 
more easier cleared by autophagy. 
 
As mentioned before, senescence can be a outcome of mitochondrial 
elongation via Opa1 and hFIS1 silencing [96]. This makes sense, and 
perhaps, the accelerated senescence induction observed while over-
expressing PGC-1β could be due to enhanced mitochondrial elongation.  
 
Although PGC-1β-null MEF have impaired mitochondrial biogenesis, some 
degree of mitochondrial mass and mitochondrial DNA copies increase is 
observed during stress-induced senescence. This suggests that other 
mitochondrial biogenesis regulator other than PGC-1β is active (as shall be 
discussed later); that the existing mitochondria elongate via Mfn2 by a PGC-
1β-independent process or, it could also represent that a fraction of 
mitochondria remain undegraded by problems in the autophagic clearance. 
Indeed the latter two hypotheses might be more plausible scenarios, because 
elongated mitochondria are known to evade autophagic degradation, in other 
words, the autophagic machinery is physically inability to encompass large 
mitochondria [249]. Secondly, because elongated mitochondria are present in 
senescent cells and human diploid fibroblasts from aged people [250]. Finally, 
long interconnected mitochondria have been reported in senescent cells due 
to impaired mitochondrial fission (decreased expression of Drp1 and Fis1) 
[54]. 
 
PGC-1β-mitochondrial biogenesis, PGC-1α and antioxidant defence 
enzymes during cellular senescence 
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Although several reports claim redundant functions of PGC-1α and PGC-1β in 
regulating mitochondrial biogenesis, in the majority of PGC-1β-/- mice tissues 
(with the exception of adipose tissue) no compensatory effects have been 
observed, supporting a pivotal role for PGC-1β in the regulation of basal 
mitochondrial activity [251]. Likewise, we observed no compensatory effects 
of PGC-1α expression in PGC-1β-/- MEF following ionizing radiation were 
observed. 
 
Similarly to PGC-1α, it is believed that PGC-1β induces expression of genes 
involved in the removal of ROS [228]. Our data contrasts with this previous 
report mainly in three points: firstly, because we do not see up-regulation of 
SOD2 protein, suggesting perhaps that other antioxidant enzymes such as 
catalase or glutathione peroxidase would be up-regulated thus compensating 
and explaining the decreased ROS levels observed on PGC-1β-null MEF; 
secondly, because PGC-1β-overexpressing MEF have higher levels of ROS 
and DNA damage, which is in divergence with the positive roles of PGC-1β 
and PGC-1α on transcriptional regulation of antioxidant enzymes [252]; 
thirdly, our PGC-1β KO MEF are less senescent despite the reduced SOD2  
expression thus, contrasting with the phenotype seen in skin ageing where 
partial loss of SOD2 sponsors mitochondrial oxidative stress and cellular 
senescence [86]. Additional experimental validation of SOD2 expression 
levels upon PGC-1β overexpression and SOD2 enzymatic activity assays 
would strengthen this data. 
 
Here we show that PGC-1β and PGC-1α increased their expression both at 
the protein and mRNA level as a consequence of X-ray induced senescence. 
PGC-1β mRNA expression was also been demonstrated to build-up following 
γ-irradiation [253]. Although hypothesized, this study does not causally link 
that the mitochondrial mass increase observed following γ-ray treatment is 
PGC-1β driven. Interestingly, they show by complementation experiments in 
human cancer cells with mutated p53 or without p53, that PGC-1β expression 
is not affected and it still increases following irradiation [253]. This data 
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questions with the canonical view that in mouse with telomere dysfunction, 
p53 sits on PGC-1β and PGC-1α promoters acting as a transcriptional 
repressor [85].  
 
Interactions between the mTOR pathway and, mitochondrial biogenesis 
and function 
Besides being an energy and oxygen sensing system, the mTOR pathway 
also coordinates metabolic features including glycolysis, the oxidative branch 
of the pentose phosphate pathway and de novo lipid synthesis [254]. When 
analysing the signalling upstream of mTORC1 we came across many 
potential nodes for interaction with mitochondrial function (FIGURE 4.19).  
 
• the AKT – PTEN axis 
Regulation of mitochondrial biogenesis and function by PTEN-Akt has led to 
contrasting results. Firstly upon PTEN loss, Akt becomes hyper-activated and 
respiratory complexes I, III and IV activity was enhanced [255]. Moreover, this 
seems not to be regulated by PGC-1α nor by its downstream targets NRF1 
and TFAM. This study proposes that Akt regulates mitochondrial respiration 
through the eukaryotic translation initiation factor 4E (eIF4E)-binding proteins 
(4E-BP)-protein translation pathway [255]. Indeed, mTORC1 favours 
translation of nuclear-encoded mitochondria related mRNA (such as TFAM 
and components of complex V) by inhibiting 4E-BP [256]. In more detail, 
mTORC1 inhibition using PP242 or Ink1341 in MCF7 breast cancers lead to 
decreased ATP turnover, total mitochondrial respiration as well as decreases 
mtDNA and mitochondrial mass (measured by MitoTracker). Additionally, 
Rictor (specific mTORC2 subunit) and Raptor (specific mTORC1 subunit) 
silencing, dampened TFAM protein levels, but only Raptor knockdown (KD) 
reduced mtDNA levels. Thus pointing out again that mTORC1 is the main 
complex that impacts onto mitochondrial function. This is in accordance with 
our data in which decreased mtDNA copy number, decreased mitochondrial 
mass and fewer mitochondrial proteins were observed with rapamycin 
! 119!
treatment (which quenches mTORC1 activity and only mTORC2 upon 
extended administration)[257]. 
Goo’s findings [255] contrast with following studies in which PTEN loss lead to 
increase mitochondrial mass by up-regulation of ERRα-PGC-1α biogenesis in 
hepatocytes [258] and that in heart, Akt overexpression inhibited PGC-1α 
gene expression [259]. 
 
• the TSC1/TSC2 complex 
MEF without TSC2 catalytic subunit showed signs of premature senescence 
[233]. Loss of TSC2 resulted in increased mitochondrial DNA replication – 
higher levels of TFAM and mtDNA copy number – higher ATP levels and total 
mitochondria respiration [256, 260]. We also observed that upon TSC2 
silencing in HEK293T cells higher ROS levels. Similarly, this data is in 
accordance with other studies namely those on hematopoietic stem cells and 
hepatocytes lacking TSC1 with consequent increased ROS and mitochondrial 
biogenesis levels [261] [234]. Despite this, and although Morita and 
colleagues [256] proposed a link from TSC2 towards 4E-BP-translation of 
TFAM and Complex V proteins, we have preliminary data suggesting that 
PGC-1β protein levels are enhanced upon TSC2 abrogation.  
 
• AMPK 
Other potential link between mTORC1 and mitochondrial function is the 
energy-sensing AMPK node. AMP kinase becomes phosphorylated upon 
energy stress and it is often seen in this state during oncogene-induced 
senescence (OIS)[76]. Muscle-specific AMPK deletion decreased PGC-1α-
mediated mitochondrial biogenesis [262]. 
 
• VHL-HIF1α 
Von Hippel-Lindau (VHL) deficient renal carcinoma cells have higher mtDNA 
copies together with increased ETC proteins and activity [263]. VHL is also a 
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negative-regulator of hypoxia factor-1α (HIF-1α), a key protein responsive to 
oxygen changes and whose loss accelerates cellular senescence onset [264]. 
HIF-1α hinders mitochondrial mass and mtDNA increase, and increased 
oxygen consumption [265]. Mechanistically, HIF-1α phenotype can be 
explained by its ability to block c-Myc protein activity, which directly promotes 
PGC-1β-mediated mitochondrial biogenesis [265]. Not only PGC-1β is a 
transcriptional target of c-Myc, so is TFAM [266]. Although not tested, our 
MEF senescence data under normoxia could be explained by HIF-1α 
degradation [267], which would up-regulate PGC-1β-mitochondrial biogenesis 
and promote cellular senescence.  
 
• mTORC1 - Raptor and mTOR kinase 
Mice models with organ specific mTOR or Raptor deletion have shown to 
impact on mitochondrial function. More detailed, Raptor deletion in muscle 
lead to decreased PPARα, PPARδ and mitochondrial proteins (MCAD, LCAD, 
COXI and COXIV)[268]. Likewise, those same targets were dampened in 
mTOR muscle knockout mice [268] and these mice have mitochondria with 
altered morphology and oxidative capacity [269]. In adipose tissue, Raptor 
deletion up-regulates UCP1 expression [270] which very recently has been 
shown to promote mitochondrial biogenesis through fission [271]. 
In proliferating cells, rapamycin-mediated mTORC1 inhibition reduced PGC-
1α expression and transcripts together with reduced mtDNA copies and 
oxygen consumption [272]. Besides these effects on muscle cells, also in 
Jurkat cells positive correlations between mTORC1 activity and mitochondrial 
function (e.g. mitochondrial membrane potential, oxidative capacity and ATP 
levels) was observed [260]. In our hands, rapamycin treated primary human 
and mouse fibroblasts had higher mitochondrial membrane potential during 
stress-induced senescence (data not shown).  
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• p70S6K1 
p70S6K1 KO mice have higher mitochondrial content in skeletal muscle and 
adipose tissue probably driven by enhanced PGC-1α and UCP1 expression 
[273]. In muscle AMPK is activated on these mice, indicating energy stress 
and potentially explain the elevation of PGC-1α levels [274]. At the cellular 
level, p70S6K1 phosphorylates PGC-1α weakening its co-activation 
interaction with HNF4α in liver, leading consequently to a block gluconeogenic 
target genes expression [275]. Of note, HNF4α was also highly enriched as 
transcription factor/ binding element in promoters of mTORC1-induced genes 
[276]. 
 
Notably, mTOR kinase knock-in mice (where exon 12 was replaced by with 
BALB/c sequences) – [277] [278], rapamycin treated mice or whole body 
p70S6K1 KO mice have extended lifespans [140, 278, 279].  
 
Non-canonical nuclear mTOR complex 
Besides the described nodes of interaction from the mTOR pathway towards 
mitochondrial orchestrators PGC-1α and PGC-1β, these proteins also impact 
on mTORC1 activity. Firstly, it was observed that PGC-1α over-expression in 
skeletal muscle lead to increased phosphorylated mTOR and S6 
phosphorylation [280, 281] and decreased p65 phosphorylation (therefore 
less NF-κB transcriptional activity)[280]. Additionally, PGC-1α over-expression 
in raptor-muscle KO mice ameliorated mitochondrial function but was unable 
to prevent muscle myopathy [268]. Finally, PGC-1β silencing in human breast 
cancer cells lead to reduced phosphorylated AMPK, reduced Rictor (Thr1135) 
and reduced Raptor and S6 protein levels, but enhanced Akt (Ser473-
mediated apoptosis [282]. Moreover, according to the authors “PGC-1β and 
mTOR levels were correlated with overall mitochondrial activity”. In 
combination to our data on PGC-1β KO MEF having less phosphorylated S6 
levels and the ability of PGC-1β to prevent DNA damage accumulation upon 
constitutively active mTORC1, overall this data on PGC-1α and PGC-1β might 
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indicate that mitochondrial biogenesis acts as a positive forward loop onto 
mTORC1 activity. 
 
mTORC1 regulation of ROS and antioxidant defence enzymes 
We have seen that activation of the DDR was accompanied by increased 
mRNA expression of antioxidant enzymes SOD1, catalase, SOD2 (data not 
shown), which is in accordance with higher expression and activity of 
antioxidant enzymes in replicative senescence [68]. This evokes an adaptive, 
albeit deficient, response to elevated ROS and it is consistent with our 
observation that rapamycin despite suppressing the increased expression of 
antioxidant enzymes (e.g. SOD2) and the increased PGC-1α and PGC-1β 
levels, it also decreased ROS levels significantly during senescence in MEF 
and replicatively senescent MRC5. 
 
The decreased ROS observed upon rapamycin treatment has also reported in 
HSC [261] and in senescent normal oral keratinocytes [283].  This last report 
tries to explain that the decreased ROS was derived from a rapamycin-
positive effect on SOD2 protein expression. Interestingly, rapamycin treatment 
does not interfere with SOD1 and even decreases catalase expression [283].   
 
In summary we show that mitochondria biogenesis is an early event and, it 
contributes to cellular senescence onset. Additionally, high content of 
mitochondria is necessary for the maintenance of a stable cell cycle arrest. 
Finally, we described mechanistic links between the DDR pathway and 
mitochondria biogenesis by induction of the mTOR pathway (FIGURE 4.20). 
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GRAPHICAL SUMMARIES  
 
 
FIGURE 4.19| Mechanistic links between mitochondrial biogenesis 
(PGC-1α and PGC-1β) and the mTOR pathway. 
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FIGURE 4.20| Modulation of mitochondrial biogenesis, mTORC1 and 
autophagy alters mitochondrial numbers within cells and it impacts on 
the development of the senescent phenotype. 
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CHAPTER 5 – PYRUVATE-INDUCED SENESCENCE (PIS) 
 
INTRODUCTION 
Pyruvate is an organic acid that is the final product of glycolysis and it is a 
major substrate for the tricarboxylic acid (TCA) cycle within mitochondria. 
Besides this, pyruvate can be metabolised back to glucose (via 
gluconeogenesis), can be converted to fatty acids by acetyl-CoA, or it can be 
synthesised into alanine. 
 
Addition of sodium pyruvate (10mM) to diploid fibroblasts leads to cell 
proliferation arrest within 5 days, increased the fraction of cells positive for 
Sen-β-Gal activity and, cells treated with pyruvate had increased p53, p21 
and p16 protein levels [102]. More recently, pyruvate metabolism has been 
implicated in oncogene-induced senescence (OIS) [284].  
 
Besides roles in senescence, pyruvate has also been shown to stimulate 
mitochondrial biogenesis in PGC-1α-independent manner in C2C12 
myoblasts [285, 286]. 
Based on this data, we thought that pyruvate might be a suitable tool to study 
the impact of mitochondrial biogenesis during senescence.  
 
AIMS 
• Does pyruvate induce DNA damage foci? 
• Does pyruvate induces cellular senescence by enhancing 
mitochondrial mass independently of PGC-1α-mitochondrial 
biogenesis? 
• Do antioxidants and rapamycin alleviate pyruvate-induced 
senescence? 
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RESULTS  
 
Pyruvate addition induces cellular senescence 
Firstly, we tested several concentration of sodium pyruvate (10, 50 and 100 
nM) based on the observations that 50mM increases mitochondrial proteins 
levels and increases respiration in myoblasts [285, 286]. We observed that 
100nM was toxic for MRC5 fibroblasts, leading to cell death in three days. As 
standard, we treated cells with 10mM sodium pyruvate since this 
concentration was sufficient to trigger cellular senescence as previously 
reported [102](FIGURE 5.1).  
 
In more detail, MRC5 fibroblasts growing in pyruvate supplemented media 
increased expression of several OXPHOS proteins including SDHA, UQCRC2, 
VDAC and MT-CO2 (FIGURE 5.1g), increased the cell-cycle inhibitor kinase 
p21 levels (FIGURE 5.1c) and, ultimately lead to premature senescence 
(measured by Sen-β-Gal activity after 20 days of this pyruvate 
regime)(FIGURE 5.1h). We found that pyruvate supplementation for three 
days was sufficient to induce a significant increase in the number of γH2A.X 
foci (FIGURE 5.1d), reactive oxygen species (FIGURE 5.1e), cell size 
(FIGURE 5.1f) and inhibition of cellular proliferation (measured by colony 
assays and by expression of the proliferation marker Ki67)(FIGURES 5.1a 
and 5.1b). 
 
Following the observations that pyruvate prompted an increase on 
mitochondrial content and promoted ROS generation, we hypothesised that 
combinatory use of pyruvate and the antioxidant N-acetylcysteine (NAC) 
would rescue appearance and maintenance of senescence markers by 
decreasing ROS levels. Firstly, we have seen that addition of NAC and 
pyruvate rescued the number of MRC5 colonies and there were higher 
frequencies of cells proliferating (FIGURES 5.2a and 5.2b). Secondly, we 
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observed that synchronous addition of these two compounds lead to a 
reduction of the number of γH2A.X damage foci (FIGURES 5.2c and 5.2d). 
Finally, we also report that combination of pyruvate with NAC quenches the 
cellular levels of ROS (FIGURE 5.2e). 
 
Earlier in this thesis we have shown that rapamycin was able to reduce 
senescence markers during stress-induced senescence. Thus, we 
hypothesised that combined addition of rapamycin and pyruvate would 
delay/rescue senescence markers. Moreover, pyruvate supplementation to 
proliferating cells lead to higher mTORC1 activity (increased p70S6K1 
phosphorylation)(B. Carrol and V. Korolchuck personal communication). 
 
As predicted, we observed that combined addition of pyruvate and rapamycin 
reduced the mitochondrial content (FIGURE 5.3a), decreased the number of 
γH2A.X damage foci (FIGURES 5.3b and 5.3d) and, moderately rescued 
cellular proliferation (FIGURES 5.3c and 5.3e). 
 
Overall, this set of data highlights the importance of cellular metabolism on 
the induction of cellular senescence. Finally, we show that the use of 
antioxidants and rapamycin might alleviate or prevent the appearance of 
senescence markers during pyruvate-induced senescence (PIS). 
 
 
FIGURE'5.1!
**!
%
!K
i6
7!
Pyruvate!!
(mM)!
0!
10!
50!
a b 
γH
2A
.X
!fo
ci
!
**!
c 
d 
e 
g h Control Pyr 
*!**! f 
128!
Figure 5.1|  Chronic pyruvate supplemmentation leads to cellular senescence 
Clonogenic assay showing that sodium pyruvate (Pyr) inhibited proliferation on MRC5 cells. 10mM was 
used for two weeks, n=3; b) Pyruvate halts cellular proliferation in a dose dependent manner. Cells 
were cultured three or five days with 10 or 50 mM pyruvate. Data are mean± s.e.m., n=4, one-way 
ANOVA **p<0.001; c) Representative WB depicting a linear p21 increase with increased levels of 
pyruvate (at day three post-treatment); d) γH2A.X damage foci increased with pyruvate addition. Data 
are mean±S.E.M. of n=4, one-way ANOVA, p<0.001; e) ROS are increased upon 10mM pyruvate 
addition (3 days). Data are mean±S.E.M. of n=3, one-way ANOVA, p<0.001; f) cell size increased upon 
addition of 10mM and 50mM pyruvate after 3 days. Fresh media was added every 48 hours. Data are 
mean± standard deviation of n=2 experiments, 100 cells analysed per condition. Two-tailed t-test, 
p<0.05; g) Mitochondrial proteins from complexes II, III and IV and VDAC increase upon pyruvate 
treatment (3 days); g) Chronic use of pyruvate leads to Sen-β-Gal positivity at day twenty. NT-non-
treated 3.41%±0.191/ Pyr-sodium pyruvate (10mM) 69.35%±13.82. Data are mean± standard deviation 
of n=2. 
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FIGURE'5.2!
Figure 5.2|  N-acetylcysteine (NAC) rescues pyruvate-induced senescence (PIS) markers 
a) Synchronous treatment of young MRC5 cells with sodium pyruvate (10 mM) and NAC rescues 
proliferation in MRC5 fibroblasts. Colony assay (n=3) and b) representative images Ki67 staining. 
Data are mean±s.e.m. of n=3, one-way ANOVA, p<0.001; c) representative images of γH2A.X (red) 
of cells jointly treated with pyruvate and NAC (n=3); d) number of DNA damage foci after 3 days of 
combined pyruvate and NAC treatments. Data are mean±s.e.m. of n=3, one-way ANOVA, p<0.05; e) 
ROS levels measured by DHE staining. For ROS analysis NAC was only administered one day prior 
to analysis. Data are mean±s.e.m. of n=3, one-way ANOVA, p<0.05 
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Figure 5.3|  Rapamycin rescues pyruvate-induced senescence (PIS) markers 
a) MRC5 increase their mitochondrial mass after pyruvate administration and combined treatment 
with rapamycin rescues mitochondrial mass increase. Data are mean±S.E.M. of n=3, one-way 
ANOVA, p<0.05; b) γH2A.X damage foci increase is halted by rapamycin co-treatment. Data are 
mean±S.E.M. of n=3, one-way ANOVA, p<0.05; c) increased fraction of Ki67 positive cells upon 
concurrent pyruvate-rapamycin treatment. Data are mean±S.E.M. of n=3, one-way ANOVA, p<0.05; 
d) representative images of γH2A.X (nuclei-blue, γH2A.X-red); e) representative images of 
Ki67(nuclei-blue, cell proliferation marker Ki67-red). 
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DISCUSSION 
Pyruvate-induced senescence and the role of metabolism in senescence 
Pharmacological targeting of pyruvate network has been suggested for 
treatment some age-related diseases such as of diabetes and ischemic heart 
disease [287], however very few is actually known regarding effects of 
pyruvate in cellular senescence. 
 
Pyruvate acts as a pivot metabolite between many catabolic and anabolic 
pathways by being involved in redox signalling, ATP generation, oxygen 
consumption, fuel selection and biomass production [288]. Here we showed 
that pyruvate addition functions as trigger metabolite inducing cellular 
senescence. Despite our findings on senescence markers induction post-
pyruvate addition are similar to an earlier report [102], the novelty lies on the 
fact that pyruvate supplementation triggers γH2A.X damage foci formation. 
This observation is contradictory with the present view that senescence 
triggered by BRAFV600E due to metabolic up-regulation of pyruvate 
dehydrogenase is DDR-independent [10]. However, our data in pyruvate-
induced senescence is compatible with the evidence that early events that 
lead to pyruvate metabolization promote cellular senescence [10]. The Kaplon 
study states that pyruvate oxidation can hinder tumour growth in BRAF-
mediated melanoma via induction of oncogene-induced senescence [10]. This 
same study demonstrated that BRAFV600E-induced senescent fibroblasts had 
enhanced mitochondrial tricarboxylic acid (TCA) cycle usage and, that the 
effects of pyruvate seem to precede the onset of oncogene induced 
senescence (OIS) rather than being a result of it. Mechanistically, pyruvate 
dehydrogenase (PDH) acts as the gatekeeper protein that bonds glycolysis to 
the TCA cycle. Senescent cells exhibited higher PDH activity, which was 
linked with decreased PDH2 inhibitory-phosphorylation due to less expression 
of PDH kinase 1 (PDK1) [10]. Activation of PDH is mandatory for oncogene-
induced senescence (OIS) under mutant BRAF mutation settings. In vivo, 
knockdown of PDK1 thwarts tumours formation by human melanoma cell lines 
and moreover, nude-mice tumours retrogress. In another model of OIS – 
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KRASG12V, PDH activity remains elevated in senescence, despite the fact that 
altered PDH flux was not due to changes in PDP2 nor PDK1 [10]. In 
summary, while PDP2 is required for OIS induction and keeps TCA on, PDK1 
switches of the TCA cycle and make cells bypass OIS. 
 
The rescue of senescence markers upon mTORC1 inhibition by rapamycin on 
cells undergoing pyruvate-induced senescence is different from the data in 
which activation of phosphatidylinositol 3-kinase (PI3K) (and consequent 
activation of mTORC1) reverses BRAFV600E oncogene-induced senescence 
[289]. The differences may lie in the fact that, PI3K activation does not only 
promote mTORC1 activation, but also can impinge on mTORC2 activity (via 
Akt) and induce a different cellular response. 
 
Besides pyruvate involvement in BRAFV600E OIS, IMR90-HRAS cells show 
distinct metabolic and bioenergetics signatures from replicative senescent 
cells [15]. IMR90-HRAS cells had preeminent levels of fatty acid oxidation 
(FAO), which lead to an unforeseen increment of basal oxygen consumption. 
Afterwards, the authors determined the effect of decreasing the activity of 
carnitine palmitoyl transferase (CPT1A) – the rate-limiting step in 
mitochondria fatty acid oxidation (FAO) – and found that it restored the pre-
senescent metabolic rate and, it resets SASP components secretion 
(including GM-CSF, GRO-α, IL-8, MIP1-α, but not IL1β)[15]. 
 
Altogether my data supports a role for pyruvate as a metabolite that can 
promote cellular senescence and, these results highlight the importance of 
metabolism, mitochondria and reactive oxygen species in the induction and 
maintenance of the senescence arrest. Additionally, it establishes a new 
connection between pyruvate and the mTOR pathway during cellular 
senescence not previously described. 
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GRAPHICAL SUMMARY 
 
 
 
FIGURE 5.4| Pyruvate addition induces cellular senescence. Jointly 
addition of pyruvate and NAC or, pyruvate and rapamycin delays 
senescence onset. 
!!!!!!!!!!!!
Pyruvate (nM) 0 10 50 100 
Proliferation Senescence Cell Death 
NAC 
Rapamycin 
toxic 
! 135!
CHAPTER 6 – EFFECTS OF RAPAMYCIN DIET AND PGC-1β DELETION 
ON MICE CELLULAR SENESCENCE IN VIVO  
 
INTRODUCTION 
Ageing is a process that leads to overlay decay of organ physiologic 
homeostasis and increases the vulnerability of death with time [290]. This 
decline constitutes a primordial risk for development of many diseases namely 
cancer, diabetes and neuropathologies. Lately, many efforts have been made 
to pin down key genetic and biochemical processes that control the rate of 
aging including the role of the nutrient-sensing pathway IGF-1/mTOR [291]. 
Numerous studies from different laboratories have uncovered the positive 
impacts of dietary restriction and IGF-1/mTOR pathway mutants on lifespan 
extension [149, 153, 292, 293]. The IGF-1/mTOR pathways control cellular 
growth by mediating cell proliferation, survival, and energy metabolism. In 
mammals, lifespan extension was also observed in IGF1-/- mice or mice 
treated with rapamycin (an mTORC1 inhibitor) [140, 294, 295]. Rapamycin 
has been advertises as the next “longevity pill” [296], not only due to the 
promotion of lifespan increase [140, 152], but also due to its positive effects 
on halting tumour growth, increasing survival of mouse models of cancer and 
modulating age-related diseases [154-159]. 
It is tentative to argue that ageing can be explained by a mTOR centric model 
- in which organismal ageing may result from an un-resolved developmental 
and growth “programme” that contributes ultimately to disease and death [18]. 
Behind this concept are the notions that while inhibiting the mTOR pathway, 
many known aspects of ageing, including protein aggregation (likely by 
potentiating autophagy), cellular senescence or stem cell exhaustion can be 
attenuated [163, 164, 297]. Therefore the use of rapamycin or other mTOR 
inhibitors constitutes a good set of drugs to combat ageing and age-related 
diseases [145, 298].  
Other aspects of mammalian ageing are telomere and mitochondria 
dysfunction [85]. In fact, mice models of telomere dysfunction show 
accelerated ageing phenotypes [53], impaired mitochondria function, 
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decreased mRNA levels of the biogenesis regulators PGC-1α and PGC-1β, 
increased ROS generation and increased oxidative lesions (measured by 
8oxodG) [28] [85]. One of the aforementioned studies claims that the effects 
on mitochondrial biogenesis are due to the repressive functions of p53 on 
promoters of mitochondrial biogenesis genes [85]. Although this seems valid 
for PGC-1α, p53 binding to PGC-1β has been recently questioned [299]. 
Regarding the regulation of mitochondrial function by the mTOR pathway 
there are disparate reports. Inhibition of mTORC1 axis either via rapamycin or 
Raptor knockout results in decreased mitochondria content in muscle [268, 
300].  
Based on the evidence that rapamycin has beneficial effects on lifespan and it 
modulates mitochondrial function, we sought to understand the impact of 
mTORC1 inhibition in liver as mice age. 
 
AIMS 
• Analyse the impact of mTORC1 inhibition by rapamycin on mitochondrial 
dysfunction in liver of wild-type mice during ageing. 
• Analyse the impact of PGC-1β absence in telomere-associated foci in 
vivo. 
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RESULTS  
Rapamycin fed mice have fewer senescent markers in liver  
In order to study the impact of mTORC1 inhibition by rapamycin on 
organismal ageing, we began to feed rapamycin to two mice cohorts (FIGURE 
6.1a). In the first study mice were continuously fed a rapamycin-diet starting at 
3.5 months of age, and mice were culled at 6.5, at 12.5 and at 15.5 months of 
age. In these settings, we observed that rapamycin promoted increased body 
weight and liver weight increase after nine months of chronic exposure to 
rapamycin (FIGURES 6.1b and 6.1c). Combined with increased mTORC1 
activity, we also saw increased p21 protein levels in liver with age (FIGURE 
6.1h – top western blot and FIGURE 6.1e, respectively).  
On the second study (4 months rapamycin diet starting at 12 months of age - 
FIGURE 6.1a – blue arrow), we noticed an increment of Sen-β-Gal activity in 
old livers that could be attenuated upon rapamycin administration (FIGURE 
6.1e). Additionally, in the subcutaneous adipose tissue we also observed a 
reduction of Sen-β-Gal activity in animal fed with rapamycin (FIGURE 6.3b). 
As proof of concept, rapamycin dampened mTORC1 activity (measured by 
the phosphorylation status of ribosomal S6 protein (FIGURE 6.1d). On this 
short-term rapamycin study, we observed a reduction of p21 levels (FIGURE 
6.1e top-right western blot). Furthermore, on mice under rapamycin treatment 
we saw reduction of SASP components at the mRNA level such as CXCL1 
and CXCL5 (data not shown). 
Previously, we described that telomeric associated foci build-up with age and 
that they are good markers of senescence in vivo [3]. Here, we saw that 12 
months-old mice fed for 4 months with a rapamycin supplemented diet had 
less damage at telomeres (FIGURE 6.1f) and, furthermore, no differences 
were spotted regarding telomere length between damage at telomeres and 
other genomic located damage (FIGURE 6.1h right). Besides liver, we also 
observed that TAF were reduced on small intestinal crypts (data not shown).  
On the same mice cohort, we observed that mTORC1 inhibition lead to 
decreased mitochondrial number and volume fraction (by electron microscopy 
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analysis) and, also reduced levels of NDUFB8 and mitochondrial DNA copies 
in liver (FIGURE 6.1g). Further analysis of the transmission electron 
micrographs showed increased percentage of lipids within hepatocytes 
(FIGURE 6.3a). In order to test whether rapamycin was affecting cellular 
respiration or only the overall mitochondrial contentment within the cell, we 
measured cellular respiration using the Seahorse machine. As result, no 
mitochondrial respiratory differences were present in livers from rapamycin-
diet and control-diet fed mice (FIGURE 6.1g). Furthermore in the liver, we 
saw that PGC-1β biogenesis orchestrator levels were increased as mice aged 
and, that mTORC1 inhibition reduced PGC-1β protein levels (FIGURE 6.1h). 
Finally, in livers from rapamycin treated mice we did not observed increased 
expression of SOD2 - mitochondrial antioxidant enzyme that catalyses the 
conversion of hydrogen peroxide into diatomic oxygen and is a marker of 
oxidative stress (FIGURE 6.1h). This data can therefore indicate that 
rapamycin does not affect mitochondrial respiration per se, but rather, 
decreases the amount of ROS-generator sites present in the cells.  
Having identified PGC-1β as core regulator of biogenesis in cellular 
senescence in vitro, we established collaboration with Dr. Antonio Vidal-Puig 
group in University of Cambridge (United Kingdom) to study senescent 
markers on PGC-1β-null mice in liver (FIGURE 6.2).  
 
PGC-1β knockout mice have fewer mitochondria and less telomere-
associated foci (TAF) in liver  
PGC-1β KO mice are leaner than wild-type littermates, metabolically healthier 
(better age-dependent glucose and insulin resistance) and, had lower energy 
expenditure levels compared to wild-type mice (data not shown and [7]). 
Furthermore, in liver there is no compensatory effects of PGC-1α on 
mitochondrial biogenesis were reported [301, 302]. 
From the material accessible from PGC-1β knockout animals at 7 and 18 
months of age, we observed that liver weighed less in 18 months-old PGC-
1β-null mice (FIGURE 6.2b) and, that there was a reduction of mitochondrial 
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components (SDHA and mtDNA copy numbers) on PGC-1β KO mice at 7 
months (FIGURES 6.2c and 6.2d). Next, we analysed the impact of PGC-1β 
deficiency on telomere associated DNA damage in hepatocytes (FIGURE 
6.2e). Despite PGC-1β KO animal have fewer TAF, we measured significant 
differences in telomere length (FIGURE 6.2e). More precisely, TAF were 
shorter than non-TAF in both genotypes (FIGURE 6.2e). Lastly, since many 
ROS detoxifying enzymes are under the control of the PGC-1 family we 
investigate if SOD2 protein levels were changed in the livers from old PGC-1β 
KO mice. We report no significant changes in SOD2 expression on these 
animals (FIGURE 6.2f). 
 
Den-induced hepatocellular carcinoma is associated with fewer DNA 
damage, lower mitochondrial and PGC-1β protein levels 
In order to examine the hypothesis that mitochondrial hypertrophy stabilizes 
the senescent arrest and maintains tumour suppression, we prompted liver 
cancer by continuous intraperitoneal injections of N-Nitrosodiethylamine (Den) 
in wild-type mice. After dissection of tumour and adjacent non-tumour tissue, 
we realised that tumour regions had decreased mtDNA copy number, reduced 
expression of PGC-1β and mitochondrial protein SDHA (FIGURES 6.2h and 
6.2g), and lastly, tumour areas had less γH2A.X foci (FIGURE 6.2i). 
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FIGURE 6.1| mTORC1-PGC-1β dependent increased mitochondrial content contributes to 
senescence in vivo  
a) summary scheme of C57BL6 mice experiments involving rapamycin supplemented diets; b) 
body weight evolution on the longitudinal mice cohort treated with rapamycin since three months of 
age.  6.5, 12.5 and 15.5 represent the age (in months) of sacrifice and those mice were under 
rapamycin diet for 3, 9 and 12 months respectively (n=5-12 mice per group and bars represent 
standard error); c) liver weight at the above mentioned conditions (n=5-12 mice per treatment and 
bars represent standard error); d) representative western blot of the expression of pS6 and S6 in 
sixteen months old mice liver with four months rapamycin-supplementation; e) Three months old 
and fifteen months old mice livers [control (-) or rapamycin (+)] stained for Sen-β-Gal activity (n=3 
mice per group); representative western blot showing effect of four months rapamycin feeding on 
p21 expression in sixteen months old mice; representative western blot for p21 in mouse livers at 
three and twelve months of age (n=3 mice per group); f) representative ImmunoFISH images of 
hepatocytes from sixteen months old mice treated for four months with or without rapamycin 
(control). Co-localising foci are amplified in the right panel; (middle) telomere-associated foci (TAF) 
increase with age and four months rapamycin treatment reduces its number, n=3 mice per group. 
Histograms depicting mean telomere intensity for both telomeres co-localizing (TAF) or not co-
localising (non-TAF) with γH2A.X DNA damage foci in liver from sixteen months old mice treated 
for four months with rapamycin (n=4 mice per condition) - red dotted line denotes median intensity. 
No statistical significance was observed using the Mann-Whitney test between telomere intensities 
distribution of TAF and non-TAF. Circa a thousand telomeres were analysed per condition; g) (top 
left) oxygen consumption rates (OCR) in liver mitochondria in the presence of pyruvate/malate. 
Data are mean ± S.E.M of n = 5 mice per group; (top right) representative electron micrographs of 
hepatocytes from sixteen months old mice under four months rapamycin-diet - mitochondria are 
labeled in pink; (bottom left) mtDNA copy number qPCR assay at three, twelve, sixteen months 
and at sixteen months after four months rapamycin treatment. Data are mean±S.E.M of n=3-4 
mice per group; (bottom right) T.E.M. quantification of mitochondrial number (N mitochondria) per 
cross section and mitochondrial volume fraction (%Vv); h) (top) western blots for pS6, total S6, 
PGC-1β and NDUFB8 in mouse livers at three and twelve months of age (n=3 mice per group), 
(middle) four months of rapamycin-supplemented diet reduces PGC-1β expression in mice at 
sixteen months of age (n=3 mice per group), (bottom) western blots showing expression of SOD2 
in 15.5 months old mice fed with rapamycin for twelve months.  
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FIGURE 6.2| PGC-1β-mediated mitochondrial biogenesis impacts on telomere-associated 
damage and cancer in liver 
a) body weight of PGC-1β KO mice at seven and eighteen months of age. n=4-10 mice per 
genotype per age - bars represent standard error; b) liver weight of PGC-1β KO mice at seven and 
eighteen months of age. n=4-10 mice per genotype per age - bars represent standard error. Two-
tailed T-test, * denotes p<0.05; c) mtDNA copy number qPCR assay on liver from PGC-1β KO mice 
at seven months of age. Data are mean±s.e.m. of n=4 mice per genotype; d) SDHA western blot on 
eighteen months old livers from PGC-1β KO mice. Data are mean±s.e.m. of n=5 mice per genotype; 
e) (left) mean telomere-associated foci (TAF) at eighteen months of age in PGC-1β KO mice. Data 
are mean±s.e.m. of n=4 mice per genotype. (right) histograms depicting mean telomere intensity for 
both telomeres co-localizing (TAF) or not co-localising (non-TAF) with 53BP1 DNA damage foci in 
liver from eighteen months old PGC-1β KO mice treated (n=4 mice per condition) - red dotted line 
denotes median intensity. No statistical significance was observed using the Mann-Whitney test 
between telomere intensities distribution of TAF and non-TAF from wild-type or PGC-1β KO. 
Statically differences were observed in both PGC-1β KO and wild-type controls, regarding mean 
telomere lenght between non-TAF and TAF. p=0.001 and 0.018 respectively. In total, between 130 
and 150 TAF were analysed and 1900-2550 non-TAF were analysed per condition; f) western blot 
showing expression of SOD2 in PGC-1β KO and wild-type at 18 months of age; g) 
Diethylnitrosamine (Den)-induced liver tumours exhibit lower protein expression of PGC-1β-
biogenesis regulator and mitochondrial SDHA in tumour areas than in adjacent non-tumour tissue. 
n=5 mice per condition; h) mitochondrial DNA copy number is reduced in DEN-tumours compared 
to non-tumour areas. Data are mean±s.e.m. of n=3 mice per condition. Two-tailed T-test, * denotes 
p<0.05; i) γH2A.X DNA foci numbers are reduced in hepatocytes of tumour areas compared to non-
tumour areas. Data are mean±s.e.m. of n=3 mice. Two-tailed T-test, * denotes p<0.05; 
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FIGURE 6.3| Mice under rapamycin diet show increased lipid content in hepatocytes and more 
senescence-associated β-Galactosidase activity in the sub-cutaneous adipose tissue 
a) Mice treated with rapamycin for 4 months starting at 12 months of age show increased lipidic 
vesicles within hepatocytes. Data are mean± s.e.m., n=3 animals per treatment, n=10 hepatocytes 
per animal, at least 300 lipid droplets quantified per condition, Two-tailed T-test, *p=0.01526; b) Sen-
β-Gal assay on sub-cutaneous fat from mice subjected to 3 and 6 months rapamycin diet starting at 
3 months of age. Rapamycin-fed mice have less senescent adipocytes than control animals. 
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DISCUSSION 
Hepatocytes from rapamycin treated mice and from PGC-1β KO mice have 
reduced telomeric associated damage 
Our data on mTORC1 inhibition by rapamycin provides new insights into 
telomere biology. Previously we have identified that telomere-associated 
damage is persistent and irreparable in liver [3]. To our understanding, the 
prevention of TAF formation upon rapamycin treatment may represent one of 
the first evidences for the impact of the mTOR pathway on telomeres in 
mammals. In mammalian cells, mTORC1 inhibition by rapamycin increased 
telomerase expression [165] suggesting perhaps that mTORC1 promotes 
telomere erosion. In the literature, the data linking mTOR to telomeres comes 
primordially from disparate yeast data. For instance, while in Saccharomyces 
cerevisiae rapamycin induced telomere shortening [303], in 
Schizosaccharomyces pombe rapamycin does not alter telomere length [304].  
Despite the fact that we cannot discard some contribution of telomere 
shortening into TAF formation, telomeres shorted similarly in both wild type and 
PGC-1β KO mice however, PGC-1β KO animals’ telomeres were less 
damaged. This piece of evidence reinforces our previous reports and 
hypothesis that telomere shortening might not be the sole reason for telomere 
damage [3]. Perhaps, the reduction of TAF observed in PGC-1β-/- hepatocytes 
could be due to decreased number of mitochondria and, hence, less number of 
ROS-generating sites that would impinge on nuclear damage (rather than 
changes in the the antioxidant defense mechanims via SOD2). Another 
possibility could be that PGC-1β KO animals would have less oxidative stress 
(similar to our observations in cells), that would keep more TRF1 and TRF2 
bound and protecting telomeres from damage [43]. 
Telomeric associated damage has been proposed to function as qualitative 
readout for mean and maximum lifespan of short- and long-lived mice cohorts 
[50]. It is possible therefore, that some of the benefic effects of rapamycin on 
lifespan extension [140] may be due to decreased telomeric dysfunction. 
mTORC1 has been shown to be activated during ageing in X-ray irradiated 
mice [283]. In this settings, rapamycin treatment suppressed mTORC1 activity.  
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A role of rapamycin and PGC-1β deletion on mitochondria 
Notwithstanding with the fact that short-term rapamycin treatment in mice 
reduced mitochondrial mass, it did not alter mitochondrial respiration. Our data 
is also in accordance with the study from Johnson and collaborators, in which 
rapamycin treatment did not change respiratory rates of COX IV null mice’s 
brain (a model of Leigh syndrome) [161]. Opposingly, in vitro, Jurkat cells 
treated with rapamycin or after Raptor silencing results in decreased oxygen 
consumption rates [260, 305]. 
 
The impact of mTORC1 inhibition on reduction of mitochondrial content 
(mitochondrial complexes proteins and mitochodnrial biogenesis regulators) has 
been previously observed in muscle [268, 300].  
 
In brain of Ndufs4-/- mice (a model of Leigh syndrome) daily rapamycin 
injections promote lifespan and health-span extension. Despite no changes are 
observed in complex I assembly or mitochondrial respiration, in wild-type mice 
rapamycin treatments effects mitochondrial protein levels differently. In more 
detail, it decreases cytochrome c and COX IV, it increases NDUFB3 (complex I) 
and, it did not altered NDUFS9 (complex I) and HSP60 protein levels [161]. 
Similar increment of HSP60 was observed on isolated primary hepatocytes 
[306]. Additionally, this study show increased ATP5 (complex V) and SDHB 
(complex II) protein increase, however decreased UQCR2 (complex III) and 
decreased MT-CO1 (complex IV) was present. Overall, this data seems indicate 
differential effects of rapamycin on mitochondrial proteins. Nevertheless, in a 
transcriptomic study in mice under rapamycin diet, mitochondrial function was 
the category on which the more than 80% of the genes expression was altered 
[307]. 
 
Also in isolated stem cells with increased mTORC1 activity (caused by TSC1 
deletion) higher mitochondria density and more ROS levels were observed. 
Moreover, the use of the antioxidant NAC halts the loss of stemness and 
haematopoiesis on these settings [164].  
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PGC-1β loss is not deleterious but, it hinges the ordinary mitochondrial 
metabolic genes and the ability to cope with physiological stresses [302]. PGC-
1β absence drives a general reduction in OXPHOS and ETC genes and this 
induces tissue-specific mitochondrial changes [302]. PGC-1β-/- animals are 
leaner that wild-type littermate controls due to diminished WAT content [302].   
 
In liver, lipid homeostasis is extremely relevant and, PGC-1β-deficient animals 
under short-term saturated fat diet have hepatic lipid accumulation and 
increased liver/body weight ratio caused by lipid infiltration. [301, 302]. Lastly, in 
liver there is no PGC-1α compensation in the absence of PGC-1β (similar to 
what we observed on PGC-1β KO MEF) but, on mice under a high-fed diet, 
PGC-1α compensation occurs in liver [301, 302].  
 
mTOR impacts on liver hepatosteatosis 
The mTOR pathway is also involved in lipid metabolism including lipogenesis, 
lipolysis, ketogenesis and adipogenesis (reviewed in [308]). When analysing 
transmission electron micrographs from mice treated with rapamycin we 
observed a large fraction of lipids within hepatocytes. Those lipid vesicles can 
perhaps either be due to enhanced lipogenesis or due to a lack of lipolysis. 
Mechanistically, this lipid accumulation phenotype under rapamycin diet could 
be a consequence of mTORC2 activation of lipogenesis (reviewed in [308]), 
rather than the axis rapamycin-mTORC1-Lipin1-SREBP1, once rapamycin 
suppresses the expression of the lipogenesis inducer SREBP1 [309]. 
   
Although mice under high fat diet (HFD) and treated with rapamycin have fewer 
lipid droplets and lower ROS levels in liver, the impact of rapamycin on mice 
under normal chow diet (LFD) was not examined [310]. Moreover, liver deletion 
of Raptor (which decreases mTORC1 activity) induces increased DNA damage 
levels (measured by γH2A.X), increased immune infiltrations and increased 
apoptosis, which could be actually due to a survival effect mediated by the 
activation of mTORC2 branch (via phosphorylation of Akt, GSK3 and 
STAT3)[310].  Similarly to our observations that rapamycin reduced p21 levels 
in liver, also Raptor KO liver after partial hepatectomy show reduced p21 levels 
(plus reduced p27 levels)[310]. Altogether these observations reinforce the idea 
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that p21 levels changes are most likely a mTORC1-downstream event, rather 
than a mTORC2 dependent effect. 
This same study puts forward that mice lacking Raptor, have more liver fibrosis 
and have increased DEN-induced hepatocellular carcinoma [310]. 
 
Is mitochondria biogenesis a tumour suppressor mechanism? 
In DEN-hepatic carcinogenesis, we observed that γH2A.X lesions are 
suppressed in tumour areas when compared to adjacent healthy zones. This is 
in accordance with very recent study, in which a persistent DDR at telomeres 
has been connected to tumour suppressor properties of cellular senescence in 
naevi melanocytes but, not in malignant melanoma [311].   
Our data showing decline of PGC-1β and mitochondrial proteins on the DEN-
induced liver cancer, opens the exciting possibility that high mitochondrial 
content by PGC-1β acts as tumour suppression mechanism. In fact, PGC-1β 
homolog - PGC-1α was recently suggested to be key in tumour progression 
[312]. In more detail, tumour volume was reduced in nude mice that were 
subcutaneously injected with A375P melanoma cells with silenced PGC-1α. The 
authors suggest that the reduction of tumour growth was due to the activation of 
apoptosis by increased ROS levels once PGC-1α was silenced [312]. In another 
earlier report, PGC-1α was found to promote tumour growth by fuelling 
lipogenesis. Additionally, DEN-induced liver carcinogenesis was reduced in 
PGC-1α KO mice compared to wild-type mice [313]. 
 
Finally, mitochondrial biogenesis is a common downstream consequence of 
activated oncogenes (e.g. c-Myc [266]). Therefore, mitochondria biogenesis and 
mitochondrial metabolism are perhaps suitable druggable targets, in 
combination with ROS or SASP (senescence associated secretory phenotype) 
suppressing compounds in order to combat senescence and cancer, and 
promote healthy ageing. 
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CONCLUSION 
 
In this dissertation, I have shown that the nutrient-sensing mTOR pathway is 
deeply intertwined and, is required for multiple aspects of cellular senescence 
both in cells and in mice tissues. In more detail, mTORC1 inhibition by 
rapamycin alleviates the DDR, reduces the mitochondrial content within cells 
and tissues, and it modulates the senescence-associated secretome.  
This work describes telomere-associated damage (TAF) as a senescence 
marker in cells. Moreover, irreparable TAF are a robust senescence biomarker 
present in both proliferative and in post-mitotic mice tissues and, it accumulates 
with age. Here, we observe and describe new effects of the mTOR pathway into 
telomere biology and, into telomere damage prevention in vivo. To my 
knowledge it is one (if not the first) description that links mammalian telomere 
biology to this signaling pathway. 
In this thesis, I have also shown that mitochondrial biogenesis is an early event 
that results from an active DNA damage response. Moreover, inhibition of 
mitochondrial proliferation impacts on how the senescent phenotype develops 
and is maintained. The reduction of the number of ROS-generator sites seems 
to alleviate the presence of senescence markers, pinpointing that this organelle 
is essential for the early events of senescence.  
I have also shown that addition of sodium pyruvate drive cells into senescence, 
via increased mitochondrial content, increased ROS, and presence of DNA 
damage foci. Once more these effects are linked to the mTOR pathway. 
Finally, mitochondria biogenesis can function and represent a common tumour 
suppression mechanism or, a novel “checkpoint”, required for senescence 
establishment and durability. This seems particularly important since tissues 
without PGC-1β have less TAF, cells without PGC-1β can escape a permanent 
cell cycle arrest and, furthermore, cancer lesions have less mitochondrial 
components and expression of this mitochondrial biogenesis orchestrator.  
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CONTRIBUTIONS 
FIGURE DESCRIPTION 
3.1  FM 
3.2 
a-e GH 
f-g FM prepared the samples, JM conducted ChIP 
3.3 
a-d FM prepared the samples 
a-c GH conducted Immuno-FISH 
d RA conducted Ki67 staining and Sen-β-Gal assay 
3.4 
a-f 
FM prepared, conducted and analysed jointly with 
JP life-cell imaging experiment (d-f) 
a-c GH conducted Immuno-FISH 
3.5  
DJ conducted Immuno-FISH in liver and gut, FM 
imaged Immuno-FISH and analysed together with 
JP, DJ and CM Immuno-FISH experiment. 
4.1  FM 
4.2 
a FM prepared the WB samples, GH ran the WB 
b-e FM 
4.3  FM 
4.4  FM 
4.5 
a FM transfected and analysed cell size 
b BC prepared samples and ran WB 
c 
FM transfected cells, did and analysed Ki67 
staining 
d BC prepared samples and ran WB 
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e 
FM transfected cells, did and analysed 53BP1 
staining 
f FM transfected cells, did and analysed Sen-β-Gal 
4.6  FM 
4.7 
 
a 
FM cultured and NAO stained the majority of the 
cell lines depicted. GH cultured Hela and did NAO 
staining. RA treated MRC5 with H2O2, NCS and 
Etoposite and did NAO staining. FM and JP ran 
all samples by Flow Cytometry. 
b RA 
c FM 
d MC conducted TEM, JP analysed experiment 
e FM 
f JP 
4.8 
a as stated in 4.7a 
b FM 
c as stated in 5.1d 
d FM prepared samples, LG ran RT-PCR 
e FM 
f FM 
g FM 
4.9  FM 
4.10 
a VK conducted WB, GH did LC-3 staining 
b-c FM 
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4.11 
a 
FM prepared and ran WB (right), MC did RT-PCR 
(left) 
b FM 
c MC did RT-PCR 
4.12 
a-b FM 
c FM prepared samples, CM ran RT-PCR 
4.13  FM 
4.14 
a-b FM 
c FM prepared samples, DJ ran RT-PCR 
4.15  FM 
4.16  FM 
4.17  FM 
4.18 
 FM 
a FM prepared sample, BC ran WB 
5.1 
 
FM designed, co-conducted and supervised TS in 
all experimental procedures 
5.2 
5.3 
6.1 
a FM 
b FM 
c FM 
d FM and VK 
e 
FM (Sen-β-Gal assay and p21 WB on livers 
treated with rapamycin), CM p21 WB on 3 and 12 
months old mice 
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f 
CM did Immuno-FISH in liver, FM imaged al 
Immuno-FISH, FM and CM analysed Immuno-
FISH 
g 
SM did respiration assay, CM prepared TEM, FM 
analysed all TEM and RA ran mtDNA copy 
number assay 
h 
FM ran WB on PGC-1β on liver from rapamycin 
fed animals, CM ran WB on 3 and 12 months old 
mice and MnSOD on mice treated with rapamycin 
6.2 
a FM and SRC 
b FM and SRC 
c 
FM obtained the samples, RA ran mtDNA copy 
number assay 
d FM obtained the samples, CM performed staning 
e 
FM obtained the samples and CM performed 
Immuno-FISH, FM imaged and analysed all 
Imunno-FISH 
f CM 
g CM 
h RA 
i DJ 
6.3 a CM performed TEM; FM analysed lipid vesicles 
within hepatocytes 
b FM 
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FM – Francisco Marques, GH – Graeme Hewitt, RA – Rhys Anderson, CM – 
Clara Melo, BC – Bernadette Carroll, TS – Thanet Sornda, MC – Michelle 
Charles, DJ – Diana Jurk, SM – Satomi Miwa, SRC – Sergio Rodriguez-
Cuenca, JM – Jelena Mann, LG – Laura Greaves, VK – Viktor Korolchuk, JP – 
João Passos 
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ANEXES 
ANNEX 1.!!
 
 
 
 
 
  
a) secreted protein array of a variety of SASP components following X-ray induced 
senescence with or without rapamycin treatment in MRC5 fibroblasts (3 and 10 days 
after 20Gy). Data are mean of 3 independent experiments;  
b) inflammatory IL-6 protein levels measured by ELISA on stress-induced senescent 
MRC5 cells.  Levels were 5-fold decreased after nine days upon rapamycin treatment; 
c) representative images of Sen-β-Gal activity (Sen-β-Gal–cytoplasmic blue; nucleus-
pink) with or without rapamycin treatment in MRC5 fibroblast induced to senescence 
using X-ray irradiation and replicatively senescent MRC5 (RS) (scale bar=40mm), 
(right) quantification of Sen-β-Gal positive cells. Data are mean±S.E.M, n=10 
randomly analysed fields (at least 150 cells were analysed per condition); Data 
generated by Rhys Anderson, Alina Merz and Clara Melo.  
a 
c 
b 
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d 
d) p21 protein levels on MRC5 fibroblasts 3 days after 20Gy treated with rapamycin (top 
left); p21 mRNA levels on MRC5 fibroblasts 3 days after 20Gy treated with rapamycin 
(top right); representative images and quantification of p21 IF staining (green) on MRC5 
fibroblasts 3 days after 20Gy treated with or without rapamycin. Data generated by Alina 
Merz.    
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e) Experimental design (top left) - MRC5 were X-ray irradiated with 20Gy were treated 
with or without rapamycin. Cells under DMSO for 10 days were used as negative 
control. Two rapamycin treatments were performed: in the first rapamycin was kept 
and replaced daily until sample collection at day 10; the second in which rapamycin 
was kept for the first three days following X-ray irradiation and then media was 
replaced by DMSO until day of collection. Cellular proliferation (Ki7 staining) 
quantification and representative images (top right and below). Short-term mTOR 
inhibition by rapamycin and consequent release leads either to a prevention of cell 
cycle arrest or, allows cells to resume proliferation post 20Gy. This might indicate that 
inhibition of mTOR immediately after senescence induction by X-ray radiation may 
control initial events that lead to a permanent cell cycle arrest. Data generated by 
Alina Merz. 
  
e 
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ANNEX 2. 
 
 
 
 
 !
(left) MRC5 in which the mTOR kinase was silenced by siRNA have reduced γH2A.X 
damage foci and only a small fraction of cells are positive for Sen-β-Gal activity when 
compared to control siRNA (csi). Cells were analysed 10 days post 20Gy X-ray radiation. 
Additionally, mTOR siRNA treated MRC5 are smaller than control siRNA treated cells; 
(right) ATM inhibitor 10µM (Ku55933) and rapamycin (100nM) had non-additive effects on 
mean number of DNA damage foci, p21 expression and induction of Sen-β-Gal on MRC5 
irradiated with 20Gy; (bottom right) mitochondrial mass measured by NAO staining is 
reduced in MRC5 cells treated with rapamycin or ATM inhibitor. No cumulative effects 
were observed when both drugs are used suggestion that mitochondrial mass is being 
controlled by this pathway in a non-cumulative manner. Data generated by Rhys 
Anderson.    
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ACHIEVEMETNS DURING THE PhD 
TEACHING 
Demonstrator  - Faculty of Medical Sciences - Newcastle University, Newcastle upon 
Tyne, United Kingdom                   
2011 - 2014 
PEER-REVIEWED PUBLICATIONS 
1. Graeme Hewitt*, Diana Jurk*, Francisco D.M. Marques*, Clara Correia-Melo, 
Timothy Hardy, Agata Gackowska, Rhys Anderson, Morgan Taschuk, Jelena 
Mann & João F. Passos, Telomeres are favoured targets of a persistent 
DNA damage response in ageing and stress-induced senescence. Nature 
Commun. 3, 708 (2012) - *First co-author. Impact Factor =10.02; total citations 
[between 34-44, May 2014]. 
 
2. Clara Correia-Melo, Francisco D.M. Marques, Rhys Anderson, Graeme 
Hewitt, Alina Merz, Michael D. Rushton, Bernadette M. Carroll, Michelle 
Charles, Diana Jurk, Stephen W.G. Tait, Glyn Nelson, James Wordsworth, 
Satomi Miwa, Antje Thien, Kathrin Thedieck, Fiona Oakley, Rafal Czapiewski, 
Jodie Birch, Mohammad Bohlooly-Y, Antonio Vidal-Puig, Sergio Rodriguez-
Cuenca, Derek Mann, Gabriele Saretzki, Thomas von Zglinicki, Viktor I. 
Korolchuk and João F. Passos, Mitochondria are required for the induction 
of the senescent phenotype. Under revision on Cell Metabolism, Impact 
Factor = 16.747  
 
3. Jodie Birch, Rhys K. Anderson, Clara Correia-Melo, Diana Jurk, Graeme 
Hewitt, Francisco Madeira Marques, Nicola J. Green, Elizabeth Moisey, Mark 
A. Birrell, Maria G. Belvisi, Fiona Black, John J. Taylor, Andrew J. Fisher, 
Anthony De Soyza, João F. Passos. DNA damage response at telomeres 
contributes to lung ageing and chronic obstructive pulmonary disease. 
Under revision in Thorax. Impact Factor =8.562 
 
4. Francisco D.M. Marques, João F. Passos. Mitochondria and the DDR: a 
moTOR of senescence?  Review (under preparation). 
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CONFERENCES, MEETINGS, SYMPOSIUMS, WORKSHOPS AND RESEARCH 
SEMINARS 
! “Applying for Fellowships” workshop - Faculty of Medical Sciences Graduate 
School – Newcastle University, Newcastle upon Tyne, UK, 16th May 2014  
! Institute of Ageing & Health and Northern Institute of Cancer Research 
(IAH/NICR) Joint Postgraduate Research Day, Newcastle University, Newcastle 
upon Tyne, UK, 7th March 2014  
! 4th Alliance for Healthy Aging Symposium – Molecular mechanisms of Age-
related multi Morbidity, Groningen, The Netherlands, 7th-9th November 2013 
! “Introduction to Learning and Teaching in Higher Education – ITLHE part A 
course” – Staff Development Unit – Newcastle University, Newcastle upon Tyne, 
UK, 29th and 30th October 2013    
! Faculty of Medical Sciences Research Symposium on the Biology of 
Ageing, Newcastle University, Newcastle upon Tyne UK, 5th and 6th September 
2013 
! Cell Senescence in Cancer and Ageing - Wellcome Trust Scientific Conference, 
Cambridge, UK, 20th-23th July 2013 
! Biochemical Society Focused Meeting: Talks about TORCs: recent advances in 
target of rapamycin signalling, Charles Darwin House, London, UK, 14th and 15th 
March 2013 
! Institute of Ageing & Health and Institute of Genetic Medicine (IAH/IGM) Joint 
Postgraduate Research Day, Newcastle University, Newcastle upon Tyne, UK, 25th 
January 2013 
! Ageing and Basic Bioscience Conference (ABBC), Babraham Institute, 
Babraham Research Campus, Cambridge University, Cambridge, UK, 20th and 21st 
September 2012 
! Gordon Research Conference (GRC) on Biology of Aging, Ventura, California, 
USA, 12th-17th February 2012 
! Gordon Research Seminar (GRS) on Biology of Aging, Ventura, California, 
USA, 11th and 12th February 2012 
! Institute of Ageing & Health and Institute of Health & Society (IAH/IHS) Joint 
Postgraduate Research Day, Newcastle University, Newcastle upon Tyne, UK, 27th 
January 2012  
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POSTER PRESENTATION 
! “Increased mitochondrial density drives and maintains cellular senescence in 
vivo and in vitro” - Institute of Ageing & Health and Northern Institute of Cancer 
Research (IAH/NICR) Joint Postgraduate Research Day, Newcastle University, 
Newcastle upon Tyne, UK, 7th March 2014  
! “Increased mitochondrial density drives and maintains cellular senescence in 
vivo and in vitro” - 4e Alliance for Healthy Aging Symposium – Molecular 
mechanisms of Age-related multi Morbidity, Groningen, The Netherlands, 7th-9th 
November 2013 
! “mTOR-dependent mitochondrial biogenesis drives the senescent phenotype” - 
Biochemical Society Focused Meeting: Talks about TORCs: recent advances in 
target of rapamycin signalling - Charles Darwin House, London, UK, 14th and 15th 
March 2013 
! “mTOR-dependent mitochondrial biogenesis drives the senescent phenotype” - 
Ageing and Basic Bioscience Conference (ABBC), Babraham Institute, Babraham 
Research Campus, Cambridge University, Cambridge, UK, 20th and 21st September 
2012 
! “Telomeres are favoured targets of a persistent DNA damage response in 
ageing and stress-induced senescence” - Gordon Research Conference (GRC) on 
Biology of Aging, Ventura, California, USA, 12th-17th February 2012 
!  “Telomeres are favoured targets of a persistent DNA damage response in 
ageing and stress-induced senescence” - Gordon Research Seminar (GRS) on 
Biology of Aging, Ventura, California, USA, 11th and 12th February 2012 
 
ORAL PRESENTATION 
“Increased mitochondrial density drives and maintains cellular senescence in vivo 
and in vitro” - Senescence Symposium 2014 – Blizard Institute – Barts and the 
London School of Medicine and Dentistry - Queen Mary university, London, UK, 
30th October 2014 
! Research seminar on the “Biology of Ageing” (BMS2014) module – Faculty of 
Medical Sciences – School of Biomedical Sciences, Newcastle upon Tyne UK, 25th 
March 2014  
!  “Mitochondrial hypertrophy drives and sustains a DNA damage response 
during senescence” - Faculty of Medical Sciences Research Symposium on the 
Biology of Ageing, Newcastle University, Newcastle upon Tyne UK, 5th and 6th 
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September 2013  
! “Increased mitochondrial density drives and maintains cellular senescence in 
vivo and in vitro” - Cell Senescence in Cancer and Ageing - Wellcome Trust 
Scientific Conference, Cambridge, UK, 20th-23th July 2013 
! “mTOR-dependent mitochondrial biogenesis drives the senescent phenotype” - 
Institute of Ageing & Health and Institute of Genetic Medicine (IAH-IGM) Joint 
Postgraduate Research Day, Newcastle University, Newcastle upon Tyne, UK, 25th 
January 2013  
!  “Only telomeres trigger a persistent DNA damage response in stress-induced 
senescence and during ageing” - Institute of Ageing & Health and Institute of Health 
& Society (IAH-IAS) Joint Postgraduate Research Day, Newcastle University, 
Newcastle upon Tyne, UK, 27th January 2012  
 
AWARDS AND BURSARIES 
! Biochemical Society Student Bursary - “mTOR-dependent mitochondrial 
biogenesis drives the senescent phenotype” - Biochemical Society Focused 
Meeting: Talks about TORCs: recent advances in target of rapamycin signalling, 
Charles Darwin House, London, UK, 14th and 15th March 2013 
! Best Oral Presentation prize: “mTOR-dependent mitochondrial biogenesis 
drives the senescent phenotype” - Institute of Ageing & Health and Institute of 
Genetic Medicine (IAH-IGM) Joint Postgraduate Research Day, Newcastle 
University, Newcastle upon Tyne, UK, 25th January 2013  
! Faculty of Medical Sciences – Newcastle University Travel Grant – 2012  
 
SUPERVISION 
! Master Research student: Mr. Thanet Sornda – 'Does pyruvate induce cellular 
senescence via mitochondrial dysfunction, ROS and the mTOR pathway?' - 
February - August 2013 – MRes poster prize and current PhD student at Dr. David 
Gems lab at UCL, UK 
! Undergraduate student: Miss Ellen Milner – 'The Potential role of OGG1 in DNA 
single stranded break repair in senescence' - January - March 2012 
 
PROFESSIONAL MEMBERSHIPS  
Member, Biochemical Society               2012- present  
Member, International Cell Senescence Association                  2013 - present 
